

To,

Date: 25.08.2022

1. BSE Limited P.J.Towers, Dalal Street Mumbai - 400001	2. Metropolitan Stock Exchange of India Limited, Vibgyor Towers, 4th floor, Plot No C 62, G - Block, Opp. Trident Hotel, BandraKurla Complex, Bandra (E), Mumbai – 400098
---	--

Dear Sir/Madam,

Sub: Annual Report for the Financial Year 2021-22

Ref: Scrip Code 539267/DRHABEEB



With reference to the subject cited, pursuant to Regulation 34 of SEBI (LODR) Regulations 2015, we are herewith enclosing the 26th Annual Report of the Company for the Financial Year 2021-22 scheduled to be held on Saturday, 17th Day of September, 2022 at 11:00 a.m. through video conferencing/OAVM.

This is for the information and records of the Exchange, please.

Thanking you.

Yours sincerely,

For Dr Habeebullah Life Sciences Limited



K. Krishnam Raju
Executive Chairman & Whole-time Director
DIN: 00874650

Encl: as above

Dr Habeebullah Life Sciences Ltd

Regd. Off & Corp Off : 6-3-354/13/B2,, Suryateja Apartments, Hindinagar, Punjagutta,
Hyderabad-500082

.CIN No.: L85110TG1996PLC099198. Email: cs@drhlsl.com, info@drhlsl.com, pcproductsindia@gmail.com

Contact No.: 9490424639, Website : www.drhlsl.com

DR HABEEBULLAH LIFE SCIENCES LIMITED

**26th
ANNUAL REPORT
2021-22**

TABLE OF CONTENTS

CONTENTS	PAGE NO.
Corporate Information	2
Board of Directors	2
Notice of AGM	4
Director's Report	18
AOC – 1 (Financial Details of Subsidiaries / Associates / Joint Ventures)	29
MR – 3 (Secretarial Audit Report)	30
AOC – 2 (Related Party Transactions)	34
Management Discussion & Analysis Report	36
Remuneration Details of Directors, KMPs and Employees (as applicable)	39
Report on Corporate Governance	42
PCS Certificate – Compliance with Corporate Governance	62
PCS Certificate for Non – Disqualification of Directors	63
CEO/CFO Certification	64
Declaration on Code of Conduct	65
Standalone Auditor's Report & Financials	66
Consolidated Auditor's Report & Financials	107

CORPORATE INFORMATION**BOARD OF DIRECTORS**

Mr. K. Krishnam Raju	- Executive Chairman & Whole-time Director (DIN 00874650)
Mr. K.N.V Narendra Kumar	- Whole time Director & CFO (DIN 09223904)
Mr. B.Suryaprakasa Rao	- Independent – Non Executive (DIN 08089189)
Ms. Aakanksha	- Independent – Non Executive (DIN 08792778)
Mr. Y. Rama Mohan Reddy	- Independent – Non Executive (DIN 08517059)
Dr. A.S.S.V.Srinivas	- Independent – Non Executive (DIN 06975221)

Chief Financial Officer

- Mr.K.N.V Narendra Kumar

Company Secretary and Compliance Officer

- Ms. Deepa R. Dudani

Corporate Identity Number (CIN)
ISIN- L85110TG1996PLC099198
- INE579N01018**REGISTERED OFFICE**

6-3-354/13/B2, Flat.No.B2,
Suryateja Apartments,
Hindi Nagar, Punjagutta,
Hyderabad-500082,
Telangana

STATUTORY AUDITORS

M/s. A.M. Reddy & D.R. Reddy
Chartered Accountants
H.No: 3-6-641/1/C, 4th Floor, Street No.9
Himayatnagar, Hyderabad-500029

SECRETARIAL AUDITORS

M/s. S.S.Reddy & Associates
Practicing Company Secretaries
Plot No. 8-2-603/23/3 & 8-2-603/23, 15,
2nd Floor, HSR Summit, Banjara Hills,
Road No. 10, Hyderabad,
Telangana – 500034

INETRNL AUDITORS

M/s. Tungala & Co.
Chartered Accountants
Hyderabad, Telangana State, India

BANKERS

HDFC Bank Limited
Kotak Mahindra Bank
IndusInd Bank

AUDIT COMMITTEE:

Mr. B.Suryaprakasa Rao	- Chairman
Dr. A.S.S.V.Srinivas	- Member
Mr. Y. Rama Mohan Reddy	- Member

NOMINATION & REMUNERATION COMMITTEE:

Dr. A.S.S.V. Srinivas	-	Chairman
Mr. B. Suryaprakasa Rao	-	Member
Mr. Y. Rama Mohan Reddy	-	Member

STAKEHOLDER RELATIONSHIP COMMITTEE:

Mr. Y. Rama Mohan Reddy	-	Chairman
Dr. A.S.S.V. Srinivas	-	Member
Mr. B. Suryaprakasa Rao	-	Member

INDEPENDENT DIRECTORS COMMITTEE

Mr. B. Suryaprakasa Rao	-	Chairman
Ms. Aakanksha	-	Member
Mr. Y. Rama Mohan Reddy	-	Member
Dr. A.S.S.V. Srinivas	-	Member

LISTING

- 1) BSE Limited
- 2) Metropolitan Stock Exchange of India Limited

REGISTRAR & SHARE TRANSFER AGENTS

M/s. Venture Capital & Corporate Investments Private Limited
12-10-167, Bharat Nagar, Hyderabad – 500018, Telangana State, India
Contact No: 040 23818475/23818476
E-mail: info@vccilindia.com
Website: www.vccilindia.com

CONTACT DETAILS

Cell : 9490424639
E-Mail : investorrelations@drhlsl.com
Website: www.drhlsl.com

NOTICE

Notice is hereby given that the 26th Annual General Meeting of members of Dr Habeebullah Life Sciences Limited will be held on Saturday, the 17th day of September, 2022 at 11.00 a. m. through Video Conferencing/ Other Audio Visual Means (OAVM), to transact the following business:

ORDINARY BUSINESS:**1. To receive, consider and adopt:**

The Audited standalone Financial Statements of the Company for the financial year ended 31st March 2022, together with the Reports of the Board of Directors and Auditor's thereon.

The Audited Consolidated Financial Statements (together with one associate Company) of the Company for the financial year ended 31st March 2022, together with the Report of the Auditor's thereon.

2. To appoint a director in place of Mr. K.N.V. Narendra Kumar who retires by rotation and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS:**3. TO CHANGE THE NAME OF THE COMPANY:**

To consider and if thought fit, to pass, with or without modification(s), the following resolution as a Special Resolution:

"RESOLVED THAT subject to the approval of the Central Government, Registrar of Companies, Telangana, under Ministry of Corporate Affairs, pursuant to the provisions of Sections 4, 13, 14 and all other applicable provisions, if any, of the Companies Act, 2013 read with the relevant rules there under (including any statutory modifications or re-enactment thereof, for the time being in force) and Memorandum of Association and Articles of Association of the Company and necessary approval(s) required, if any, from appropriate authorities, including in-principle approval under regulation 45 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, consent of the members be and is hereby accorded to change the name of the Company from "DR HABEEBULLAH LIFE SCIENCES LIMITED" to "SAMSRITA LABS LIMITED" as made available by the Central Registration Centre, Ministry of Corporate Affairs."

"RESOLVED FURTHER THAT consequent to aforesaid change of name of the Company, the Name Clause of the Memorandum of Association be and is hereby altered by substituting existing clause I with the following new clause I:

"I. The name of the Company is **SAMSRITA LABS LIMITED.**"

"RESOLVED FURTHER THAT in the Articles of Association of the Company the name "DR HABEEBULLAH LIFE SCIENCES LIMITED" be and is hereby substituted by "SAMSRITA LABS LIMITED".

"RESOLVED FURTHER THAT wherever the name "DR HABEEBULLAH LIFE SCIENCES LIMITED" is appearing in the Memorandum of Association and the Articles of Association of the Company, the same be and is hereby substituted by **"SAMSRITA LABS LIMITED"**.

"RESOLVED FURTHER THAT the Board be and is hereby authorized to make, sign and execute and file necessary applications, forms, papers, documents and furnish information as may be considered necessary or expedient including appointing attorney/s or authorised representatives under appropriate Letter/s of Authority/ies, to appear before the office of the Ministry of Corporate Affairs / Registrar of Companies, Stock Exchanges where securities of the Company are listed and other Regulatory or Statutory Authority/ies, as may be required from time to time and to do all such acts, deeds, matters and things as may be considered necessary to give effect to the above mentioned resolution."

4. AMENDMENT OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY:

To consider and if thought fit, to pass with or without modification(s) the following resolution as a Special Resolution:

“RESOLVED THAT pursuant to the provisions of Section 13 and other applicable provisions, if any, of the Companies Act, 2013 (“the Act”) read with applicable rules and regulations made thereunder, including any statutory modifications or re-enactments thereof, for the time being in force and subject to such approvals, permissions and sanctions of Registrar of Companies and appropriate authorities, consent of members of the Company be and is hereby accorded for effecting alterations in the existing sub-clause 11 of clause III (B) of the objects Incidental or ancillary to the attainment of the main objects Clause of the Memorandum of Association (“the MOA”) of the Company in the following manner:

CLAUSE III (B) of the Memorandum of Association be altered by substituting existing sub-clause 11. with the following new sub-clause 11.:

11. To enter into Partnership or into any arrangement for sharing profits, merger, demerger, amalgamation, Union of Interest, Co-Operation, Joint Venture, reciprocal concession or otherwise with any person or company carrying on or engaged in any business or transaction which this company is authorised to carry on or engage any business undertaking or transaction capable of being conducted so as directly to benefit this company or to amalgamate with any other company having objects all together or in similar to those of the company.

“RESOLVED FURTHER THAT the Board be and is hereby authorized to make, sign and execute and file necessary applications, forms, papers, documents and furnish information as may be considered necessary or expedient and to do all such acts, deeds, matters and things as may be considered necessary to give effect to the above mentioned resolution.”

**For and on behalf of the Board of
Dr Habibullah Life Sciences Limited**

**Sd/-
K. Krishnam Raju
Executive Chairman & Whole-time Director
(DIN: 00874650)**

**Place: Hyderabad
Date: 10.08.2022**

NOTES:

1. Explanatory Statement pursuant to Section 102 of the Companies Act, 2013, in respect of the Special Business to be transacted at the 26th Annual General Meeting as set out in the Notice is annexed hereto.
2. In pursuance of Regulation 36 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings, details in respect of the Directors seeking appointment/ re-appointment at the AGM, form part of this Notice.
3. In view of the continuing COVID-19 pandemic, the Ministry of Corporate Affairs ("MCA") has vide its General Circular nos. 14/2020 and 17/2020 dated April 8, 2020 and April 13, 2020 respectively, in relation to "Clarification on passing of ordinary and special resolutions by companies under the Companies Act, 2013 and the rules made thereunder on account of the threat posed by Covid -19", General Circular no. 20/2020 dated May 5, 2020, General Circular nos. 02/2021 and 21/2021 dated January 13, 2021 and December 14, 2021 Circular No. 03/2022 dated 05.05.2022, Circular SEBI/HO/CFD/CMD2/CIR/P/2022/62 dated May 13, 2022 issued by SEBI (hereinafter collectively referred to as "the Circulars"), in relation to "Clarification on holding of annual general meeting (AGM) through video conferencing (VC) or other audio visual means (OAVM)", (collectively referred to as "MCA Circulars") permitted the holding of the Annual General Meeting ("AGM") through VC/OAVM, without the physical presence of the Members at a common venue. In compliance with the MCA Circulars, the AGM of the Company is being held through VC/OAVM.
4. The Deemed Venue of the 26th AGM of the Company shall be its Registered Office.
5. Pursuant to the provisions of the Act, a Member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on his/her behalf and the proxy need not be a Member of the Company. Since this AGM is being held pursuant to the MCA Circulars through VC / OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will not be available for the AGM and hence the Proxy Form and Attendance Slip are not annexed to this Notice.
6. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and MCA Circulars dated April 08, 2020, April 13, 2020 and May 05, 2020 the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with Central Depository Services (India) Limited (CDSL) for facilitating voting through electronic means, as the authorized e-Voting's agency. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the AGM will be provided by CDSL.
7. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available to all members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
8. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Companies Act, 2013.
9. Pursuant to the provisions of the Act and other applicable Regulations, a Member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on their behalf and the proxy need not be a Member of the Company. However since this AGM is being held pursuant to the MCA/SEBI Circulars through VC/OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will also not be available for the AGM and hence the Proxy Form and Attendance Slip are not annexed to the Notice.
10. Corporate/institutional Members (i.e. other than individuals, HUF, NRI, etc.) are required to send a scanned copy (PDF/ JPG format) of the relevant Board Resolution/Authority Letter / Power of Attorney etc. together with attested specimen signature of the duly authorised signatory(ies) who is /are authorised to vote, to the Scrutinizer through e-mail at info@drhsl.com/ investorrelations@drhsl.com.

11. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM along with the Annual report has been uploaded on the website of the Company at <https://www.drhlsl.com>. The Notice calling the AGM along with the Annual report can also be accessed from the website of the Stock Exchanges i.e. BSE Limited at www.bseindia.com and MSEI Limited i.e. www.msei.in. The AGM Notice along with annual report is also disseminated on the website of CDSL (agency for providing the Remote e-Voting facility and e-voting system during the AGM) i.e. www.evotingindia.com.
12. The Register of Members and Share Transfer Books of the Company will remain closed from 10.09.2022 to 17.09.2022 (Both days inclusive) for the purpose of 26th Annual General Meeting.
13. Recent circular requires submission of Aadhar/PAN number by every participant in securities market. Members holding shares in demat form are, therefore, requested to submit Aadhar card/PAN details to the Depository Participants with whom they have demat accounts. Members holding shares in physical form can submit their Aadhar card/PAN details to the Company/ Registrar and Share Transfer Agents (Venture Capital Corporate Investments Private Limited)
14. Members holding shares in the same name under different ledger folios are requested to apply for Consolidation of such folios and send the relevant share certificates to Venture Capital Corporate Investments Private Limited., Share Transfer Agents of the Company for their doing the needful.
15. Members are requested to send their queries at least 5 days before the date of meeting so that information can be made available at the meeting.
16. In respect of shares held in physical mode, all shareholders are requested to intimate changes, if any, in their registered address immediately to the registrar and share transfer agent of the Company and correspond with them directly regarding share transfer/transmission /transposition, Demat/Remat, change of address, issue of duplicate shares certificates, ECS and nomination facility.
17. In terms of Section 72 of the Companies Act, 2013, a member of the Company may nominate a person on whom the shares held by him/her shall vest in the event of his/her death. Members desirous of availing this facility may submit nomination in prescribed Form-SH-13 to the Company/RTA in case shares are held in physical form, and to their respective depository participant, if held in electronic form.
18. Members holding shares in the electronic form are requested to inform any changes in address/bank mandate directly to their respective Depository Participants.
19. The company has appointed M/s. S.S. Reddy & Associates, Practicing Company Secretaries, as scrutinizer of the company to scrutinize the voting process.
20. Since securities of the Company are traded compulsorily in dematerialized form as per SEBI mandate, members holding shares in physical form are requested to get their shares dematerialized at the earliest.
21. In compliance with the MCA Circulars and SEBI Circular dated January 15, 2021 as aforesaid, Notice of the AGM along with the Annual Report 2021-2022 is being sent only through electronic mode to those Members whose email addresses are registered with the Company/Depositories.
22. Since the AGM will be held through VC / OAVM, the Route Map is not annexed in this Notice.
23. The Members can join the e-AGM 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice.
24. The Register of Directors' and Key Managerial Personnel and their shareholding maintained under Section 170 of the Companies Act, 2013, the Register of Contracts or arrangements in which the Directors are interested under Section 189 of the Companies Act, 2013, will be available for inspection at the AGM.
- 25. THE INTRUCTIONS FOR SHAREHOLDERS FOR REMOTE E-VOTING ARE AS UNDER:**
 - (i) The voting period begins on 14.09.2022 at 09.00 A.M. and ends on 16.09.2022 at 05.00 P.M. During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date of 09.09.2022 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.

- (ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- (iii) Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

- (iv) In terms of SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.
- (v) Pursuant to above said SEBI Circular, Login method for e-Voting and joining virtual meetings for Individual shareholders holding securities in Demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL	<ol style="list-style-type: none"> 1) Users who have opted for CDSL Easy / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easy / Easiest are https://web.cdslindia.com/myeasi/home/login or visit www.cdslindia.com and click on Login icon and select New System Myeasi. 2) After successful login the Easy / Easiest user will be able to see the e-Voting option for eligible companies where the e-voting is in progress as per the information provided by company. On clicking the e-voting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers i.e. CDSL/NSDL/KARVY/LINKINTIME, so that the user can visit the e-Voting service providers' website directly. 3) If the user is not registered for Easy/Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration 4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the e-voting is in progress and also able to directly access the system of all e-Voting Service Providers.

Individual Shareholders holding securities in demat mode with NSDL	<ol style="list-style-type: none"> 1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2) If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select “Register Online for IDeAS “Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting
Individual Shareholders (holding securities in demat mode) login through their Depository Participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note:

Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022- 23058738 and 22-23058542-43.
Individual Shareholders holding securities in Demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30

(vi) Login method for e-Voting and joining virtual meeting for shareholders other than individual shareholders holding in Demat form & physical shareholders.

- 1) The shareholders should log on to the e-voting website www.evotingindia.com.
- 2) Click on “Shareholders” module.
- 3) Now enter your User ID
 - a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
- 4) Next enter the Image Verification as displayed and Click on Login.
- 5) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.
- 6) If you are a first time user follow the steps given below:

For Shareholders holding shares in Demat Form and other than individual and Physical Form	
PAN	<p>Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders)</p> <ul style="list-style-type: none"> Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details OR Date of Birth (DOB)	<p>Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login.</p> <ol style="list-style-type: none"> If both the details are not recorded with the depository or company please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (v).

(vii) After entering these details appropriately, click on “SUBMIT” tab.

(viii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

- (ix) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (x) Click on the EVSN for the relevant <DR HABEEBULLAH LIFE SCIENCES LIMITED> on which you choose to vote.
- (xi) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (xii) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- (xiii) After selecting the resolution you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- (xiv) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- (xv) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
- (xvi) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xvii) Shareholders can also cast their vote using CDSL’s mobile app “m-Voting”. The m-Voting app can be downloaded from respective Store. Please follow the instructions as prompted by the mobile app while Remote Voting on your mobile.
- (xviii) Facility for Non – Individual Shareholders and Custodians – Remote Voting
 - Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the “Corporates” module.
 - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
 - After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
 - The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
 - A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
 - Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address investorrelations@drhsl.com (designated email address by company), if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM & E-VOTING DURING MEETING ARE AS UNDER:

1. The procedure for attending meeting & e-Voting on the day of the AGM is same as the instructions mentioned above for Remote e-voting.
2. The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for Remote e-voting.
3. Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM.
4. Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.

5. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
6. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
7. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance at least 5 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at (company email id). The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance 5 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at investorrelations@drhlsl.com. These queries will be replied to by the company suitably by email.
8. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.
9. Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
10. If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders shall be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to Company/RTA email id.
2. For Demat shareholders -, please update your email id & mobile no. with your respective Depository Participant (DP).
3. For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at 022- 23058738 and 022-23058542/43.

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call on 022-23058542/43

26. OTHER INSTRUCTIONS:

- (i) The voting rights of shareholders shall be in proportions to the shares held by them in the paid equity share capital of the Company as on the cut-off date i.e. 09.09.2022.
- (ii) The Scrutinizer shall after the conclusion of the Voting at the Annual General Meeting first count the votes cast at the meeting and thereafter unblock the votes cast through remote e-voting in the presence of at least two (2) witnesses not in the employment of the Company and make not later than three days of conclusion of the meeting a consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, to the Chairman or person authorized by him.
- (iii) Voting is provided to the members through e-voting and at the Annual General Meeting of the Company. A Member can opt for only one mode of voting i.e. either through e-voting or at the Annual General Meeting of the Company.
- (iv) If a Member cast votes by both modes, then voting done through e-voting shall prevail.

- (v) The results declared along with the Scrutinizer's Report shall be placed on the Company's website www.drhlsl.com and on the website of CDSL and will be communicated to the BSE Limited and MSEI Limited.
27. Relevant documents referred to in the accompanying Notice, as well as Annual Report is open for inspection at the Registered Office of the Company, during the office hours, on all working days up to the date of Annual General Meeting.
28. SEBI has notified vide Notification No. SEBI/LAD-NRO/GN/2018/24 that securities of the listed companies can be transferred only in dematerialized form. In view of the above and to avail various benefits of dematerialization, members are advised to dematerialize shares held by them in physical form.

**For and on behalf of the Board of
Dr Habeebullah Life Sciences Limited**

**Sd/-
K. Krishnam Raju
Executive Chairman & Whole-time Director
(DIN: 00874650)**

**Place: Hyderabad
Date: 10.08.2022**

EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013**ITEM No. 3.****TO CHANGE THE NAME OF THE COMPANY:**

The Board of Directors of the Company vide circular resolution dated 03.08.2022 approved to change the name of the Company from "DR HABEEBULLAH LIFE SCIENCES LIMITED" to "SAMSRITA LABS LIMITED". The name availability for the same was obtained from Central Registration Centre, Ministry of Corporate Affairs on 03.08.2022. Accordingly, Memorandum of Association and Articles of Association of the Company is to be altered by substituting the old name with the new name as set out in the Notice for approval by the Shareholders of the Company.

The proposed change of name will not affect any of the rights of the Company or of the shareholders/stakeholders of the Company. All existing share certificates bearing the current name of the Company will, after the change of name, continue to be valid for all purposes.

Pursuant to Regulation 45(3) of SEBI (LODR), Regulations, 2015 a certificate certifying the compliance with the conditions specified in Reg. 45(1) of SEBI (LODR), Regulations, 2015 as provided by M/s. A.M. Reddy & D.R. Reddy, Practicing Chartered Accountant is annexed herewith.

As per the provisions of Sections 13 and 14 of the Companies Act, 2013, approval of the shareholders is required to be accorded for changing the name of the Company & consequent alteration in the Memorandum of Association and Articles of Association by way of passing a Special Resolution.

Your directors recommend the Resolution No. 3 of the Notice for the approval of the Members as a Special Resolution.

None of the Directors or Key Managerial Personnel or any relative of any of the Directors/ Key Managerial Personnel of the Company are, in any way, concerned or interested, financially or otherwise, in the resolution.

ITEM No. 4.**AMENDMENT IN MEMORANDUM OF ASSOCIATION OF THE COMPANY:**

The Board in its meeting held on 10.08.2022 has decided to amend the Memorandum of Association of the Company so that in future company may enter into any scheme of arrangement including merger, demerger etc., with other company to enjoy the synergies of scheme of arrangement. To enable the company to enter into scheme of arrangement, the company must have enabling clause in Memorandum of Association for Arrangement / Amalgamation which empower them to amalgamate or vice versa with other companies.

Therefore, it is proposed to alter the Memorandum of Association to include the enabling clause of Arrangement / Amalgamation by substituting one of the sub-clause of "the objects incidental or ancillary to the attainment of the main objects".

As per the provisions of Sections 13 of the Companies Act, 2013, approval of the shareholders is required to be accorded for alteration of "the objects incidental or ancillary to the attainment of the main objects" by way of passing a Special Resolution.

Your directors recommend the Resolution No. 4 of the Notice for the approval of the Members as a Special Resolution.

None of the Directors or Key Managerial Personnel or any relative of any of the Directors/ Key Managerial Personnel of the Company are, in any way, concerned or interested, financially or otherwise, in the resolution.

ANNEXURE-A: ITEM NO. 2 OF THE NOTICE

Details of Directors seeking appointment and re-appointment at the forthcoming Annual General Meeting [Pursuant to Regulation 36(3) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 and Secretarial Standard 2 on General Meetings]

Name of the Director	Mr. K.N.V. Narendra Kumar
Date of Birth	09/06/1977
Address	Plot no.168, Flat No. S1, Swarna Apartments, Kalyan Nagar, Phase.1, S.R. Nagar Post, Hyderabad.500038
Email-id	knarendra2009@gmail.com
Nationality	Indian
Date of Appointment on the Board	02/07/2021
Brief Resume	Mr. K.N.V. Narendra Kumar is a graduate having More than 18 Years of Experience in Finance and Accounts
Qualifications	Graduate
Expertise in specific functional area	Finance and Accounts
Number of shares held in the Company	Nil
List of the directorships held in other companies*	Nil
Relationships between Directors inter-se	Nil
Chairman/ Member in the Committees of the Boards of companies in which he is Director*	Nil
Remuneration details (Including Sitting Fees& Commission)	Rs.70,000/- p.m.

*Excluding Dr Habeebullah Life Sciences Limited

**For and on behalf of the Board of
Dr Habeebullah Life Sciences Limited**

**Sd/-
K. Krishnam Raju
Executive Chairman & Whole-time Director
(DIN: 00874650)**

**Place: Hyderabad
Date: 10.08.2022**



A.M. REDDY & D.R. REDDY

CHARTERED ACCOUNTANTS

To,

BSE Limited
P.J. Towers, Dalal Street
Mumbai-400001


Dear Sir/Madam,

Sub: Certificate pursuant to Regulation 45 (3) of SEBI (LODR) Regulations, 2015

We, M/s. A.M. Reddy & D.R. Reddy, Chartered Accountants, hereby certify that Dr Habeebullah Life Sciences Limited, a Company incorporated under the Companies Act, 1956 and having its registered office at 6-3-354/13/B2, Flat. No. B2, Suryateja Apartments Hindi Nagar, Punjagutta, Hyderabad-500082, Telangana, has complied with Regulation 45(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 with regard to proposed change of name from **Dr Habeebullah Life Sciences Limited to Samsrita Labs Limited**". The compliance as per regulation 45(1) of SEBI (LODR) Regulations, 2015 is as follows:


Sl. No.	Conditions	Remarks
a	A time period of at least one year has elapsed from the last name change;	The company has undergone name change from "PC Products India Limited" to "Dr Habeebullah Life Sciences Limited" on 25.10.2017 which is more than one year since last name change.
b.	At least fifty percent. of the total revenue in the preceding one year period has been accounted for by the new activity suggested by the new name; or -	Not Applicable. The Company's main objects includes health care activities, designing, research and development, manufacturing, processing, pro-drugs, components, medical devices and services, commercializing as well as providing technologies etc. At present, the company is into : 1. Designing, research and development, manufacturing, processing, distilling, compounding, storing, formulating, patenting, acquiring, marketing, distribution, buying, selling, importing, exporting and dealing and developing innovative molecules, modified molecules, pro-drugs, components, medical devices and services, commercializing as well as providing technologies, processes, solutions, training in all or any branches of sub-branches related to life sciences, bio-pharma, chemical sciences, plant sciences, Nutraceuticals, biological sciences, medical sciences, animal sciences, bio-

H.O.: #14/186, Flat No. 203, Anantha Sai Residency, Kamalnagar, Anantapur-515 001 | Phone : 08554-231666
B.O.: H.No. 3-6-640/1/C, 4th Floor, Street No.9, Himayatnagar, Hyderabad - 500 029. | Phone : 040-40077393
Cell: +91-9848032382, 94944 94458, 98660 95897 | Email : rkreddy1999@yahoo.com, carsrreddy@gmail.com; ramachandra_ca@yahoo.com



		<p>nanotechnology, bio-electronics, molecular biology, nuclear molecules, synthetic biology etc.</p> <p>2. Establishing, running hospitals, nursing homes, diagnostic centres both molecular and non-molecular, operation theatres, post operation management centres, rehabilitation centres, physio-therapy centres, super speciality hospitals.</p> <p>3. To carry on the business of manufactures, buyers, sellers, importers, exporters of and dealers in all kinds of organic and inorganic chemicals, chemical compounds, alkalies, salts, derivatives, chemical preparations, industrial, agricultural, medicinal, pharmaceutical and aromatic and other allied products, cosmetics, perfumeries, cleaners, detergents, oils, fats, paints, varnishes, colours, ingredients, dyestuffs and intermediaries.</p> <p>And the entire revenue has been generated from the said activity only and hence, there is only change in the name of the Company and not in the business activity.</p>
c.	The amount invested in the new activity/project is at least fifty percent of the assets of the listed entity.	Not Applicable as there is no change in the activity of the Company.

For M/s.A.M. Reddy & D.R. Reddy
Chartered Accountants
FRN: 009068S



D. Rama Krishna Reddy
Partner

M. No. 209211

Date: 10.08.2022

Place: Hyderabad

UDIN: 22209211APKSVE7225



BOARD'S REPORT

To the Members,

The Directors have pleasure in presenting before you the 26th Boards' Report of the Company together with the Audited Statements of Accounts for the year ended 31st March, 2022.

1. FINANCIAL SUMMARY/HIGHLIGHTS:

The performance during the period ended 31st March, 2022 has been as under:

(Rs. In Lakhs)

Particulars	Amount	
	2021-22	2020-21
Revenue from operations	2.25	1.30
Other income	190.62	14.77
Profit/loss before Depreciation, Finance Costs,	149.30	(76.01)
Exceptional items and Tax Expense	-	-
Less: Depreciation/ Amortisation/ Impairment	0.54	0.96
Profit /loss before Finance Costs, Exceptional items and Tax Expense	149.84	(77.97)
Less: Finance Costs	-	-
Profit /loss before Exceptional items and Tax Expense	149.84	(76.97)
Add/(less): Exceptional items	-	-
Profit /loss before Tax Expense	149.84	(76.97)
Less: Tax Expense (Current & Deferred)	-	-
Profit /loss for the year (1)	149.84	(76.97)
Total Comprehensive Income/loss (2)	-	14.08
Total (1+2)	149.84	(62.89)
Balance of profit /loss for earlier years	-	-
Less: Transfer to Reserves	-	-
Less: Dividend paid on Equity Shares	-	-

2. REVIEW OF OPERATIONS:

The total revenue of the Company for the financial year on standalone basis under review was Rs. 192.87/- lakhs as against total revenue of Rs. 16.07/- lakhs for the previous financial year. The company recorded a net profit of Rs. 149.84 Lakhs for the financial year 2021-22 as against the net loss of Rs. (62.89) lakhs for the previous year.

During the year the company has written off creditors to the tune of Rs. 174.16 Lakhs and Interest on ICD is Rs. 16.46 Lakhs.

The total revenue of the Company for the financial year on consolidated basis along with associate company under review was Rs. 192.87/- lakhs and recorded a net profit of Rs. 148.73 Lakhs.

3. BUSINESS UPDATE AND STATE OF COMPANY'S AFFAIRS:

The information on Company's affairs and related aspects is provided under Management Discussion and Analysis report, which has been prepared, inter-alia, in compliance with Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and forms part of this Report.

4. CHANGE IN THE NATURE OF BUSINESS, IF ANY:

During the period under review and the date of Board's Report there was no change in the nature of Business.

5. RESERVES:

The Closing balance of reserves, including retained earnings, of the Company as at March 31st 2022 is Rs. (1,50,99,165).

6. DIVIDEND:

Your Directors have decided not to recommend any dividend for the year 2021-22.

7. MATERIAL CHANGES AND COMMITMENTS:

There were no material changes and commitments affecting financial position of the company between 31st March and the date of Board's Report (i.e. 10.08.2022).

8. BOARD MEETINGS:

The Board of Directors duly met Five (5) times on 11.06.2021, 29.06.2021, 11.08.2021, 12.11.2021, and 27.01.2022 in respect of which meetings, proper notices were given and the proceedings were properly recorded and signed in the Minutes Book maintained for the purpose.

9. APPOINTMENT / RE-APPOINTMENT / RESIGNATION / RETIREMENT OF DIRECTORS /CEO/ CFO AND KEY MANAGERIAL PERSONNEL:

During the year under review following changes were taken place in the composition of Board of Directors:

Directors Resigned:

S. No.	Name of the Director/KMP	Designation	Date
1	Mr. Mohammed Aejaz Habeeb	Non- Executive Director	29.06.2021
2	Mr. Syed Ameer Basha Paspala	Non- Executive Director	29.06.2021
3	Ms. Akka Jyothy	Independent Director	02.07.2021
4	Mr. T.V. Rama Krishna Murthy	Independent Director	02.07.2021

Directors Appointed:

S. No.	Name of the Director/KMP	Designation	Date
1	Ms. Aakanksha	Independent Director	29.06.2021
2	Mr. Y. Rama Mohan Reddy	Independent Director	29.06.2021
3	Dr. A.S.S.V. Srinivas	Independent Director	02.07.2021
4	Mr. K.N.V. Narendra Kumar	Whole time Director	02.07.2021

The Board places on record its sincere appreciation for the services rendered by the Directors during their association with the Company.

10. REVISION OF FINANCIAL STATEMENTS:

There was no revision of the financial statements for the year under review.

11. DECLARATION FROM INDEPENDENT DIRECTORS ON ANNUAL BASIS:

The Company has received declarations from all the Independent Directors of the Company to the effect that they are meeting the criteria of independence as provided in Sub-Section (6) of Section 149 of the Companies Act, 2013 and Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Independent Directors have also confirmed that they have complied with the Company's Code of Conduct. In terms of Regulations 25(8) of the Listing Regulations, the Independent Directors have confirmed that they are not aware of any circumstance or situation, which exists or may be reasonably anticipated, that could impair or impact their ability to discharge their duties with an objective independent judgment and without any external influence.

During the year, Independent Directors of the Company had no pecuniary relationship or transactions with the Company, other than sitting fees, commission and reimbursement of expenses incurred by them for the purpose of attending meetings of the Board of Directors and Committee(s).

12. FAMILIARISATION PROGRAMMES FOR INDEPENDENT DIRECTORS:

The Company familiarises its Independent Directors on their appointment as such on the Board with the Company, their roles, rights, responsibilities in the Company, nature of the industry in which the Company operates, etc. through familiarisation programme. The Company also conducts orientation programme upon induction of new Directors, as well as other initiatives to update the Directors on a continuing basis. The familiarisation programme for Independent Directors is disclosed on the Company's website www.drhlsl.com.

13. COMPANY'S POLICY ON DIRECTORS' APPOINTMENT AND REMUNERATION INCLUDING CRITERIA FOR DETERMINING QUALIFICATIONS, POSITIVE ATTRIBUTES, INDEPENDENCE OF A DIRECTOR AND OTHER MATTERS PROVIDED UNDER SUB-SECTION (3) OF SECTION 178:

The assessment and appointment of Members to the Board is based on a combination of criterion that includes ethics, personal and professional stature, domain expertise, gender diversity and specific qualification required for the position. The potential Board Member is also assessed on the basis of independence criteria defined in Section 149(6) of the Companies Act, 2013 and Regulation 27 of SEBI (LODR) Regulations, 2015. In accordance with Section 178(3) of the Companies Act, 2013 and Regulation 19(4) of SEBI (LODR) Regulations, 2015, on the recommendations of the Nomination and Remuneration Committee, the Board adopted a remuneration policy for Directors, Key Management Personnel (KMPs) and Senior Management. The Policy is attached a part of Corporate Governance Report. We affirm that the remuneration paid to the Directors is as per the terms laid down in the Nomination and Remuneration Policy of the Company.

14. DIRECTOR'S RESPONSIBILITY STATEMENT:

Pursuant to Section 134(5) of the Companies Act, 2013, the Board of Directors, to the best of their knowledge and ability, confirm that:

- (a) In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- (b) The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;
- (c) The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- (d) The Directors had prepared the annual accounts on a going concern basis; and
- (e) The Directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.

- (f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

15. TRANSFER OF SHARES AND UNPAID/UNCLAIMED AMOUNTS TO INVESTOR EDUCATION AND PROTECTION FUND (IEPF):

Pursuant to the provisions of Section 124 of the Act, Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules") read with the relevant circulars and amendments thereto, the amount of dividend remaining unpaid or unclaimed for a period of seven years from the due date is required to be transferred to the Investor Education and Protection Fund ("IEPF"), constituted by the Central Government.

During the Year, no amount of dividend was unpaid or unclaimed for a period of seven years and therefore no amount is required to be transferred to Investor Education and Provident Fund under the Section 125(1) and Section 125(2) of the Act.

16. INFORMATION ABOUT THE FINANCIAL PERFORMANCE / FINANCIAL POSITION OF THE SUBSIDIARIES / ASSOCIATES/ JOINT VENTURES:

The company has no subsidiary and joint venture companies but during the year under review Krisani Bio Sciences Private Limited has become an associate company with effect from 12.11.2021 because of dilution of control of the company in Krisani Bio Sciences Private Limited due to preferential allotment.

As per the provisions of Section 129 of the Companies Act, 2013 read with Companies (Accounts) Rules, 2014, a separate statement containing the salient features of the financial statements of the associate company is prepared in Form AOC-1 and is attached as Annexure -1 and forms part of this report.

17. ANNUAL RETURN:

As required pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014, an annual return is uploaded on website of the Company www.drhlsl.com.

18. STATUTORY AUDITORS AND STATUTORY AUDITORS REPORT:

At the 24th Annual General Meeting held on 26.12.2020, the members of the company approved the appointment of M/s. A.M. Reddy & D.R. Reddy., chartered Accountants Statutory Auditors of the company for the term of five years from the financial year 2020-21 onwards on such terms and conditions and remuneration as may be decided by the Board. M/s. A.M. Reddy & D.R. Reddy will continue as statutory auditors of the company till the conclusion of the 29th Annual General Meeting to hold for the financial year 2024-25.

The Auditors' Report for fiscal 2022 does not contain any qualification, reservation or adverse remark. The Auditors' Report is enclosed with the financial statements in this Annual Report. The Company has received audit report with unmodified opinion for on basis of audited financial results of the Company for the Financial Year ended March 31, 2022 from the statutory auditors of the Company.

The Auditors have confirmed that they have subjected themselves to the peer review process of Institute of Chartered Accountants of India (ICAI) and hold valid certificate issued by the Peer Review Board of the ICAI.

19. SECRETARIAL AUDIT REPORT:

In terms of section 204 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, based upon the recommendations of the Audit Committee, the Board of Directors had appointed M/s. S.S. Reddy & Associates, Practicing Company Secretaries (CP No. 7478) as the Secretarial Auditor of the Company, for conducting the Secretarial Audit for financial year ended March 31, 2022.

The Secretarial Audit was carried out by M/s. S.S. Reddy & Associates, Company Secretaries (CP No. 7478) for the financial year ended March 31, 2022. The Report given by the Secretarial Auditor is annexed herewith as Annexure- 2 and forms integral part of this Report.

The observations in the Secretarial Audit Report are self-explanatory and do not require any comments thereon.

20. ANNUAL SECRETARIAL COMPLIANCE REPORT:

SEBI vide its Circular No. CIR/CFD/CMD1/27/2019 dated February 08, 2019 read with Regulation 24(A) of the Listing Regulations, directed listed entities to conduct Annual Secretarial compliance audit from a Practicing Company Secretary of all applicable SEBI Regulations and circulars/guidelines issued thereunder. Further, Secretarial Compliance Report dated 19.05.2022, was given by M/s. S.S. Reddy & Associates, Practicing Company Secretary which was submitted to Stock Exchanges within 60 days of the end of the financial year.

21. DISCLOSURE ABOUT COST AUDIT:

Maintenance of cost records and requirement of cost audit as prescribed under the provisions of Section 148(1) of the Act, are not applicable for the business activities carried out by the Company.

22. INTERNAL AUDITORS:

Pursuant to provisions of Section 138 read with Rule 13 of the Companies (Accounts) Rules, 2014 and Section 179 read with Rule 8(4) of the Companies (Meetings of Board and its Powers) Rules, 2014; during the year under review the Internal Audit of the functions and activities of the Company was undertaken by the Internal Auditor of the Company on quarterly basis by M/s. Tungala & Co., Chartered Accountants., the Internal Auditors of the Company.

Deviations are reviewed periodically and due compliance ensured. Summary of Significant Audit Observations along with recommendations and its implementations are reviewed by the Audit Committee and concerns, if any, are reported to Board. There were no adverse remarks or qualification on accounts of the Company from the Internal Auditor.

The Board has re-appointed by M/s Tungala & Co., Chartered Accountants, Hyderabad as Internal Auditors for the Financial Year 2022-23.

23. NO FRAUDS REPORTED BY STATUTORY AUDITORS:

During the Financial Year 2021-22, the Auditors have not reported any matter under section 143(12) of the Companies Act, 2013, therefore no detail is required to be disclosed under section 134(3) (ca) of the Companies Act, 2013.

24. INTERNAL AUDIT AND FINANCIAL CONTROLS:

The Company has adequate internal controls consistent with the nature of business and size of the operations, to effectively provide for safety of its assets, reliability of financial transactions with adequate checks and balances, adherence to applicable statutes, accounting policies, approval procedures and to ensure optimum use of available resources. These systems are reviewed and improved on a regular basis. It has a comprehensive budgetary control system to monitor revenue and expenditure against approved budget on an ongoing basis.

25. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:

The Company has not given any loan, guarantees or made any investments exceeding the limits under the provisions as prescribed in Section 186 of the Companies Act, 2013.

26. RELATED PARTY TRANSACTIONS:

All related party transactions that were entered into during the financial year were on arm's length basis and were in the ordinary course of business. During the financial year 2021-22, there were no materially significant related party transactions made by the Company with Promoters, Directors, Key Managerial Personnel or other designated persons which may have a potential conflict with the interest of the Company at large.

The transactions with the related parties are routine and repetitive in nature.

The summary statement of transactions entered into with the related parties are approved by the Audit Committee and the Board of Directors on a quarterly basis. The summary statements are supported by an independent audit report certifying that the transactions are at an arm's length basis and in the ordinary course of business

The Form AOC-2 pursuant to Section 134(3)(h) of the Companies Act, 2013 read with Rule 8(2) of the Companies (Accounts) Rules, 2014 is annexed herewith as Annexure 3 to this report.

27. CONSOLIDATED FINANCIAL STATEMENTS:

The company does not have any subsidiary at the end of financial year under the review. However it is having an associate company and in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as the 'Listing Regulations') and Section 129 of the Companies Act, 2013, the Consolidated Financial Statements have been prepared by the Company in accordance with the applicable provisions of the Companies Act, 2013 and the applicable Indian Accounting Standards (Ind AS) and forms part of this Annual Report.

28. NAMES OF THE COMPANIES WHICH HAVE BECOME OR CEASED TO BE ITS SUBSIDIARIES, JOINT VENTURES OR ASSOCIATE COMPANIES DURING THE YEAR.

There have been no companies which have become the subsidiaries, joint ventures during the year. However Krisani Bio Sciences Private Limited ceased to be the subsidiary of the company with effect from 12.11.2021 and has become the associate company because of the allotment of 64,00,000 equity shares at Rs. 10/- each by Krisani Bio Sciences Private Limited, erstwhile Subsidiary of Dr. Habeebullah Life Sciences Limited on a preferential basis and as a result the shareholding of the Company in Krisani Bio Sciences Private Limited has come down from 51.33% to 32.91%.

29. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE OUTGO:

The required information as per Sec.134 (3) (m) of the Companies Act 2013 is provided hereunder:

- A. Conservation of Energy: Your Company's operations are not energy intensive. Adequate measures have been taken to conserve energy wherever possible by using energy efficient computers and purchase of energy efficient equipment
- B. Research & Development and Technology Absorption: All the Factors mentioned in Rule 8 (3)(b) Technology absorption are not applicable to the Company.
 1. Research and Development (R&D): NIL
 2. Technology absorption, adoption and innovation: NIL
- C. Foreign Exchange Earnings and Out Go:
 1. Foreign Exchange Earnings: NIL
 2. Foreign Exchange Outgo: NIL

30. COMMITTEES:

- (I). **AUDIT COMMITTEE:** The Audit Committee of the Company is constituted in line with the provisions of Regulation 18(1) of SEBI (LODR) Regulations with the Stock Exchanges read with Section 177 of the Companies Act, 2013 are included in the Corporate Governance report, which forms part of this report.
- (II). **NOMINATION AND REMUNERATION COMMITTEE:** The Nomination and Remuneration Committee of the Company is constituted in line with the provisions of Regulation 19(1) of SEBI (LODR) Regulations with the Stock Exchanges read with Section 178 of the Companies Act, 2013 are included in the Corporate Governance report, which forms part of this report.
- (III). **STAKEHOLDERS RELATIONSHIP COMMITTEE:** The Stakeholders Relationship Committee of the Company is constituted in line with the provisions of Regulation 20 of SEBI (LODR) Regulations with the Stock Exchanges read with Section 178 of the Companies Act, 2013 are included in the Corporate Governance report, which forms part of this report.

31. COMPOSITION OF CSR COMMITTEE AND CONTENTS OF CSR POLICY:

Since the Company does not have the net worth of Rs. 500 Crore or more, or turnover of Rs. 1000 Crore or more, or a net profit of Rs. 5 Crore or more during the financial year, section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility is not applicable and hence the Company need not adopt any Corporate Social Responsibility Policy.

32. VIGIL MECHANISM/WHISTLE BLOWER POLICY:

The Board of Directors has formulated a Whistle Blower Policy which is in compliance with the provisions of Section 177(10) of the Companies Act, 2013 and Regulation 22 of the Listing Regulations. The Company promotes ethical behavior and has put in place a mechanism for reporting illegal or unethical behavior. The Company has a Vigil Mechanism and Whistle-blower policy under which the employees are free to report violations of applicable laws and regulations and the Code of Conduct. Employees may report their genuine concerns to the Chairman of the Audit Committee. During the year under review, no employee was denied access to the Audit Committee.

Vigil Mechanism Policy has been established by the Company for directors and employees to report genuine concerns pursuant to the provisions of section 177(9) & (10) of the Companies Act, 2013. The same has been placed on the website of the Company www.drhlsl.com.

33. DETAILS RELATING TO DEPOSITS, COVERING THE FOLLOWING:

The Company has not accepted any public deposits during the Financial Year ended March 31, 2022 and as such, no amount of principal or interest on public deposits was outstanding as on the date of the balance sheet.

34. DETAILS OF DEPOSITS NOT IN COMPLIANCE WITH THE REQUIREMENTS OF THE ACT:

Since the Company has not accepted any deposits during the Financial Year ended March 31, 2022, there has been no non-compliance with the requirements of the Act.

Pursuant to the Ministry of Corporate Affairs (MCA) notification dated 22nd January 2019 amending the Companies (Acceptance of Deposits) Rules, 2014, the Company is required to file with the Registrar of Companies (ROC) requisite returns in Form DPT-3 for outstanding receipt of money/loan by the Company, which is not considered as deposits.

The Company complied with this requirement within the prescribed timelines.

35. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS

There are no significant and material orders passed by the regulators /courts that would impact the going concern status of the Company and its future operations.

36. DETAILS OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS:

The Internal Financial Controls with reference to financial statements as designed and implemented by the Company are adequate. The Company maintains appropriate system of internal control, including monitoring procedures, to ensure that all assets are safeguarded against loss from unauthorized use or disposition. Company policies, guidelines and procedures provide for adequate checks and balances, and are meant to ensure that all transactions are authorized, recorded and reported correctly.

During the period under review, there is no material or serious observations have been noticed for inefficiency or inadequacy of such controls.

Further, details of internal financial control and its adequacy are included in the Management Discussion and Analysis Report which is appended as Annexure 4 and forms part of this Report.

37. INSURANCE:

The Company is not having any major fixed asset and therefore no insurance is taken.

38. CREDIT & GUARANTEE FACILITIES:

The Company has not availed credit and guarantee facilities.

39. RISK MANAGEMENT POLICY:

Business Risk Evaluation and Management is an ongoing process within the Organization. The Company has a robust risk management framework to identify, monitor and minimize risks and also to identify business opportunities. As a process, the risks associated with the business are identified and prioritized based on severity, likelihood and effectiveness of current detection. Such risks are reviewed by the senior

management on a quarterly basis. Risk Management Committee of the Board of Directors of your Company assists the Board in (a) overseeing and approving the Company's enterprise wide risk management framework; and (b) overseeing that all the risks that the organization faces such as strategic, financial, credit, market, liquidity, security, property, IT, legal, regulatory, reputational, other risks have been identified and assessed, and there is an adequate risk management infrastructure in place capable of addressing those risks. The development and implementation of risk management policy has been covered in the Management Discussion and Analysis, which forms part of this Report.

40. SHARE CAPITAL:

The authorized share capital of the Company stands at Rs.16,00,00,000/- divided into 1,60,00,000 equity shares of Rs.10/- each.

The paid-up share capital of the Company stands at Rs. 14,80,87,060/- divided into 1,48,08,706 equity shares of Rs.10/- each.

41. STATEMENT SHOWING THE NAMES OF THE TOP TEN EMPLOYEES IN TERMS OF REMUNERATION DRAWN AND THE NAME OF EVERY EMPLOYEE AS PER RULE 5(2) & (3) OF THE COMPANIES (APPOINTMENT & REMUNERATION) RULES, 2014:

Disclosure pertaining to remuneration and other details as required under section 197 of the Companies Act, 2013 read with rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is given in Annexure 5a to this Report.

The Statement containing the particulars of employees as required under section 197(12) of the Companies Act, 2013 read with rule 5(2) and other applicable rules (if any) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is provided in Annexure 5b to this report.

During the year, NONE of the employees is drawing a remuneration of Rs.1,02,00,000/- and above per annum or Rs.8,50,000/- and above in aggregate per month, the limits specified under the Section 197(12) of the Companies Act, 2013 read with Rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

42. MANAGEMENT DISCUSSION AND ANALYSIS REPORT:

The Management Discussion and Analysis Report, pursuant to the SEBI (LODR) Regulation provides an overview of the affairs of the Company, its legal status and autonomy, business environment, mission & objectives, sectoral and operational performance, strengths, opportunities, constraints, strategy and risks and concerns, as well as human resource and internal control systems is appended as Annexure 4 for information of the Members.

43. POLICIES:

The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 mandated the formulation of certain policies for all listed companies. All the policies are available on our website www.drhlsl.com.

44. ENVIRONMENTS AND HUMAN RESOURCE DEVELOPMENT:

Your Company always believes in keeping the environment pollution free and is fully committed to its social responsibility. The Company has been taking utmost care in complying with all pollution control measures from time to time strictly as per the directions of the Government.

We would like to place on record our appreciation for the efforts made by the management and the keen interest shown by the Employees of your Company in this regard.

45. STATUTORY COMPLIANCE:

The Company has complied with the required provisions relating to statutory compliance with regard to the affairs of the Company in all respects.

46. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of The Sexual Harassment of Women at workplace (Prevention, Prohibition and Redressal) Act, 2013. Internal Committee (IC) has not been constituted since there are less than 10 employees in the Company.

During the year 2021-22, there were no complaints received by the Company.

47. CORPORATE GOVERNANCE AND SHAREHOLDERS INFORMATION:

The Company has implemented all of its major stipulations as applicable to the Company. As stipulated under Regulation 34 read with schedule V of SEBI (LODR) Regulations, 2015, a report on Corporate Governance duly audited is appended as Annexure 6 for information of the Members. A requisite certificate from the Secretarial Auditors of the Company confirming compliance with the conditions of Corporate Governance is attached to the Report on Corporate Governance.

48. RATIO OF REMUNERATION TO EACH DIRECTOR:

Under section 197(12) of the Companies Act, 2013, and Rule 5(1) (2) & (3) of the Companies (Appointment & Remuneration) Rules, 2014 read with Schedule V of the Companies Act, 2013 the ratio of remuneration of (Mr. K.N.V. Narendra Kumar), Whole time director of the Company to the median remuneration of the employee is 1.52:1.

49. CODE OF CONDUCT FOR THE PREVENTION OF INSIDER TRADING:

The Board of Directors has adopted the Insider Trading Policy in accordance with the requirements of the SEBI (Prohibition of Insider Trading) Regulation, 2015 and the applicable Securities laws. The Insider Trading Policy of the Company lays down guidelines and procedures to be followed, and disclosures to be made while dealing with shares of the Company, as well as the consequences of violation. The policy has been formulated to regulate, monitor and ensure reporting of deals by employees and to maintain the highest ethical standards of dealing in Company securities.

The Insider Trading Policy of the Company covering code of practices and procedures for fair disclosure of unpublished price sensitive information and code of conduct for the prevention of insider trading, is available on our website (www.drhlsl.com).

50. BOARD EVALUATION:

Evaluation of all Board members is performed on an annual basis. The evaluation is performed by the Board, Nomination and Remuneration Committee and Independent Directors with specific focus on the performance and effective functioning of the Board and Individual Directors.

In line with Securities and Exchange Board of India Circular No. SEBI/HO/CFD/CMD/CIR/P/2017/004, dated January 5, 2017 and the Companies Amendment Act, 2017 the Company adopted the recommended criteria by Securities and Exchange Board of India.

The criteria for performance evaluation covers the areas relevant to the functioning of the Board and Board Committees such as its composition, oversight and effectiveness, performance, skills and structure etc.

The evaluation of Board of Directors is performed by the Board after seeking all the inputs from the Directors and the Board Committees by seeking inputs from the Committee members.

The performance evaluation of the individual directors is done by the Nomination and Remuneration Committee.

The performance evaluation of non-independent directors, the Board as a whole and the Chairman is done by a separate meeting of Independent directors after taking inputs from the Executive directors.

51. SECRETARIAL STANDARDS:

The Company is in compliance with the applicable secretarial standards.

52. EVENT BASED DISCLOSURES:

During the year under review, the Company has not taken up any of the following activities except as mentioned:

1. Issue of sweat equity share: NA
2. Issue of shares with differential rights: NA
3. Issue of shares under employee's stock option scheme: NA
4. Disclosure on purchase by Company or giving of loans by it for purchase of its shares: NA
5. Buy back shares: NA
6. Disclosure about revision: NA
7. Preferential Allotment of Shares: NA

53. DETAILS OF APPLICATION MADE OR PROCEEDING PENDING UNDER INSOLVENCY AND BANKRUPTCY CODE, 2016:

During the year under review, there were no applications made or proceedings pending in the name of the Company under Insolvency and Bankruptcy Code, 2016.

54. DETAILS OF DIFFERENCE BETWEEN VALUATION AMOUNT ON ONE TIME SETTLEMENT AND VALUATION WHILE AVAILING LOAN FROM BANKS AND FINANCIAL INSTITUTIONS:

During the year under review, there has been no one time settlement of loans taken from banks and financial institutions.

55. CEO/ CFO CERTIFICATION:

The Whole time Director and Chief Financial Officer Certification on the financial statements under regulation 17 (8) of SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015 for the year 2021-2022 is annexed in this Annual Report.

56. DEVIATIONS, IF ANY OBSERVED ON FUNDS RAISED THROUGH PUBLIC ISSUE, PREFERENTIAL ISSUE ETC:

During the year under review, company has not raised any funds from public or through preferential allotment.

57. DECLARATION BY THE COMPANY:

The Company has issued a certificate to its Directors, confirming that it has not made any default under Section 164(2) of the Companies Act, 2013, as on March 31, 2022.

58. NON-EXECUTIVE DIRECTORS' COMPENSATION AND DISCLOSURES:

None of the Independent / Non-Executive Directors has any pecuniary relationship or transactions with the Company which in the Judgment of the Board may affect the independence of the Directors.

No compensation was paid to the Independent and Non-Executive Directors.

59. ACKNOWLEDGEMENTS:

Your Directors place on record their appreciation for the overwhelming co-operation and assistance received from the investors, customers, business associates, bankers, vendors, as well as regulatory and governmental authorities. Your Directors also thanks the employees at all levels, who through their dedication, co-operation, support and smart work have enabled the company to achieve a moderate growth and is determined to poise a rapid and remarkable growth in the year to come.

Your Directors also wish to place on record their appreciation of business constituents, banks and other financial institutions and shareholders of the Company, SEBI, BSE, MSEI, NSDL, CDSL, Banks, RBI etc. for their continued support for the growth of the Company.

**For and on behalf of the Board of
Dr Habeebullah Life Sciences Limited**

**Sd/-
K. Krishnam Raju
Executive Chairman & Whole-time Director
(DIN: 00874650)**

**Place: Hyderabad
Date: 10.08.2022**

Annexure 1
Form AOC – 1

Statement containing salient features of the financial statements of Subsidiaries/Associate (Pursuant to proviso to sub-section (3) of section 129 read with Rule 5 of the Companies (Accounts) Rules, 2014)

1. Name of the Associate: Krisani Bio Sciences Private Limited
2. Reporting Period: 01.04.2021 to 31.03.2022
3. Reporting Currency: Indian Rupee

Amount In Rupees

Sl. No.	Particulars	Krisani Bio Sciences Private Limited
1.	Share Capital	17,83,32,000
	Reserves and surplus for the year ending	(3,24,39,131)
2.	Total Assets	15,91,99,949
3.	Total Liabilities	1,86,26,671
4.	Investments	75,000
5.	Turnover (Income)	0
6.	Profit / loss before Taxation	(4,96,173)
7.	Provision for Taxation	(1,59,176)
8.	Profit / loss after Taxation	(3,36,997)
9.	Proposed Dividend	Nil
10.	% of Shareholding	32.91

1. Names of Subsidiaries which are yet to commence operation: NA
2. Names of subsidiaries which have been liquidated or sold during the year: Krisani Bio Sciences Private Limited cease to be the subsidiary and has become associate w.e.f., 12.11.2021

**For and on behalf of the Board of
Dr Habeebullah Life Sciences Limited**

Sd/-

K. Krishnam Raju
Executive Chairman & Whole-time Director
(DIN: 00874650)

Place: Hyderabad
Date: 10.08.2022

Annexure 2

FORM MR-3

SECRETARIAL AUDIT REPORT

{Pursuant to section 204(1) of the Companies Act, 2013 and
Rule 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014}
FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2022

To

The Members of
Dr Habeebullah Life Sciences Limited
Hyderabad.

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Dr Habeebullah Life Sciences Limited (hereinafter called "the Company"). Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's Books, Papers, Minute Books, Forms and Returns filed and other Records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the company has, during the audit period covering the financial year ended on 31st March, 2022, complied with the statutory provisions listed hereunder and also that the Company has proper Board process and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by Dr Habeebullah Life Sciences Limited ("The Company") for the financial year ended on 31st March, 2022 according to the provisions of:

- i. The Companies Act, 2013 (the Act) and the rules made there under;
- ii. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under;
- iii. The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
- iv. Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of Foreign Direct Investment (FDI) and Overseas Direct Investment and External Commercial Borrowings;
1. Compliance status in respect of the provisions of the following Regulations and Guideline prescribed under the Securities and Exchange Board of India Act, 1992 (SEBI Act) is furnished hereunder for the financial year 2021-22:
 - i. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; **Complied with yearly and event-based disclosures, wherever applicable.**
 - ii. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Amended Regulations 2018; **The Company has framed code of conduct for regulating & reporting trading by insiders and for fair disclosure and displayed the same on the Company's website i.e., www.drhlsl.com**
 - iii. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; **Not Applicable as the Company has not issued any shares during the year under review.**
 - iv. Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; **Not Applicable as the Company has not issued any Employee Stock Options during the year under review.**

- v. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008/ The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; **Not Applicable as the Company has not issued and listed any debt or non-convertible securities during the year under review.**
- vi. The Securities and Exchange Board of India (Registrars to an issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client; **Not Applicable as the Company is not registered as Registrar to an Issue and Share Transfer Agent during the year under review. However, the company has Venture Capital and Corporate Investments Private Limited as its Share Transfer Agent.**
- vii. Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009/2021; **Not Applicable as the company has not delisted/ proposed to delist its equity shares during the year under review.**
- viii. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **Not Applicable as the Company has not bought back/ proposed to buy-back any of its securities during the year under review.**
- ix. Other applicable laws include the following:
 - The Payment of Gratuity Act, 1972
 - Employees Provident Fund and Miscellaneous Provisions Act, 1952
 - Employees State Insurance Act, 1948
 - Income Tax Act, 1961
 - Minimum Wages Act, 1948
 - Payment of Bonus Act, 1965
 - Payment of Wages Act, 1936
 - Goods and Services Tax Act, 2016 and Rules made there under
 - Shops and Establishments Act, 1948
 - Trade License from Greater Hyderabad Municipal Corporation
 - Acts relating to Pharmaceuticals and Bio-Pharma Sector
 - a) Drugs and Cosmetic Act 1940
 - b) T.S. Allopathic Private Medical Care Establishments Registration and Regulation Act, 2002

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (ii) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 were complied with to the extent applicable.

During the period under review the Company has complied with the provisions of the Companies Act, 2013, Rules, Regulations, Guidelines, Standards, etc. mentioned above subject to the following observations:

- a) During the year the Company has conducted 5 meetings of the Board of Directors, 5 meetings of the Audit committee, 1 Meetings of Stakeholder Relationship Committee, 2 meeting of Nomination, Remuneration Committee and 1 meeting of Independent Directors.
- b) As per the information and explanations provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we report that
- (i) The provisions of the Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of:

- External Commercial Borrowings were not attracted to the Company under the financial year under review;
- Overseas Direct Investment by Residents in Joint Venture/Wholly Owned Subsidiary abroad was not attracted to the company under the financial year under report.
- (ii) As per the information and explanations provided by the company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we report that the Company has not made any GDRs/ADRs or any Commercial Instrument under the financial year under report.

We further report that:

- i. The Company that Mr. K.N.V Narendra Kumar is the Chief Financial Officer and Ms. Deepa R. Dudani is the Company Secretary and Compliance Officer of the Company.
- ii. The Company has internal auditors namely M/s. Tungala & Co., Chartered Accountants, Hyderabad.
- iii. The website of the company contains applicable policies as specified by SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 and the provisions of Companies Act, 2013.
- iv. The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. There was a change in the composition of the Board of Directors during the period under review.
- v. Adequate notice of board meeting is given to all the directors along with agenda at least seven days in advance or on shorter notice, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and meaningful participation at the meeting.
- vi. As per the minutes of the meeting duly recorded and signed by the Chairman, the decisions of the Board were unanimous and no dissenting views have been recorded.
- vii. We, further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.
- viii. We further report that during the year under report, the Company has not undertaken event/action having a major bearing on the company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards etc.
- ix. The compliance by the Company of applicable financial laws like Direct and Indirect tax laws has not been reviewed thoroughly in this audit since the same have been subject to review by statutory financial audit and other designated professionals.
- x. The Company was required to file the Secretarial Compliance Report for the year ended 2020-21 within the due date i.e., on or before 30.05.2021 with MSEI, but the same was filed on 30.07.2021 for which a penalty of Rs. 70,800/- was imposed by MSEI. However, the same was waived off by Metropolitan Stock Exchange of India Limited (MSEI).
- xi. The Company was required to file the related party transactions for the half-year ended 30.09.2021 in both pdf and XBRL mode with MSEI. Company had filed the same in XBRL mode only but not in pdf mode for which a penalty of Rs. 1,88,800/- was imposed by MSEI. However, the same was waived off by Metropolitan Stock Exchange of India Limited (MSEI).

For S.S. Reddy & Associates

Sd/-

**S. Sarveswar Reddy
Proprietor**

M No. A12611, CP No. 7478

UDIN: A012611D000788969

Peer Review Cer. No.: 1450/2021

**Place: Hyderabad
Date: 10.08.2022**

ANNEXURE A

To

The Members of

Dr Habeebullah Life Sciences Limited

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have relied on the reports given by the concerned professionals in verifying the correctness and appropriateness of financial records and books of accounts of the company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The secretarial Audit report is neither an assurance as to future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

For S.S. Reddy & Associates

Sd/-

S. Sarveswar Reddy

Proprietor

M No. A12611, CP No. 7478

UDIN: A012611D000788969

Peer Review Cer. No.: 1450/2021

Place: Hyderabad

Date: 10.08.2022

Annexure 3**Form No. AOC-2**

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

This form pertains to the disclosure of particulars of contracts/arrangements entered into between the Company with related parties referred to in Sub-Section (1) of Section 188 of the Companies Act, 2013 including arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at arm's length basis: NotApplicable

- a) Name(s) of the related party and nature of relationship : NotApplicable
- b) Nature of contracts/arrangements/transactions : None
- c) Duration of the contracts/arrangements/transactions : NotApplicable
- d) Salient terms of the contracts or arrangements or
Transactions including the value, if any : NotApplicable
- e) Justification for entering into such contracts or
Arrangements or transactions : NotApplicable
- f) Date(s) of approval of the Board : NotApplicable
- g) Amounts paid as advances, if any : None
- h) Date on which the special resolution was passed in
General meeting as required under first proviso to
Section 188 : NotApplicable

2. Details of material contracts or arrangement or transactions at arm's length basis:

S. No.	Name of the Party	Designation	Nature of Transaction	Amount (in Rs.)
1	Mr. K. Krishnam Raju	Executive Chairman and Whole-time Director	Remuneration Unsecured Loan Rent	- 2,74,07,000 4,52,500
2	Ms. Deepa R Dudani	Company Secretary and Compliance officer	Remuneration	2,64,000
3	Mr. K.N.V. Narendra Kumar	Whole time Director & CFO	Remuneration	6,30,000
4	Innovision Life Sciences Private Limited	Mr. K. Krishnam Raju is Director in the said company	Interest Income	52,58,630

3. Details of contracts or arrangements or transactions not in the ordinary course of business

S.No	Particulars	Details
a)	Name(s) of the related party & nature of relationship	None
b)	Nature of contracts/arrangements/transaction	Nil
c)	Duration of the contracts/arrangements/transaction	Nil
d)	Salient terms of the contracts or arrangements or transaction including the value, if any	None
e)	Justification of entering into such contracts or arrangements or transactions	None
f)	Date of approval by the Board	Not Applicable
g)	Amount paid as advances, if any	Nil
h)	Date on which the special resolution was passed in General Meeting as required under first proviso to Section 188	Not Applicable

All related party transactions that were entered during the financial year were on arms-length basis and are according to the policy of related party transactions adopted by the Company.

**For and on behalf of the Board of
Dr Habeebullah Life Sciences Limited**

**Place: Hyderabad
Date: 10.08.2022**

**Sd/-
K. Krishnam Raju
Executive Chairman & Whole-time Director
(DIN: 00874650)**

Annexure 4**MANAGEMENT DISCUSSION & ANALYSIS REPORT****OVERVIEW:**

The Company has decided to put more focus towards bio-pharma related business than the previous Healthcare related Stem cell Hospitals and Diagnostics. Due to Covid and delay in fund raising and other reasons, we are restructuring our business model and bend towards Bio-pharma. Since the company through its associate company Krisani Bio Sciences Private limited proven its strength in new drug discovery by obtained total 12 international granted patents. The company will continue in research in pharma and planning to tie-up with R&D companies in US and India to take these molecules into commercial stage.

INDUSTRY STRUCTURE AND DEVELOPMENTS:

DR Habeebullah Life Sciences Ltd initially focused on three different verticals called, Stem cell related Hospitals, Molecular Diagnostics and R&D in New Drug Discovery but due to COVID and other reasons, aimed to shifting into Bio-pharma activities like Trading, Exports & imports, manufacturing of Bulk drugs, APIs, Specialty drugs, R&D etc through joint ventures or associations or mergers or by its own. We are under discussions with existing pharma companies in these lines and shall inform to shareholders any developments in these exercises at an appropriate time.

INDIAN PHARMACEUTICAL INDUSTRY:

The Indian pharmaceutical industry is the world's third largest in terms of volume and ranks 11th in terms of value. It is among the faster-growing markets and the largest exporter of generic drugs by volume. Outside of the USA, India has the largest number of USFDA-approved pharmaceutical manufacturing facilities. Going forward, India is likely to maintain a leadership position in the manufacture and supply of High-quality generic medicines as well as a major manufacture of Covid-19 vaccines. The Indian Pharmaceutical market recorded ~9.5% CAGR between 2016-20 to reach US\$ 21 Billion. It is expected to grow at 7.5%-10.5% CAGR tp US\$ 28-32 Billion by 2025.

OUTLOOK:

DRHLSL wish to restrict its business as Biopharma Company and to out from Hospitals and diagnostics business. The Indian pharmaceutical industry is the world's third largest in terms of volume and ranks 11th in terms of value. It is among the faster-growing markets and the largest exporter of generic drugs by volume. Outside of the USA, India has the largest number of USFDA-approved pharmaceutical manufacturing facilities. Going forward, India is likely to maintain a leadership position in the manufacture and supply of high-quality generic medicines as well as a major manufacture of Covid-19 vaccines.

The Indian Pharmaceutical market recorded ~9.5% CAGR between 2016-20 to reach US\$ 21 Billion. It is expected to grow at 7.5%-10.5% CAGR tp US\$ 28-32 Billion by 2025. The outlook of Indian pharma industry is expected to be good for the next one decade; DRHLS expands its R&D division into manufacturing and trading of bio- pharma products.

RISKS AND CONCERNS:

The Company is committed to conducting business in accordance with all applicable statutory laws and regulations, and pursuing its core organizational values. The Company's business model is a bilateral approach. It focuses on striking a balance between the high value creation divisions like Stem cell therapy, new drug discovery on one hand and daily revenue generating divisions likes Molecular Diagnostics on the other. This is aimed at minimizing the risk and maximizing the shareholder wealth.

DRHLSL acknowledges that its research and development, manufacture and sale of products and services may face several challenges such as human capital risk, risk of failure or delay of R&D products in a timely manner, risk arising out of strategic co-development arrangements with a partner, changing global and national political and regulatory landscape amongst others. Although the comprehensive eradication of risks associated with the business of the Company is unfeasible, constant efforts are made to analyze their potential impact, assess the changes to risk environment and define actions to mitigate their adverse impact.

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY:

DRHLSL strongly believes that a robust internal control mechanism is a prerequisite to ensure that an organization functions ethically, complies with all legal and regulatory requirements and observes the generally accepted principles of good corporate governance. To enable this, the Company has established a strong internal control system for the Company, which is comprised of policies, guidelines and procedures to ensure the orderly and efficient financial and business conduct.

DRHLSL has adopted strong internal control systems backed by constant reviews and up-gradation. Internal Audit, Statutory Audit by external agencies and the Audit Committee, look into the internal control aspects and further advice on the corrective measures as and when required.

DISCUSSION ON FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE:

The management discussion and Analysis given below relates to the Audited Financial Statements of Dr. Habeebullah Life Sciences Limited. The discussion should be read in conjunction with the financial statements and related notes for the year ended 31st March 2022.

SUMMARY:

The revenue from the core segment of the business, aggregated to INR 2.25 Lakhs in FY21-22. Combined with a non-operating income of INR 190.62 Lakhs, the Revenue for the year ended 31st March 2022, totaled to INR 192.87 Lakhs.

The Company has generated revenue (operating income) from trading of drugs and medicines during FY 21-22.

MATERIAL DEVELOPMENTS IN HUMAN RESOURCES / INDUSTRIAL RELATIONS FRONT, INCLUDING NUMBER OF PEOPLE EMPLOYED:

DRHLSL's employees are the backbone of the Company. It is their knowledge, scientific skills and innovative capabilities that enable DRHLSL to harness the power of science and serve its clients. DRHLSL recognizes that an inclusive culture which promotes diversity, ethics and integrity is crucial. Through a range of HR- led initiatives, we offer customized training programs to enhance the staff's scientific and leadership skills with special attention to collaborative learning amongst the several teams.

FINANCIAL RATIOS:

RATIOS:			
Particulars	2021-22	2020-21	Remarks
Debtors turnover ratio	0.01	0.08	Decrease in Debtors
Inventory turnover ratio	0.35	1.24	Decrease in Inventory
Interest coverage ratio	N/A	N/A	-
Current ratio	1.84	1.28	Increase in current assets on account of writing off the liability during the year
Debt equity ratio	0.21	0.20	-
Operating profit margin (%)	6649%	-385%	Increase in Operating Profit margin on account of writing off the liability during the year
Net profit margin (%)	6673%	-391%	Increase in Net Profit margin on account of writing off the liability during the year
Return on Net worth	10.12%	-4.29%	Increase in Net Profit on account of Sundry creditors Written off

RETURN ON NET WORTH:

There is a change in the Return on Net Worth which is at 10.12% for the Financial Year 2021-22 as compared to immediately previous year 2020-21 which was at -4.29 %. Reasons for Increase in Net Profit on account of Sundry creditors Written off.

DISCLOSURE OF ACCOUNTING TREATMENT:

Financial Statements are prepared as per Ind AS duly following the principles laid in the Ind AS. Management has not adopted any other standards other than the prescribed Accounting Standards in preparing the financial statements.

CAUTIONARY STATEMENT/ DISCLAIMER CLAUSE:

Certain statements in the Management Discussion and Analysis describing the Company's objectives, predictions may be "forward-looking statements" within the meaning of applicable laws and regulations. Actual results may vary significantly from the forward-looking statements contained in this document due to various risks and uncertainties. These risks and uncertainties include the effect of economic and political conditions in India, new regulations and Government policies that may impact the Company's business as well as its ability to implement the strategy. The Company does not undertake to update this statement.

**For and on behalf of the Board of
Dr Habeebullah Life Sciences Limited**

Sd/-

**K. Krishnam Raju
Executive Chairman & Whole-time Director
(DIN: 00874650)**

**Place: Hyderabad
Date: 10.08.2022**

Annexure 5a

STATEMENT SHOWING THE NAMES OF TOP TEN EMPLOYEES PURSUANT TO SEC. 197 READ WITH RULE 5 (1) (2) and (3) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

1. The ratio of remuneration to each director to the median remuneration of the employees of the company for the financial year.

Director	Total Remuneration (in Rs.)	Ratio to median remuneration
Mr. K.N.V. Narendra Kumar	6,30,000	1.52:1

2. The percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year

Name	Designation	Remuneration (in Rs.)		Increase/ (Decrease) %
		FY 2021-22	FY 2020-21	
Mr. K.N.V. Narendra Kumar	Whole time Director cum CFO	6,30,000	5,25,000	--
Ms. Deepa R. Dudani	Company Secretary and compliance officer	2,64,000	33,785	--

3. The percentage increase in the median remuneration of employees in the financial year

Particulars	Remuneration		Increase/ (Decrease) %
	FY 2021-22	FY 2020-21	
Median Remuneration of all the employees per annum*	46,000	60,500	(23.97)

*Employees who have served for whole of the respective financial years have been considered.

- 4.

Particulars	Number
The number of employees on the rolls of the company as on March 31, 2022	3

5. **Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and details if there are any exceptional circumstances for increase in the managerial remuneration**

Particulars	Increase/ (Decrease) %
Average percentage increase in the remuneration of all Employees*	-
(Other than Key Managerial Personnel)	-
Average Percentage increase in the Remuneration of Key Managerial Personnel	-
*Employees who have served for whole of the respective financial years have been considered.	-

6. **Affirmation that the remuneration is as per the remuneration policy of the company.**

The Company is in compliance with its remuneration policy.

Annexure 5b

List of Top 10 Employees *

In terms of Remuneration drawn as per Rule 5(3) of the Companies (Appointment and Remuneration of Management personnel) Rules 2014:

S . n o	Name of the Employee	Remuneration received	Designation of the employee	Nature of employment whether contractual or otherwise	Qualification and experience of the employee	Date of the commencement of employment	The age of Employee	The employment last held by such employee before joining the Company	The percentage of equity shares held by the employee in the Company within the meaning of clause (iii) of subrule (2) of Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014	Whether any such employee is a relative of any director or manager of the Company and if so name of such director or manager
1	Mr. K.N.V. Narndra Kumar	630000	Whole-time Director and CFO	Permanent	B.com	14.02.2020	43 years	Krisani Bio Sciences Private Limited	Nil	Nil
2	Ms. Deepa R. Dudani	264000	Company Secretary and Compliance officer	Permanent	CS	13.02.2021	30 years	--	Nil	Nil

*The company is having only three employees. Mr. K. Krishnam Raju, Executive Chairman and Whole-time Director of the Company has not drawn any remuneration during the year.

Annexure 6**CORPORATE GOVERNANCE REPORT****COMPANY'S PHILOSOPHY ON CORPORATE GOVERNANCE:**

Corporate Governance is a set of principles, processes and systems to be followed by the Directors, Management and Employees of the Company for enhancement of shareholder value while keeping in view the interest of other stakeholders as well.

Company believes that good corporate governance is the foundation for being a truly sustainable Company.

Set procedures, guidelines and practices have been evolved to ensure timely disclosures of information regarding the financials, performance, significant events and governance etc. of the Company. The Company has adopted a code of conduct for its Board, Key Managerial Personnel (KMPs) and Senior Management Employees which has been communicated to them and they have affirmed the compliances of the same through their annual disclosures to the Company.

The Company lays emphasis on transparency across the entire spectrum of its business as well as in discharging its Corporate Social Responsibility activities in a meaningful manner. The Company, as a conscientious corporate citizen, is fully committed to the principles of integrity, transparency and compliance with applicable regulations while dealing with the Government, Customers, Suppliers, Employees and other Stakeholders. Directors fully endorse and support the Corporate Governance practices in accordance with the provisions of Listing Regulations of SEBI.

DATE OF REPORT

The information provided in the Report on Corporate Governance for the purpose of unanimity is as on 31st March, 2022. The Report is updated as on the date of the report wherever applicable.

BOARD DIVERSITY:

The Company recognizes and embraces the importance of a diverse Board in its success. We believe that a truly diverse Board will leverage differences in thought, perspective, knowledge, skill, regional and industry experience, cultural and geographical background, age, ethnicity, race and gender, which will help us retain our competitive advantage. The Board has adopted the Board Diversity Policy which sets out the approach to diversity of the Board of Directors. The Board Diversity Policy is available on our website i.e. www.drhlsl.com.

BOARD OF DIRECTORS**A. COMPOSITION OF THE BOARD**

The Company is managed and controlled through a professional body of Board of Directors which comprises of an optimum combination of Executive and Independent Directors headed by the Chairman & whole-time Director. As on date of this report, the Board of Directors of the Company has 6 members (including four independent Non-Executive Directors) with vast experience and knowledge. None of the Directors on the Board is a Member of more than 10 committees or Chairman of more than 5 companies across all the Companies in which he/she is a Director.

The Board has been enriched with the advices and skills of the Independent Directors. The composition of the Board of Directors and details of number of Directorships/committee chairmanships/memberships attendance particulars is as under:

Dates on which Board meetings were held: 11.06.2021, 29.06.2021, 11.08.2021, 12.11.2021, and 27.01.2022.

Name	Category	Attendance at the AGM held on 15.09.2021	Attendance in Board Meetings		No. of Directorships in other companies (name of the listed company to be mentioned)		No. of committee positions held in other public companies	
			Held [^]	Present	Chairman	Director	Chairman	Member (include chairmanship)
Mr. K. Krishnam Raju	Promoter, Executive Chairman and whole-time Director	Yes	5	5	-	-	-	-
Mr. K.N.V Narendra Kumar**	Whole time Director & CFO	Yes	3	3	-	-	-	-
Mr. B. Suryaprakasa Rao	Independent Director	Yes	5	5	-	4	4	5
Ms. Aakanksha \$	Independent Director	Yes	4	4	-	4	1	6
Mr. Y. Rama Mohan Reddy\$	Independent Director	Yes	4	4	-	4	2	6
Dr. A.S.S.V. Srinivas**	Independent Director	Yes	3	3	-	-	--	--
*Dr. Mohammed Aejaaz Habeeb	Promoter and Non Executive Director	NA	2	2	-	-	--	--
*Dr. Syed Ameer Basha Paspala	Promoter and -Non Executive Director	NA	2	2	-	-	--	--
@Dr. Akka Jyothy	Independent Director	NA	2	2	-	-	--	--
@Dr. T.V. Rama Krishna Murthy	Independent Director	NA	2	2	-	--	--	--

[^]held during the tenure of the director

* resigned w.e.f 29.06.2021

@ resigned w.e.f 02.07.2021

** appointed w.e.f 02.07.2021

\$ appointed w.e.f 29.06.2021

The Name of other listed entities where directors of the company are directors and the category of directorship are shown in Table 2.

Table 2		
Name of Director	Name of listed entities in which the concerned Director is a Director	Category of Directorship
Mr. B. Suryaprakasa Rao	1. Jeevan Scientific and Technology Limited 2. Bandaram Pharma Packtech Limited 3. Punit Commercials Limited	Independent Director
Ms. Aakanksha	1. Vintage Coffee and Beverages Limited 2. Palred Technologies Limited 3. Punit Commercials Limited	Independent Director
Mr. Y. Rama Mohan Reddy	1. Taaza International Limited 2. Sankhya Infotech Limited 3. G.R. Cables Limited	Independent Director

B. A CHART OR A MATRIX SETTING OUT THE SKILLS/EXPERTISE/COMPETENCE OF THE BOARD OF DIRECTORS:

Sl.No	Skills / Expertise / Competence of the Board of Directors are required in the context of business of the Company	Names of the Directors who have such skills / expertise / competence
1	Strategic planning & Management	Mr. K. Krishnam Raju
2.	Accounting , Finance & Taxation	Mr. K.N.V Narendra Kumar , Mr. B. Suryaprakasa Rao, Mr. Y. Rama Mohan Reddy
3	Regulatory, Corporate Governance & Compliance Management	Mr. K. Krishnam Raju, Ms. Aakanksha
4	Research & Development	Dr. A.S.S.V. Srinivas

C. DISCLOSURE OF RELATIONSHIPS BETWEEN DIRECTORS INTER-SE

There is no relationship between Director to Director/ promoter and Directors of the Company.

D. NUMBER OF SHARES AND HELD BY NON-EXECUTIVE DIRECTORS:

As on date, none of the Non-Executive directors of the company holds any Equity Shares in the company.

E. INDEPENDENT DIRECTORS

The Company has complied with the definition of Independence as per Regulation 16(1) (b) of the SEBI (LODR), Regulations, 2015 and according to the Provisions of Section 149(6) of the Companies Act, 2013.

The Company has also obtained declarations from all the Independent Directors pursuant to Section 149(7) of the Companies Act, 2013. It is also confirmed that in the opinion of the Board, the Independent Directors fulfil the conditions specified in the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are independent of the management.

During the year under review, Dr. T.V. Rama Krishna Murthy and Dr. A. Jyothy have resigned as Independent Directors of the company due to their pre - occupation and have confirmed that there is no other material reason other than this. Further, Ms. Aakanksha and Mr. Y. Rama Mohan Reddy were appointed as Independent Directors of the Company w.e.f. 29.06.2021.

F. INDEPENDENT DIRECTORS' MEETING: As per Clause 7 of the Schedule IV of the Companies Act (Code for Independent Directors), a separate meeting of the Independent Directors of the Company (without the attendance of Non-Independent Directors) was held on 27.01.2022, and discussed the following:

1. Evaluation of the performance of Non-Independent Directors and the Board of Directors as whole;
2. Evaluation of the quality, content and timelines of flow of information between the management and the Board that is necessary for the Board to effectively and reasonably perform its duties.

All the Independent Directors of the Company eligible to attend were present at the meeting.

As required under Regulation 34(3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the Company regularly familiarizes Independent Directors with the Company, their roles, rights, responsibilities in the Company, nature of the industry in which the Company operates, business model of the Company etc.

G. FAMILIARIZATION PROGRAM FOR INDEPENDENT DIRECTORS:

Independent Directors are familiarized about the Company's operations and businesses. Interaction with the Business heads and key executives of the Company is also facilitated. Detailed presentations on important policies of the Company are also made to the directors.

The details of Familiarization Programme held in FY 2021-22 are also disclosed on the Company's website at www.drhlsl.com.

H. INFORMATION SUPPLIED TO THE BOARD:

The Board has complete access to all information of the Company and is regularly provided advanced detailed information as a part of the agenda papers or is tabled therein. In addition, detailed quarterly performance report by the CFO is presented in the quarterly Board meeting, encompassing all facets of the Company's operations during the quarter etc.

I. DECLARATION BY BOARD:

The Board has confirmed that in its opinion, the Independent Directors fulfil the conditions specified in these regulations and are independent of the management.

J. COMMITTEES OF THE BOARD:

The Company has three Board-level Committees - Audit Committee, Stakeholders Relationship Committee and Nomination & Remuneration Committee.

All decisions pertaining to the constitution of Committees, appointment of members and fixing of terms of service for Committee members are taken by the Board of Directors. Details on the role and composition of these Committees, including the number of meetings held during the financial year and the related attendance are provided in this report below:

1. **AUDIT COMMITTEE:** (Audit Committee constituted in terms of Section 177 of Companies Act, 2013 read with Regulation 18 of SEBI (LODR) Regulations, 2015)

A. BRIEF DESCRIPTION OF TERMS OF REFERENCE:

The terms of reference of the Audit Committee encompasses the requirements of Section 177 of Companies Act, 2013 and as per Regulation 18 of SEBI (LODR) Regulations, 2015 and, inter alia, includes

- i. Oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- ii. Recommending the appointment and removal of External Auditors, fixation of audit fee and approval for payment for any other services;
- iii. Reviewing the utilization of loans and/ or advances from/investment by the holding company in the subsidiary exceeding Rs. 100 Crores or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments existing as on the date of coming into force of this provision.

- iv. Review with the management and statutory auditors of the annual financial statements before submission to the Board with particular reference to:
 - (a) Matters required to be included in the directors' responsibility statement to be included in the Board's report in terms of clause (c) of sub-section (3) of Section 134 of the Act;
 - (b) Changes, if any, in accounting policies and practices and reasons for the same;
 - (c) Major accounting entries involving estimates based on the exercise of judgment by management;
 - (d) Significant adjustments made in the financial statements arising out of audit findings;
 - (e) Compliance with listing and other legal requirements relating to financial statements;
 - (f) Disclosure of any related party transactions;
 - (g) Modified opinion(s) in the draft audit report;
- v. Review of the quarterly and half yearly financial results with the management before submission to the board for approval;
- vi. Reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the board to take up steps in this matter;
- vii. Review and monitor statutory auditor's independence and performance and effectiveness of audit process;
- viii. Approval or any subsequent modification of transactions with related parties;
- ix. Scrutiny of inter-corporate loans and investments;
- x. Review of valuation of undertakings or assets of the company wherever it is necessary;
- xi. Evaluation of internal financial controls and risk management systems;
- xii. Review with the management, statutory auditors and the internal auditors about the nature and scope of audits and of the adequacy of internal control systems;
- xiii. Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure, coverage and frequency of internal audit;
- xiv. discussion with internal auditors of any significant findings and follow up there on;
- xv. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;
- xvi. discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- xvii. Look into the reasons for any substantial defaults in payment to the depositors, debenture-holders, shareholders (in case of non-payment of declared dividend) and creditors, if any;
- xviii. Review the functioning of the whistle blower mechanism;
- xix. Approval of appointment of Chief Financial Officer after assessing the qualifications, experience and background, etc. of the candidate
- xx. Review of the following information:
 - (a) Management discussion and analysis of financial condition and results of operations;

- (b) Management letters / letters of internal control weaknesses issued by the statutory auditors;
- (c) Internal audit reports relating to internal control weaknesses;
- (d) The appointment, removal and terms of remuneration of the Chief Internal Auditor; (f) Statement of deviations:
 - Quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1) of the Listing Regulations.
 - Annual statement of funds utilized for purposes other than those stated in the offer document/ prospectus in terms of Regulation 32(7) of the Listing Regulations.
- xxi. Carrying out any other function as may be referred to the Committee by the Board.
- xxii. Authority to review / investigate into any matter covered by Section 177 of the Companies Act, 2013 and matters specified in Part C of Schedule II of the Listing Regulations.
- xxiii. consider and comment on rationale, cost-benefits and impact of schemes involving merger, demerger, amalgamation etc., on the listed entity and its shareholders.

B. COMPOSITION, MEETINGS & ATTENDANCE

There were five (5) Audit Committee Meetings held during the year on 11.06.2021, 29.06.2021, 11.08.2021, 12.11.2021 and 27.01.2022.

Name	Designation	Category	No of Meetings held	No of Meetings attended
Mr. B. Suryaprakasa Rao	Independent Director	Chairman	5	5
\$Mr. Y. Rama Mohan Reddy	Independent Director	Member	4	4
**Dr. A.S.S.V. Srinivas	Independent Director	Member	4	4
*Dr. Syed Ameer Basha Paspala	Non - Executive Director	Member	2	2
@Dr. Akka Jyothy	Independent Director	Member	2	2
@Dr. T.V. Rama Krishna Murthy	Independent Director	Member	2	2

^held during the tenure of the member

* resigned w.e.f. 29.06.2021

@ resigned w.e.f. 02.07.2021

** appointed w.e.f. 02.07.2021

\$ appointed w.e.f. 29.06.2021

- C. Previous Annual General Meeting of the Company was held on 15th September 2021 and Mr. B. Suryaprakasa Rao, Chairman of the Audit Committee for that period, attended previous Annual General Meeting.

2. NOMINATION AND REMUNERATION COMMITTEE (Nomination and Remuneration Committee constituted in terms of Section 178 of Companies Act, 2013 read with Regulation 19 of SEBI (LODR) Regulations, 2015).

The terms of reference of the Nomination and Remuneration committee constituted in terms of Section 178 of Companies Act, 2013 and as per Regulation 19 of SEBI (LODR) Regulations, 2015 are as under:

A. BRIEF DESCRIPTION OF TERMS OF REFERENCE

To approve the fixation/revision of remuneration of Executive Directors of the Company and while approving:

- a. To take into account the financial position of the Company, trend in the industry, appointee's qualification, experience, past performance, past remuneration etc.
- b. To bring out objectivity in determining the remuneration package while striking a balance between the interest of the Company and the Shareholders.
- c. To identify persons who are qualified to become Directors and who may be appointed in senior management in accordance with the criteria laid down and to recommend to the Board their appointment and /or removal.
- d. To carry out evaluation of every Director's performance.
- e. To formulate the criteria for determining qualifications, positive attributes and independence of a Director, and recommend to the Board a policy, relating to the remuneration for the Directors, key managerial personnel and other employees.
- f. For every appointment of an independent director, the Nomination and Remuneration Committee shall evaluate the balance of skills, knowledge and experience on the Board and on the basis of such evaluation, prepare a description of the role and capabilities required of an independent director. The person recommended to the Board for appointment as an independent director shall have the capabilities identified in such description. For the purpose of identifying suitable candidates, the Committee may:
 - a. use the services of an external agencies, if required;
 - b. consider candidates from a wide range of backgrounds, having due regard to diversity; and
 - c. consider the time commitments of the candidates.
- g. To formulate the criteria for evaluation of Independent Directors and the Board.
- h. To recommend/review remuneration of the Managing Director and Whole-time Director(s) based on their performance and defined assessment criteria.
- i. devising a policy on diversity of board of directors;
- j. whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors.
- k. Recommend to the board, all remuneration, in whatever form, payable to senior management.

B. COMPOSITION OF THE NOMINATION AND REMUNERATION COMMITTEE, MEETINGS & ATTENDANCE

Two Nomination and Remuneration Committee Meetings were held during the financial year on 29.06.2021&11.08.2021.

Name	Designation	Category	No of Meetings held	No of Meetings attended
@Dr. Akka Jyothy	Independent, Non-Executive	Chairperson	1	1
@Dr. T.V. Rama Krishna Murthy	Independent, Non-Executive	Member	1	1
**Dr. A.S.S.V. Srinivas	Independent, Non-Executive	Chairman	1	1
Mr. B. Surya Prakasa Rao	Independent, Non-Executive	Member	2	2
\$Mr. Y. Rama Mohan Reddy	Independent, Non-Executive	Member	1	1

^held during the tenure of the member

@ resigned w.e.f. 02.07.2021

** appointed w.e.f. 02.07.2021

\$ appointed w.e.f. 29.06.2021

C. REMUNERATION POLICY:

The objectives of the remuneration policy are to motivate Directors to excel in their performance, recognize their contribution and retain talent in the organization and reward merit. The remuneration levels are governed by industry pattern, qualifications and experience of the Directors, responsibilities shouldered and individual performance.

POLICY FOR SELECTION OF DIRECTORS AND DETERMINING DIRECTORS' INDEPENDENCE:**1. Scope:**

This policy sets out the guiding principles for the Nomination & Remuneration Committee for identifying persons who are qualified to become Directors and to determine the independence of Directors, in case of their appointment as independent Directors of the Company.

2. Terms and References:

2.1 "Director" means a Director appointed to the Board of a Company.

2.2 "Nomination and Remuneration Committee" means the committee constituted in accordance with the provisions of Section 178 of the Companies Act, 2013 and Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2.3 "Independent Director" means a Director referred to in sub-Section (6) of Section 149 of the Companies Act, 2013 and Regulation 16 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3. Policy:

Qualifications and criteria

3.1.1 The Nomination and Remuneration Committee, and the Board, shall review on annual basis, appropriate skills, knowledge and experience required of the Board as a whole and its individual members. The objective is to have a board with diverse background and experience that are relevant for the Company's operations.

3.1.2 In evaluating the suitability of individual Board member the Nomination and Remuneration Committee may take into account factors, such as:

- General understanding of the Company's business dynamics, global business and social perspective;
- Educational and professional background
- Standing in the profession;
- Personal and professional ethics, integrity and values;
- Willingness to devote sufficient time and energy in carrying out their duties and responsibilities effectively.

3.1.3 The proposed appointee shall also fulfil the following requirements:

- shall possess a Director Identification Number;
- shall not be disqualified under the companies Act, 2013;
- shall Endeavour to attend all Board Meeting and wherever he is appointed as a Committee member, the committee meeting;
- shall abide by the code of conduct established by the company for Directors and senior management personnel;
- shall disclose his concern or interest in any Company or companies or bodies corporate, firms, or other association of individuals including his shareholding at the first meeting of the Board in every financial year and thereafter whenever there is a change in the disclosures already made;

- Such other requirements as any prescribed, from time to time, under the Companies Act, 2013, Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other relevant laws.

3.1.4 The Nomination & Remuneration Committee shall evaluate each individual with the objective of having a group that best enables the success of the Company's business.

3.2 Criteria of Independence

3.2.1 The Nomination & Remuneration Committee shall assess the independence of Directors at time of appointment/ re-appointment and the Board shall assess the same annually. The Board shall re-assess determinations of independence when any new interest or relationships are disclosed by a Director.

3.2.2 The criteria of independence shall be in accordance with the guidelines as laid down in Companies Act, 2013 and Regulation 16 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

An independent Director in relation to a Company, means a Director other than a managing Director or a whole-time Director or a nominee Director

- who, in the opinion of the Board, is a person of integrity and possesses relevant expertise and experience;
- (i) who is or was not a promoters of the Company or its holding, subsidiary or associate Company or member of the promoter group of the listed entity;
- (ii) who is not related to promoters or Directors of the Company its holding, subsidiary or associate Company
- who, apart from receiving director's remuneration, who has or had no pecuniary relationship with the Company, its holding, subsidiary or associate Company, or their promoters, or Director, during the two immediately preceding financial year or during the current financial year;

d. none of whose relative

- is holding securities of or interest in the listed entity, its holding, subsidiary or associate company during the three immediately preceding financial years or during the current financial year of face value in excess of fifty lakh rupees or two percent of the paid-up capital of the listed entity, its holding, subsidiary or associate company, respectively, or such higher sum as may be specified;
- is indebted to the listed entity, its holding, subsidiary or associate company or their promoters or directors, in excess of such amount as may be specified during the three immediately preceding financial years or during the current financial year;
- has given a guarantee or provided any security in connection with the indebtedness of any third person to the listed entity, its holding, subsidiary or associate company or their promoters or directors, for such amount as may be specified during the three immediately preceding financial years or during the current financial year; or
- has any other pecuniary transaction or relationship with the listed entity, its holding, subsidiary or associate company amounting to two percent or more of its gross turnover or total income:

Provided that the pecuniary relationship or transaction with the listed entity, its holding, subsidiary or associate company or their promoters, or directors in relation to points (A) to (D) above shall not exceed two percent of its gross turnover or total income or fifty lakh rupees or such higher amount as may be specified from time to time, whichever is lower.

e. who, neither himself nor any of his relative-

- Holds or has held the position of a key managerial personnel or is or has been employee of the or associate Company or any company belonging to the promoter group of the listed entity in any of the three financial years immediately preceding the financial year in which he is proposed to be appointed;

Provided that in case of a relative, who is an employee other than key managerial personnel, the restriction under this clause shall not apply for his / her employment

- (ii) Is or has been an employee or proprietor or a partner, in any of the three financial year immediately preceding the financial year in which he is proposed to be appointed of-
 - (A) a firm of auditors or Company secretaries in practice or cost auditors of the Company or its holding, subsidiary or associate Company; or
 - (B) any legal or a consulting firm that has or had any transaction with the Company, its holding subsidiary or associate Company amounting to ten per cent or more of the gross turnover of more of the gross turnover of such firm;
- (i) holds together with his relatives two per cent or more of the total voting power of the Company; Or
- (ii) is a chief Executive or Director, by whatever name called, of any non-profit organization that receives twenty-five per cent or more of its receipt from the Company any of its promoters, Directors or its holding subsidiary or associate Company or that holds two per cent or more of the total voting power of the Company; or
- (iii) is a material supplier, service provider or customer or a lesser or lessee of the Company.
- f. Shall possess appropriate skills experience and knowledge in one or more field of finance, law Management, sales, marketing administration, research, corporate governance, technical operations, corporate social responsibility or this disciplines related to the Company's business.
- g. Shall possess such other qualifications as may be prescribed from time to time, under the Companies Act, 2013.
- h. who is not less than 21 years of age
- i. Who is not a non-independent Director of another company on the Board of which any non-independent director of the listed entity is an independent director.

3.2.3 The independent Director shall abide by the "code for independent Directors "as specified in Schedule IV to the companies Act, 2013.

3.3 Other Directorships/ Committee Memberships

- 3.3.1 The Board members are expected to have adequate time and expertise and experience to contribute to effective Board performance Accordingly, members should voluntarily limit their Directorships in other listed public limited companies in such a way that it does not interfere with their role as Director of the Company. The Nomination and Remuneration Committee shall take into account the nature of, and the time involved in a director service on other Boards, in evaluating the suitability of the individual Director and making its recommendations to the Board.
- 3.3.2 A Director shall not serve as Director in more than 20 companies of which not more than 10 shall be public limited companies.
- 3.3.3 A Director shall not serve as an independent Director in more than 7 listed companies and not more than 3 listed companies in case he is serving as a whole-time Director in any listed Company.
- 3.3.4 A Director shall not be a member in more than 10 committee or act as chairman of more than 5 committee across all companies in which he holds Directorships.

For the purpose of considering the limit of the committee, Audit committee and stakeholder's relationship committee of all public limited companies, whether listed or not, shall be included and all other companies including private limited companies, foreign companies and companies under Section 8 of the companies Act, 2013 shall be excluded.

D. Remuneration policy for Directors, key managerial personnel and other employees:

The objectives of the remuneration policy are to motivate Directors to excel in their performance, recognize their contribution and retain talent in the organization and reward merit. The remuneration levels are governed by industry pattern, qualifications and experience of the Directors, responsibilities shouldered and individual performance.

Remuneration policy for Directors, key managerial personnel and other employees

1. Scope:

- 1 This policy sets out the guiding principles for the Nomination and Remuneration committee for recommending to the Board the remuneration of the Directors, key managerial personnel and other employees of the Company.
2. Terms and Reference: In this policy the following terms shall have the following meanings:
 - 2.1 “Director” means a Director appointed to the Board of the Company.
 - 2.2 “key managerial personnel” means
 - (i) The Chief Executive Officer or the managing Director or the manager;
 - (ii) The Company Secretary;
 - (iii) The Whole-time Director;
 - (iv) The Chief Financial Officer; and
 - (v) Such other office as may be prescribed under the companies Act, 2013
 - 2.3 “Nomination and Remuneration committee” means the committee constituted by Board in accordance with the provisions of Section 178 of the companies Act, 2013, clause 49 of the Equity Listing Agreement and Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
3. Policy:
 - 3.1 Remuneration to Executive Director and key managerial personnel
 - 3.1.1 The Board on the recommendation of the Nomination and Remuneration (NR)
 - 3.1.2 The Board on the recommendation of the NR committee shall also review and approve the remuneration payable to the key managerial personnel of the Company.
 - 3.1.3 The remuneration structure to the Executive Director and key managerial personnel shall include the following components:
 - (i) Basic pay
 - (ii) Perquisites and Allowances
 - (iii) Stock Options
 - (iv) Commission (Applicable in case of Executive Directors)
 - (v) Retrial benefits
 - (vi) Annual performance Bonus
 - 3.1.4 The Annual plan and Objectives for Executive committee shall be reviewed by the Nomination and Remuneration committee and Annual performance bonus will be approved by the committee based on the achievement against the Annual plan and Objectives.
 - 3.2 Remuneration to Non – Executive Directors
 - 3.2.1 The Board, on the recommendation of the Nomination and Remuneration Committee, shall review and approve the remuneration payable to the Non – Executive Directors of the Company within the overall limits approved by the shareholders as per the provisions of the Companies Act.
 - 3.2.2 Non – Executive Directors shall be entitled to sitting fees attending the meetings of the Board and the Committees thereof. The Non- Executive Directors shall also be entitled to profit related commission in addition to the sitting fees.

3.3. Remuneration to other employees

- 3.3.1. Employees shall be assigned grades according to their qualifications and work experience, competencies as well as their roles and responsibilities in the organization. Individual remuneration shall be determined within the appropriate grade and shall be based on various factors such as job profile skill sets, seniority, experience and prevailing remuneration levels for equivalent jobs.

E. MECHANISM FOR EVALUATION OF THE BOARD:

Evaluation of all Board members is performed on an annual basis. The evaluation is performed by the Board, Nomination and Remuneration Committee and Independent Directors with specific focus on the performance and effective functioning of the Board and Individual Directors.

In line with Securities and Exchange Board of India Circular No. SEBI/HO/CFD/CMD/CIR/P/2017/004, dated January 5, 2017 and the Companies Amendment Act, 2017 the Company adopted the recommended criteria by Securities and Exchange Board of India.

The Directors were given six Forms for evaluation of the following:

- (i) Evaluation of Board;
- (ii) Evaluation of Committees of the Board;
- (iii) Evaluation of Independent Directors;
- (iv) Evaluation of Chairperson;
- (v) Evaluation of Non-Executive and Non-Independent Directors; and
- (vi) Evaluation of Whole time Director.

The Directors were requested to give following ratings for each criteria:

1. Could do more to meet expectations;
2. Meets expectations; and
3. Exceeds expectations.

The Directors have sent the duly filled forms to Nomination & Remuneration committee. Based on the evaluation done by the Directors, the Committee has prepared a report and submitted the Evaluation Report. Based on the report, the Board of Directors has informed the rankings to each Director and also informed that the performance of Directors is satisfactory and they are recommended for continuation as Directors of the Company.

F. REMUNERATION TO DIRECTORS:

Name of the Director	Remuneration (Rs)	Sitting Fee (Rs)	Total (Rs)	No. of Equity Shares held
Mr. K. Krishnam Raju	-	-	-	28,99,630
Mr. K.N.V Narendra Kumar	6,30,000	-	6,30,000	-
Mr. B. Surya prakasa Rao	-	-	-	-
Ms. Aakanksha	-	-	-	-
Mr. Y. Rama Mohan Reddy	-	-	-	-
Dr. A.S.S.V. Srinivas	-	-	-	-

Except for the remuneration details mentioned above, there is no other pecuniary relationship or transactions of the non-executive Director's vis-à-vis the listed entity in terms of salary, benefits, bonuses, stock options, pension, fixed component and performance linked incentives.

G. PERFORMANCE EVALUATION CRITERIA FOR INDEPENDENT DIRECTORS:

The performance evaluation criteria for Independent Directors are already mentioned under the head "Board Evaluation" in Directors' Report.

H. WEB LINK FOR CRITERIA OF MAKING PAYMENTS TO NON-EXECUTIVE DIRECTORS: www.drhlsl.com

3. STAKEHOLDERS RELATIONSHIP COMMITTEE:

(Stakeholders Relationship Committee constituted in terms of Section 178(5) of Companies Act, 2013 read with Regulation 20 of SEBI (LODR) Regulations, 2015)

A. BRIEF DESCRIPTION OF TERMS OF REFERENCE: The Committee's role includes:

- Resolving the grievances of the security holders of the Company including complaints related to transfer/transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, general meetings etc;
- Review of measures taken for effective exercise of voting rights by shareholders;
- Review of adherence to the service standards adopted by the Company in respect of various services being rendered by the Registrar & Share Transfer Agent;
- Review of the various measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the company;
- Such other matter as may be specified by the Board from time to time.
- Authority to review / investigate into any matter covered by Section 178 of the Companies Act, 2013 and matters specified in Part D of Schedule II of the Listing Regulations.

B. COMPOSITION OF THE STAKEHOLDER RELATIONSHIP COMMITTEE, MEETINGS & ATTENDANCE:

During the Financial Year April 2021 to March 2022, One (1) Stakeholders Relationship Committee Meeting was held. The date on which the said meeting was held is 27.01.2022.

Name	Designation	Category	No of Meetings held	No of Meetings attended
@Dr. Akka Jyothy	Independent, Non-Executive	Member	--	--
@Dr. T.V. Rama Krishna Murthy	Independent, Non-Executive	Chairman	--	--
*Dr. Mohammed Aejaz Habeeb	Non - Executive Director	Member	--	--
\$Mr. Y. Rama Mohan Reddy	Independent, Non-Executive	Chairman	1	1
Mr. B. Suryaprakasa Rao	Independent, Non-Executive	Member	1	1
**Dr. A.S.S.V. Srinivas	Independent, Non-Executive	Member	1	1

^held during the tenure of the director

* resigned w.e.f 29.06.2021

@ resigned w.e.f 02.07.2021

** appointed w.e.f 02.07.2021

\$ appointed w.e.f 29.06.2021

C. NAME AND DESIGNATION OF COMPLIANCE OFFICER

Ms. Deepa R. Dudani, Company Secretary of the Company is the Compliance Officer of the Company

D. DETAILS OF COMPLAINTS/REQUESTS RECEIVED, RESOLVED AND PENDING DURING THE YEAR 2021-22

INVESTOR COMPLAINTS	
Particulars	Year ended 31.03.2022
Pending at the beginning of the year	0
Received during the year	0
Disposed of during the year	0
Remaining unresolved at the end of the year	0

K. GENERAL BODY MEETINGS**1. LOCATION, DATE AND TIME OF LAST THREE AGMS AND SPECIAL RESOLUTIONS THERE AT AS UNDER:**

Year	Date	Time	Venue	Special Resolution Passed
2018-19	28.09.2019	10.30 am	2-5-36/CLRD/1, Survey No. 36, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad– 500048, Telangana	Yes
2019-20	26.12.2020	11.00 am	Through Video conference	Yes
2020-21	15.09.2021	09.00 am	Through Video conference	Yes

2. PASSING OF RESOLUTIONS BY POSTAL BALLOT

There were no resolutions passed by the Company through Postal Ballot during the Financial Year 2021-22.

L. MEANS OF COMMUNICATION:

- i. The Board of Directors of the Company approves and takes on record the quarterly, half yearly and yearly financial results in the Performa prescribed by Regulation 33 of SEBI (LODR), Regulations, 2015 within forty-five days/sixty days of the close of the respective period.

Company Registration Details	The Company is registered in the State of Telangana, India. The Corporate Identity Number (CIN) allotted to the Company by the Ministry of Corporate Affairs (MCA) is L85110TG1996PLC099198
Date	17.09.2022
Time	11.00 A.M
Venue of AGM	Through video conference
Tentative Schedule for considering Financial Results:	
For the Quarter ending June,2022	10.08.2022
For the Quarter ending September, 2022	October/ November, 2022
For the Quarter ending December,2022	January/ February, 2022
For the Quarter/year ending March, 2023	April/ May, 2023
Date of Book Closure	10 th September,2022 to 17 th September, 2022

Name and address of each stock exchange(s) at which the Company's securities are listed	BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400 023 Metropolitan Stock Exchange of India limited Vibjyor Towers, 4 th Floor, Plot. No. C62, Opp. Trident Hotel, Bandra Kurla Complex, Bandra€ Mumbai -400098
Confirmation of Payment of annual listing fees to stock exchanges	Paid to BSE Limited & Metropolitan Stock Exchange of India Limited, where the shares of the Company are listed
Scrip Code	BSE – 539267, MSEI - DRHABEEB
ISIN Number for NSDL & CDSL	INE579N01018
In case the securities are suspended from trading, the directors report shall explain the reason thereof In case the securities are suspended from trading, the directors report shall explain the reason thereof	The securities of the Company are not suspended from trading by the Stock Exchanges.
Plant Location	Nil
Address for correspondence:	6-3-354/13/B2, Flat. No. B2, Suryateja Apartments Hindi Nagar, Punjagutta Hyderabad-500082 Telangana.
List of all Credit Ratings obtained by the entity along with any revisions thereto during the relevant financial year, for all debt instruments of such entity or any fixed deposit programme or any scheme or proposal of the listed entity involving mobilization of funds, whether in India or abroad.	Since the Company has not issued any Debt Instruments or Fixed Deposit Programme, therefore company has not obtained any Credit Ratings during the Financial Year.
Address for Correspondence RTA	M/s. Venture Capital & Corporate Investments Private Limited 12-10-167, Bharat Nagar, Hyderabad – 500018, Telangana State, India Contact No: 040 23818475/23818476 E-mail: info@vccilindia.com Website: www.vccilindia.com
Investor Correspondence / Query on Annual Report, etc.	Deepa R. Dudani Company Secretary and Compliance Officer 6-3-354/13/B2, Flat.No.B2, Suryateja Apartments Hindi Nagar, Punjagutta Hyderabad-500082 Telangana. Ph.No. : 040 2970 3333 E-Mail : investorrelations@drhlsl.com Website: www.drhlsl.com

a. Registrars & Transfer Agents:

Venture Capital & Corporate Investments Private Limited

12-10-167, Bharat Nagar, Hyderabad – 500018, Telangana State, India

Contact No: 040 23818475/23818476- E-mail: info@vccilindia.com Website: www.vccilindia.com

b. Share transfer system:

The transfers are normally processed within 10-12 days from the date of receipt, if the documents are complete in all respects. The Company Secretary has been empowered to approve the transfer of shares.

Effective April 1, 2019, SEBI has amended Regulation 40 of the SEBI Listing Regulations, which deals with transfer, transmission or transposition of securities. According to this amendment, the requests for effecting the transfer of listed securities shall not be processed unless the securities are held in dematerialised form with a Depository. Therefore, for effecting any transfer, the securities shall mandatorily be required to be in demat form.

The transmission or transposition of securities held in physical or dematerialised form shall be effected only in dematerialised form.

According to SEBI, this amendment will bring the following benefits:

- It shall curb fraud and manipulation risk in physical transfer of securities by unscrupulous entities.
- Transfer of securities only in demat form will improve ease, convenience and safety of transactions for investors.

c. MARKET PRICE DATA:

MONTHLY HIGH/LOW OF MARKET PRICE OF THE COMPANY'S SHARES TRADED ON THE BSE LIMITED.

S.No	Month	Open Price (in Rs.)	High Price (in Rs.)	Low Price (in Rs.)	Close Price (inRs.)
1	Apr-21	45.80	48.05	38.85	38.85
2	May-21	38.85	40.75	30.95	31.20
3	Jun-21	32.75	38.15	27.90	30.75
4	Jul-21	29.50	34.90	28.10	31.20
5	Aug-21	30.60	33.70	25.20	29.55
6	Sep-21	29.55	42.70	27.75	42.05
7	Oct-21	40.40	44.15	26.50	28.50
8	Nov-21	27.95	29.10	23.00	23.15
9	Dec-21	23.15	27.50	22.80	27.30
10	Jan-22	28.60	34.90	25.30	31.50
11	Feb-22	32.15	33.10	27.55	28.60
12	Mar-22	29.95	31.00	25.55	28.50

d. SHAREHOLDING PATTERN AS ON 31ST MARCH, 2022:

S. No	Category	No. of shares held	% of shareholding
A	SHAREHOLDING OF PROMOTER AND PROMOTER GROUP		
1.	Indian	--	--
	Individual	78,29,030	52.87
	Body Corporate	--	--
2.	Foreign	--	--
	Individual	--	--
	Sub-Total A	78,29,030	52.87
B	PUBLIC SHAREHOLDING		
1.	Institutions	--	--
2.	Non-Institutions		
	a. Bodies Corporate	2,10,898	1.42
	b. Indian Public	59,58,517	40.24
	c. Foreign	8,09,795	5.47
	d. Clearing Members	466	0.00
	Sub Total B	69,79,676	47.13
	Grand Total (A+B)	1,48,08,706	100.00

e. DISTRIBUTION OF SHAREHOLDING AS ON 31.03.2022

Category (Amount)	No. of Cases	% of Cases	Total Shares	Amount	% of Amount
Upto - 5000	946	76.85	919,10	919100	0.62
5001 - 10000	71	5.77	61144	611440	0.41
10001 - 20000	44	3.57	66426	664260	0.45
20001 - 30000	32	2.6	85136	851360	0.57
30001 - 40000	20	1.62	68969	689690	0.47
40001 - 50000	13	1.06	61592	615920	0.42
50001 - 100000	30	2.44	216374	2163740	1.46
100001 and above	75	6.09	14157155	141571550	95.6
TOTAL	1231	100.00	14808706	148087060	100.00

f. DEMATERIALISATION & LIQUIDITY OF SHARES:

Trading in Company's shares is permitted only in dematerialized form for all investors. Investors are therefore advised to open a demat account with a Depository participant of their choice to trade in dematerialized form.

Particulars	No. of Shares	% Share Capital
NSDL	79,76,482	53.86
CDSL	63,58,624	42.94
Physical	4,73,600	3.20
TOTAL	1,48,08,706	100.00

N. OUTSTANDING GLOBAL DEPOSITORY RECEIPTS OR AMERICAN DEPOSITORY RECEIPTS OR WARRANTS OR ANY CONVERTIBLE INSTRUMENTS, CONVERSION DATE AND LIKELY IMPACT ON EQUITY:

The Company has not issued these types of securities.

O. LIST OF ALL CREDIT RATINGS OBTAINED BY THE ENTITY ALONG WITH ANY REVISIONS THERETO DURING THE RELEVANT FINANCIAL YEAR, FOR ALL DEBT INSTRUMENTS OF SUCH ENTITY OR ANY FIXED DEPOSIT PROGRAMME OR ANY SCHEME OR PROPOSAL OF THE LISTED ENTITY INVOLVING MOBILIZATION OF FUNDS, WHETHER IN INDIA OR ABROAD

During the year under review, the Company has not issued any debt instrument or fixed deposit receipts etc. in India or abroad.

P. DISCLOSURES**1. MATERIALLY SIGNIFICANT RELATED PARTY TRANSACTIONS:**

During the year under review, the Company had not entered in to any materially significant transaction with any related party. During the year, the Company had not entered into any other contract/arrangement/transaction with related parties which could be considered material in accordance with the policy of the Company on materiality of related party transactions that may have potential conflict with the interests of the Company at large. All the related party transactions during the year are in the ordinary course of business and on arm's length basis.

The policy on related party transactions is available in the Company's website www.drhlsl.com

2. DETAILS OF NON-COMPLIANCE BY THE LISTED ENTITY, PENALTIES, STRICTURES IMPOSED ON THE LISTED ENTITY BY STOCK EXCHANGE(S) OR THE BOARD OR ANY STATUTORY AUTHORITY, ON ANY MATTER RELATED TO CAPITAL MARKETS, DURING THE LAST THREE YEARS:

The Company was required to file the Secretarial Compliance Report for the year ended 2020-21 within the due date i.e., on or before 30.05.2021 with MSEI, but the same was filed on 30.07.2021 for which a penalty of Rs. 70,800/- was imposed by MSEI. However, the same was waived off by Metropolitan Stock Exchange of India Limited (MSEI).

The Company was required to file the related party transactions for the half-year ended 30.09.2021 in both pdf and XBRL mode with MSEI. Company had filed the same in XBRL mode only but not in pdf mode for which a penalty of Rs. 1,88,800/- was imposed by MSEI. However, the same was waived off by Metropolitan Stock Exchange of India Limited (MSEI).

3. WEB LINK WHERE POLICY FOR DETERMINING 'MATERIAL' SUBSIDIARIES IS DISCLOSED;

The Company does not have any material subsidiary as defined under Listing Regulations, however, the policy for determining its 'Material' Subsidiaries was formulated and the same is available on the website of the Company www.drhlsl.com.

4. WEB LINK WHERE POLICY ON DEALING WITH RELATED PARTY TRANSACTIONS: www.drhlsl.com.**5. DISCLOSURE OF COMMODITY PRICE RISKS, FOREIGN EXCHANGE RISK AND COMMODITY HEDGING ACTIVITIES:**

The company does not have any significant exposure to commodity price risk, Foreign Exchange and hedging activities.

6. DETAILS OF UTILIZATION OF FUNDS RAISED THOROUGH PREFERENTIAL ALLOTMENT OR QUALIFIED INSTITUTIONS PLACEMENT

During the year, the Company has not raised any funds by the way of preferential allotment or qualified institutions placement.

7. WHISTLE BLOWER POLICY:

The Company has adopted a Whistle Blower Policy and has established the necessary vigil mechanism as defined in Regulation 22 of SEBI (LODR) Regulations 2015 and in terms of Section 177 of the Companies Act, 2013.

With a view to adopt the highest ethical standards in the course of business, the Company has a whistle blower policy in place for reporting the instances of conduct which are not in conformity with the policy. Directors, employees, vendors or any person having dealings with the Company may report non-compliance to the Chairman of the Audit Committee, who reviews the report. Confidentiality is maintained of such reporting and it is ensured that the whistle blowers are not subjected to any discrimination. No person has been denied access to the Chairman of the Audit Committee.

8. CERTIFICATE FROM PRACTICING COMPANY SECRETARY

The Company has obtained certificate from Practicing Company Secretary that none of the Directors on the Board of the Company are debarred or disqualified from being appointed or continuing as Directors of Companies by the Board/Ministry of Corporate Affairs or any such authority. And the Certificate to this effect, duly signed by the Practicing Company Secretary is annexed to this Report.

9. RECOMMENDATIONS OF COMMITTEES

The Board has accepted and acted upon all the recommendations by the Audit & Nomination and Remuneration Committees.

10. TOTAL FEES FOR ALL SERVICES PAID BY THE COMPANY, ON A CONSOLIDATED BASIS, TO THE STATUTORY AUDITOR.

The fees paid by the Company to its statutory Auditors is Rs. 1,00,000/- per annum (DR Habeebullah Life Sciences Limited Rs.75,000 Krisani Bio Sciences Private Limited Rs. 25,000).

11. DISCLOSURE IN RELATION TO THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013.

The following is the summary of sexual harassment complaints received and disposed during the calendar year.

- No. of complaints received during the financial year: Nil
- No. of complaints disposed off during the financial year: Nil
- No. of complaints pending at the end of the financial year: Nil

12. NON-COMPLIANCE OF ANY REQUIREMENT OF CORPORATE GOVERNANCE REPORT.

The company has complied with the requirement of Corporate Governance Report of sub-paras (2) to (10) of Schedule-V of the Securities Exchange Board of India (LODR) Regulations, 2015.

13. ADOPTION OF DISCRETIONARY REQUIREMENTS AS SPECIFIED IN PART E OF SCHEDULE II of SEBI (LODR) REGULATIONS, 2015.

The company has adopted discretionary requirements to the extent of Internal Auditors reporting to the Audit Committee.

14. DISCLOSURE OF COMPLIANCE WITH CORPORATE GOVERNANCE REQUIREMENTS SPECIFIED IN REGULATIONS 17 TO 27 AND CLAUSES (b) TO (i) OF SUB-REGULATION (2) OF REGULATION 46 ARE AS FOLLOWS:

Regulation	Particulars	Compliance Status
17	Board of Directors	yes
18	Audit Committee	yes
19	Nomination and Remuneration Committee	yes
20	Stakeholders Relationship Committee	yes
21	Risk Management Committee	NA
22	Vigil Mechanism	yes
23	Related Party Transactions	yes
24	Corporate Governance requirements with respect to subsidiary of Listed company	NA
25	Obligations with respect to Independent Directors	yes
26	Obligations with respect to Directors and Senior Management	yes
27	Other Corporate Governance Requirements	yes
46 (2) (b) to (i)	Website	yes

15. Disclosure by listed entity and its subsidiaries of 'Loans and advances in the nature of loans to firms/companies in which directors are interested by name and amount: Nil**Q. CODE OF CONDUCT**

The Company has formulated and implemented a Code of Conduct for Board Members and Senior Management of the Company. Requisite annual affirmations of compliance with the respective Codes have been made by the Directors and Senior Management of the Company.

R. DECLARATION ON CODE OF CONDUCT FOR THE YEAR 2021-22.

This is to confirm that the Board has laid down a code of conduct for all Board members and senior management personnel of the Company. The code of Conduct has also been posted on the website of the Company. It is further confirmed that all Directors and senior management personnel of the Company have affirmed compliance with the Code of Conduct of the Company for the Financial Year ended on March 31, 2022 as envisaged in Regulation 26(3) of the SEBI (Listing obligations and disclosure requirements) Regulations, 2015.

S. WTD/CFO Certification

The Whole time Director / CFO certification of the financial statements as specified in Regulation 17(8) read with Part B of Schedule II of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the Financial Year 2021-2022 is provided elsewhere in this Annual Report

T. NON-EXECUTIVE DIRECTORS' COMPENSATION AND DISCLOSURES

None of the Independent / Non-Executive Directors has any pecuniary relationship or transactions with the Company which in the Judgment of the Board may affect the independence of the Directors. And no such directors is getting any remuneration.

U. RECONCILIATION OF SHARE CAPITAL:

A qualified Practicing Company Secretary carry out audit to reconcile the total admitted capital with the National Securities Depository Limited (NSDL) and the Central Depository Services (India) Limited (CDSL) and the total issued and listed capital. Reconciliation of Share Capital Audit Report confirms that the total paid up capital was in agreement with the total number of shares in physical firm and the total number of dematerialized shares held with NSDL and CDSL.

**For and on behalf of the Board of
Dr Habeebullah Life Sciences Limited**

**Sd/-
K. Krishnam Raju
Executive Chairman & Whole-time Director
(DIN: 00874650)**

**Place: Hyderabad
Date: 10.08.2022**

CERTIFICATE ON CORPORATE GOVERNANCE

To

The Members Of
Dr. Habeebullah Life Sciences Limited

We have examined the compliance of the conditions of Corporate Governance by Dr. Habeebullah Life Sciences Limited ('the Company') for the year ended on March 31, 2022, as stipulated under Regulations 17 to 27, clauses (b) to (i) of sub-regulation (2) of Regulation 46 and para-C, D & E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations').

The compliance of the conditions of Corporate Governance is the responsibility of the Management. Our examination was limited to the review of procedures and implementation thereof, as adopted by the Company for ensuring compliance with conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, and the representations made by the Directors and the Management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the SEBI Listing Regulations for the year ended on March 31, 2022.

We further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

For S.S. Reddy & Associates

**Sd/-
S. Sarveswar Reddy
Proprietor
M. No. A12611 C.P. No: 7478
UDIN:A012611D000788892
Peer Review Cer. No.: 1450/2021**

**Date: 10.08.2022
Place: Hyderabad**

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,

The Members of
Dr Habeebullah Life Sciences Limited
Hyderabad

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Dr Habeebullah Life Sciences Limited having CIN: L85110TG1996PLC099198 and having registered office situated at 6-3-354/13/B2, Flat. No. B2, Suryateja Apartments Hindi Nagar, Punjagutta Hyderabad-500082 Telangana India (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers. We hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2022 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

Sr. No.	Name of Director	DIN	Date of Appointment in Company
1.	Mr. Krishnam Raju Kalidindi	00874650	27/12/2016
2.	Mr. A.S.S.V. Srinivas	06975221	02/07/2021
3.	Mr. Suryaprakasa Rao Bommiseti	08089189	22/03/2019
4.	Mr. Y. Ramamohan Reddy	08517059	29/06/2021
5.	Ms. Aakanksha	08792778	29/06/2021
6.	Mr. K.N.V. Narendra Kumar	09223904	02/07/2021

Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For S.S. Reddy & Associates

Sd/-

S. Sarveswar Reddy
Proprietor

M. No. A12611 C.P. No: 7478
UDIN:A012611D000788892
Peer Review Cer. No.: 1450/2021

Date: 10.08.2022
Place: Hyderabad

CERTIFICATE BY THE WHOLE TIME DIRECTOR AND CFO OF THE COMPANY

To

The Board of Directors
Dr. Habeebullah Life Sciences Limited

Dear Sirs,

As required under Regulation 17(8) read with Part B, Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we state that:

1. We have reviewed the financial statements and the cash flow statement for the year ended 31st March 22 and to the best of our knowledge and belief;
 - a. These statements do not contain any materially untrue statement nor omit any material fact nor contain statements that might be misleading, and
 - b. These statements present a true and fair view of the company's affairs and are in compliance with the existing accounting standards, applicable laws and regulations.
2. There are, to the best of my knowledge and belief, no transactions entered into by the company during the year, which are fraudulent, illegal or violative of the company's code of conduct.
3. We accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the company and I have disclosed to the auditors and the audit committee, deficiencies in the design or the operation of internal controls, if any, of which I was aware and the steps that I have taken or propose to take and rectify the identified deficiencies and,
4. That we have informed the auditors and the audit committee of:
 - a) Significant changes in the internal control during the year;
 - b) Significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - c) Instances of significant fraud of which we have become aware and the involvement of any employee having a significant role in the company's internal control system.

**For and on behalf of the Board of
Dr Habeebullah Life Sciences Limited**

Sd/-

K. Krishnam Raju

**Executive Chairman & Whole-time Director
(DIN: 00874650)**

Sd/-

K.N.V Narendra Kumar

**Whole-time Director & CFO
(DIN: 09223904)**

Place: Hyderabad

Date: 10.08.2022

DECLARATION ON CODE OF CONDUCT AS REQUIRED BY SCHEDULE V OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

I, K. Krishnam Raju Executive Chairman & Whole-time Director of Dr. Habeebullah Life Sciences Limited ("The Company") hereby state and affirm Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 the members of board of directors and senior management personnel have affirmed compliance with the code of conduct of board of directors and senior management of the company during Financial Year 2021-2022

**For and on behalf of the Board of
Dr Habeebullah Life Sciences Limited**

Sd/-

**K. Krishnam Raju
Executive Chairman & Whole-time Director
(DIN: 00874650)**

**Place: Hyderabad
Date: 10.08.2022**

INDEPENDENT AUDITOR'S REPORT

To the Members of Dr Habeebullah Life Sciences Limited

Report on the Audit of the Standalone Financial Statements**Opinion**

We have audited the standalone financial statements of Dr Habeebullah Life Sciences Limited ("the Company"), which comprise the balance sheet as at March 31, 2022, and the statement of Profit and Loss, statement of changes in equity and statement of Cash Flows for the year then ended, and notes to the standalone financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015 as amended and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, and its profit, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined the matters described below to be the key audit matters to be communicated in our report.

S.No	Key Audit Matter	Auditor's Response
1.	<p>During the year the ended March 31,2022, the holding company has lost its control in the existing subsidiary company due to fresh Issue of Shares in the Subsidiary, consequent to which it has now become an associate to the holding Company.</p> <p>Accordingly, the Holding company has ceased accounting of subsidiary by adding line to line item in preparation of financial statements and now it has accounted by using the equity method of accounting as per Ind As 28. The Identification and valuation of loss of control is an area that involves the Judgement. Because this is a non-routine transaction and the accounting treatment is complex, we consider this a key audit matter for our audit.</p>	<p>Our audit procedures included, among others, the following:</p> <ul style="list-style-type: none"> We analysed the transaction and the loss of control and discussed it with the Directors and management of the Company. We assessed the accounting treatment as per equity method of accounting and reviewed relevant underlying documents. Our audit procedures included among others, an assessment of the loss of control accounting, evaluated the procedures applied to identify and value additional assets and liabilities on loss of control and evaluated the key judgements. In performing these procedures, we obtained and reviewed the external fair valuation report used by the management for determining the fair value of identifiable assets and liabilities.

		<ul style="list-style-type: none"> We ensured that the previous stake held has been re measured in accordance with the provisions of relevant Ind AS. We assessed the relevant disclosures in the consolidated financial statements.
2.	During the year ended 31 March 2022, The company has written off the TDS liabilities and interest there on and the same offered as Income and related expenses on which tds had been deducted has also offered as income except expenses related to the extent of TDS liability INR 15,89,044 has not written off. Because this is a non-routine transaction which requires the management judgement and the accounting treatment is complex, we consider this a key audit matter for our audit. (refer Note No 36 of notes to Financial Statements)	<p>Our audit procedures included, among others, the following:</p> <ul style="list-style-type: none"> We have analysed the transactions and identified the TDS liability and related expenses and discussed it with the Directors and management of the Company. We ensured that the total TDS liability and related expenses are offered as income. But to the extent of the TDS liability of INR 15,89,044 has not offered as income. We assessed the relevant disclosures in the financial statements.

Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the Director's report but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, changes inequity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

That Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

We give in "Annexure A" a detailed description of Auditor's responsibilities for Audit of the Standalone Financial Statements.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

As required by Section 143(3) of the Act, based on our audit, we report, to the extent applicable that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- (c) The Balance Sheet, the Statement of Profit and Loss, the Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the books of account;
- (d) In our opinion, the aforesaid standalone financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the directors as on 31st March, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to the adequacy of the internal financial controls with reference to standalone financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure C".
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.
- (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position;
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses; and
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - iv. a) The Management has represented that, to the best of its knowledge and belief, as disclosed in the note 34(vi) to the Standalone financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

- b) The Management has represented, that, to the best of it's knowledge and belief, as disclosed in the note 34(vii) to Standalone financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- c) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- v. No Interim dividend has declared by the company during the year or previous year so the provisions of section 123 of the Companies Act, 2013 are not applicable to the company.

For A.M.REDDY & D.R.REDDY
Chartered Accountants
ICAI Firm Registration No. 009068S

Sd/-
D.Rama Krishna Reddy
Partner
Membership No.209211
UDIN: 22209211AJGLBW9448

Place: Hyderabad
Date: 19.05.2022

ANNEXURE A TO THE INDEPENDENT AUDITOR'S REPORT ON EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF DR HABEEBULLAH LIFE SCIENCES LIMITED**Auditor's Responsibilities for the Audit of the Financial Statements**

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned Scope and timing of the audit and significant audit findings, including any significant deficiencies in

Internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore, the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

For A.M.REDDY & D.R.REDDY
Chartered Accountants
ICAI Firm Registration No. 009068S

Sd/-
D.Rama Krishna Reddy
Partner
Membership No.209211
UDIN: 22209211AJGLBW9448

Place: Hyderabad
Date: 19.05.2022

ANNEXURE B TO INDEPENDENT AUDITORS' REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF DR HABEEBULLAH LIFE SCIENCES LIMITED FOR THE YEAR ENDED MARCH 31, 2022

[Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditors' Report]

In terms of the information and explanations sought by us and given by the Company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that

- i. In respect of the Company's Property, Plant and Equipment:
 - (a) The company has maintained proper records showing full particulars including quantitative details and situation of fixed assets (Property, Plant and Equipment) and relevant details right of use of assets.
The Company has maintained proper records showing full particulars of intangible assets.
 - (b) Fixed assets (Property, Plant and Equipment) have been physically verified by the management during the year and no material discrepancies were identified on such verification.
 - (c) According to the information and explanations given to us, there are no immovable properties, and accordingly, the requirements under paragraph 3(i)(c) of the Order are not applicable to the Company.
 - (d) The Company has not revalued any of its property, plant and equipment (including right of use assets) and intangible assets during the year.
 - (e) No proceedings have been initiated during the year or are pending against the Company as at March 31, 2022 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.
- ii. According to the information and explanations given to us, there are no Inventories, and accordingly, the requirements under paragraph 3(ii) of the Order are not applicable to the Company.
- iii. The Company has not made any investments in, provided guarantee and granted unsecured loans to companies during the year, and accordingly the requirements under paragraph 3(iii) (a), (b), (c) of the Order not applicable to the company.
- (d) The According to the information and explanations given to us and on the basis of our examination of the records of the Company, the details of amount overdue for more than ninety days are as follows:

No. of Cases	Relation with the company	Principal amount overdue	Interest overdue	Total overdue	Remarks (specify whether reasonable steps have been taken by the Company for recovery of principal amount and interest)
1	Other	94,00,000	52,58,630	1,46,58,630	Company is discussing with Borrower to recover the loan.

- (e) No loan granted by the Company which has fallen due during the year, has been renewed or extended or fresh loans granted to settle the over dues of existing loans given to the same parties.
- iv. In our opinion and according to the information and explanations given to us, the Company has not either directly or indirectly, granted any loan to any of its directors or to any other person in whom the director is interested, in accordance with the provisions of section 185 of the Act and the Company has not made investments through more than two layers of investment companies in accordance with the provisions of section 186 of the Act. Accordingly, provisions stated in paragraph 3(iv) of the Order are not applicable to the Company.
- v. In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits from the public within the meaning of Sections 73, 74, 75 and 76 of the Act and the rules framed there under. Accordingly, provisions stated in paragraph 3(v) of the Order are not applicable to the Company.

- vi. The provisions of sub-section (1) of section 148 of the Act are not applicable to the Company as the Central Government of India has not specified the maintenance of cost records for any of the products of the Company. Accordingly, the provisions stated in paragraph 3 (vi) of the Order are not applicable to the Company.
- vii. According to the information and explanations given to us, in respect of statutory dues:
 - (a) According to the information and explanations given to us and the records of the Company examined by us, in our opinion, undisputed statutory dues including provident fund, employees' state insurance, income-tax, goods and service tax, cess and other statutory dues have not been regularly deposited with the appropriate authorities and there have been delays in certain number of cases.
 - (b) According to the information and explanations given to us, there are no undisputed dues in respect of provident fund, employees' state insurance, income-tax, goods and service tax, cess and other statutory dues which were outstanding, at the year end, for a period of more than six months from the date they became payable.
 - (c) According to the information and explanation given to us and the records of the Company examined by us, there are no dues of income tax, goods and service tax, customs duty, cess and any other statutory dues which have not been deposited on account of any dispute.
- viii. There were no transactions relating to previously unrecorded income that were surrendered or disclosed as income in the tax assessments under the Income Tax Act, 1961 (43 of 1961) during the year.
- ix. The Company does not have any loans or borrowings from any financial institution, banks, government or debenture holders during the year. Accordingly, the provision stated in paragraph 3(ix) of the Order is not applicable to the Company.
- x.
 - a) The Company did not raise any money by way of initial public offer or further public offer (including debt instruments) and term loans during the year. Accordingly, the provisions stated in paragraph 3 (x)(a) of the Order are not applicable to the Company.
 - b) During the year the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause (x)(b) of the order is not applicable to the Company.
- xi. During the course of our audit, examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us.
 - a) To the best of our knowledge, no fraud by the Company and no material fraud on the Company has been noticed or reported during the year.
 - b) To the best of our knowledge, no report under subsection (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and up to the date of this report.
 - c) As represented to us by the management, there were no whistle blower complaints received by the company during the year.
- xii. The Company is not a Nidhi Company. Accordingly, the provisions stated in paragraph 3(xii) of the Order are not applicable to the Company.
- xiii. According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- xiv.
 - a) In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business.
 - b) We have considered, the internal audit reports issued to the Company during the year and covering the period up to March 2022.

- xv. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him. Accordingly, provisions stated in paragraph 3(xv) of the Order are not applicable to the Company.
- xvi. In our opinion, the Company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions stated in paragraph clause 3 (xvi)(a), (b) and (c) of the Order are not applicable to the Company.
- d) The Group does not have any core investment company as part of the group and accordingly reporting under clause (xvi)(d) of the Order is not applicable.
- xvii. The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.
- xviii. There has been no resignation of the statutory auditors of the Company during the year.
- xix. On the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- xx. According to the provisions of Companies Act, 2013 provisions of Corporate Social Responsibility (CSR) are not applicable to the company. Accordingly, reporting under clause (xx) (a) and (b) of the order is not applicable for the year.

For A.M.REDDY & D.R.REDDY
Chartered Accountants
ICAI Firm Registration No. 009068S

Sd/-
D.Rama Krishna Reddy
Partner
Membership No. 209211
UDIN: 22209211AJGLBW9448

Place: Hyderabad
Date: 19/05/2022

ANNEXURE C**TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF DR HABEEBULLAH LIFE SCIENCES LIMITED**

[Referred to in paragraph 2(f) under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditors' Report]

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls with reference to standalone financial statements of Dr Habeebullah Life Sciences Limited ("the Company") as of March 31, 2021 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI) (the "Guidance Note"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 .

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to standalone financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether internal financial controls with reference to standalone financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the internal financial controls with reference to standalone financial statements and their operating effectiveness. Our audit of internal financial controls with reference to standalone financial statements included obtaining an understanding of internal financial controls with reference to standalone financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to standalone financial statements.

Meaning of Internal Financial Controls with Reference to Standalone Financial Statements

A Company's internal financial control with reference to standalone financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of standalone financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control with reference to standalone financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of standalone financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the standalone financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Standalone Financial Statements

Because of the inherent limitations of internal financial controls with reference to standalone financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to standalone financial statements to future periods are subject to the risk that the internal financial control with reference to standalone financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, internal financial controls with reference to standalone financial statements and such internal financial controls with reference to standalone financial statements were operating effectively as at March 31, 2022, based on the internal control with reference to standalone financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI.

For A.M.REDDY & D.R.REDDY
Chartered Accountants
ICAI Firm Registration No. 009068S

Sd/-
D.Rama Krishna Reddy
Partner
Membership No. 209211
UDIN: 22209211AJGLBW9448

Place: Hyderabad
Date: 19/05/2022

BALANCE SHEET AS AT 31st MARCH 2022

(Amount in Rs.)

	PARTICULARS	Note No.	As at March 31, 2022	As at March 31, 2021
I	ASSETS:			
(1)	Non-current assets			
	(a) Property, Plant and Equipment	2	1,24,849	1,78,460
	(b) Capital work-in-progress		-	-
	(c) Goodwill		-	-
	(d) Other Intangible Assets		-	-
	(e) Intangible Assets under development	3	3,25,95,370	3,25,95,370
	(f) Financial assets			
	(i) Investments	4	4,87,06,060	4,87,06,060
	(ii) Other Financial Assets	5	2,00,25,000	2,03,98,662
(2)	Current assets			
	(a) Inventories	6	-	12,92,128
	(b) Financial assets			
	(i) Investments		-	-
	(i) Trade receivables	7	2,12,45,408	2,14,25,710
	(ii) Cash and cash equivalents	8	93,213	41,317
	(iii) Loans and advances	9	94,00,000	94,00,000
	(iv) Other financial assets	10	52,58,630	37,76,850
	(c) Other current assets	11	3,45,53,548	3,44,38,501
	TOTAL ASSETS		17,20,02,078	17,22,53,057
II	EQUITY AND LIABILITIES:			
	Equity			
	(a) Equity Share Capital	12	14,80,87,060	14,80,87,060
	(b) Other Equity			
	(i) Reserves and Surplus	13	(1,50,99,165)	(3,00,83,066)
	Liabilities			
(1)	Non Current Liabilities			
	(a) Financial Liabilities			
	(i) Borrowings		-	-
	(ii) Provisions	14	7,08,491	4,56,345
(2)	Current Liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	15	2,74,07,000	2,34,05,000
	(ii) Trade Payables	16	12,15,251	28,72,255
	(b) Other current liabilities	17	96,83,441	2,75,15,367
	(c) Provisions	18	-	96
	TOTAL EQUITY AND LIABILITIES		17,20,02,078	17,22,53,057
		1 to 39		

As per our report of even date
for A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No: 009068S

Sd/-
(D.Rama Krishna Reddy)
Partner
Membership No. 209211
UDIN: 22209211AJGLBW9448

Place: Hyderabad
Date : 19-05-2022

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31st MARCH 2022

(Amount in Rs.)

S.No.	PARTICULARS	Note No.	Year Ended March 31, 2022	Year Ended March 31, 2021
I	Revenue from operations	19	2,24,541	1,29,724
II	Other Income	20	1,90,62,617	14,77,331
III	Total Income (I+II)		1,92,87,158	16,07,055
IV	Expenses:			
	Purchase of Medicines	21	2,15,932	-
	Raw materials consumed	22(a)	-	19,273
	Change in Inventories (Raw Materials)	22(b)	12,92,128	-
	Employee Benefits Expenses	23	11,46,950	33,17,297
	Depreciation and amortization expenses	2	53,611	96,014
	Other expenses	24	15,94,636	58,71,543
	Total Expenses		43,03,257	93,04,127
V	Profit before tax (III-IV)		1,49,83,901	(76,97,072)
VI	Tax Expenses			
	- Current tax		-	-
	- Deferred tax		-	-
VII	Profit for the period (V-VI)		1,49,83,901	(76,97,072)
VIII	Other Comprehensive Income (OCI)			
	i) Items that will not be reclassified to profit & loss		-	14,08,499
	Other comprehensive income for the year (net of tax)		-	14,08,499
IX	Total Comprehensive Income (VII+VIII)		1,49,83,901	(62,88,573)
X	Earnings per equity share: (Equity shares of par value of Rs.10/- each)			
	- Basic	28	1.01	(0.42)
	- Diluted	28	1.01	(0.42)
Significant accounting policies and notes to accounts		1 to 39		

As per our report of even date
for A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No: 009068S

Sd/-
(D.Rama Krishna Reddy)
Partner
Membership No. 209211
UDIN: 22209211AJGLBW9448

Place: Hyderabad
Date : 19-05-2022

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31st MARCH, 2022

(Amount in Rs.)

PARTICULARS	Year Ended March 31, 2022	Year Ended March 31, 2021
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	1,49,83,901	(62,88,573)
Adjustment for:		
Depreciation and Amortisation	53,611	96,014
Interest Expenses	-	-
Interest Earned	-	-
Cash Flows from Operations before changes in assets and liabilities	1,50,37,512	(61,92,559)
Movements in Working Capital::		
(Increase)/ Decrease in trade receivables	1,80,302	3,25,722
(Increase)/ Decrease in Short Term Loans and Advances	-	-
(Increase)/ Decrease in other Current Assets	(1,15,047)	(7,173)
(Increase)/ Decrease in other other financial Assets	(14,81,780)	(13,66,531)
(Increase)/ Decrease in Inventories	12,92,128	19,273
Increase /(Decrease) in Trade Payables	(16,57,004)	(1,77,649)
Increase/ (Decrease) in Other current liabilities	(1,78,31,926)	51,95,363
Increase/ (Decrease) in Current Provisions	(96)	(2,42,944)
Change in Working Capital	(1,96,13,423)	37,46,061
Changes in non current assets and liabilities		
Decrease/(Increase) in other financials Assets	3,73,662	29,000
(Decrease)/Increase in Long Term Borrowings	-	-
(Decrease)/Increase in Long Term Provisions	2,52,146	(9,93,399)
Changes in non current assets and liabilities	6,25,808	(9,64,399)
Cash Generated From Operations	(39,50,103)	(34,10,897)
Less: Taxes paid	-	-
Net Cash from operating activities(A)	(39,50,103)	(34,10,897)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Increases) / Decrease in Fixed assets and Capital Work In progress	-	(22,72,849)
Bank Balances not considered as Cash and Cash equivalents	-	-
Investment in equity Shares	-	-
Balance of Unclaimed Dividend	-	-
Net cash used in Investing activities (B)	-	(22,72,849)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	-	-
Increase / (Decrease) in Borrowings	40,02,000	54,90,000
Interest paid	-	-
Net cash Flow from Financing Activities (C)	40,02,000	54,90,000
D. Effect of exchange differences on translation of foreign currency cash and cash equivalents	-	-
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	51,897	(1,93,745)
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	41,317	2,35,061
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	93,213	41,317

As per our report of even date
for A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No: 009068S

Sd/-
(D.Rama Krishna Reddy)
Partner
Membership No. 209211
UDIN: 22209211AJGLBW9448

Place: Hyderabad
Date : 19-05-2022

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31st MARCH, 2022

a. Equity share capital

(Amount in Rs.)

Particular	Amount
Balance as at the 31 March 2020	14,80,87,060
Changes in equity share capital during 2020-21	-
Balance as at the 31 March 2021	14,80,87,060
Changes in equity share capital during 2021-22	-
Balance as at the 31 March 2022	14,80,87,060

b. Other equity

(Amount in Rs.)

Particular	Share Warrants	Reserves and surplus		Items of Other comprehensive income (OCI)	Total
		Securities Premium Reserve	Retained earnings	Others	
Balance at 31 March 2020	50,00,000	4,55,00,000	(6,95,42,776)	2,48,284	(1,87,94,492)
Profit or loss	-	-	(76,97,072)	-	(76,97,072)
Other comprehensive income(net of tax)	-	-	-	14,08,499	14,08,499
Total Income	-	-	(76,97,072)	14,08,499	(62,88,573)
Transactions with owners in their capacity as owners	-	-	-	-	-
Balance at 31 March 2021	-	4,55,00,000	(7,72,39,848)	16,56,783	(3,00,83,065)
Profit or loss	-	-	1,49,83,901	-	1,49,83,901
Other comprehensive income(net of tax)	-	-	-	-	-
Total Income	-	-	1,49,83,901	-	1,49,83,901
Transactions with owners in their capacity as owners	-	-	-	-	-
Balance at 31 March 2022	-	4,55,00,000	(6,22,55,947)	16,56,783	(1,50,99,164)

As per our report of even date
for A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No: 009068S

Sd/-
(D.Rama Krishna Reddy)
Partner
Membership No. 209211
UDIN: 22209211AJGLBW9448

Place: Hyderabad
Date : 19-05-2022

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

Notes to Financial Statements

1. Significant Accounting Policies & Notes annexed to and forming part of the financial Statements**1.1. Basis for preparation of financial statements:****a) Compliance with Indian Accounting Standards (Ind AS)**

The financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) as per the Companies (Indian Accounting Standards) Rules, 2015 notified under section 133 of the Companies Act, 2013.

The same accounting policies have been applied for all the periods presented except when the company has made use of certain exceptions.

The financial statements have been prepared on the historical cost basis except for certain instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies below.

Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique.

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the schedule III of the Act. The Company has determined its operating cycle as twelve months for the purpose of current-noncurrent classification of assets and liabilities.

The financial statements are presented in Indian Rupees which is also its functional currency. All amounts have been rounded – off to the nearest rupees, unless otherwise indicated.

b) Use of estimates and judgment

In preparing these financial statements, management has made judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of certain assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.

1.2. Property, Plant and Equipment & Depreciation

Items of Property, Plant and Equipment are stated at cost less accumulated depreciation.

Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labor, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in profit or loss.

Assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less cost of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units).

Depreciation on the fixed assets has been provided based on useful lives as prescribed under part C of the schedule II of the companies' act, 2013.

Depreciation method, useful lives and residual values are reviewed at each financial year-end and adjusted if appropriate.

Depreciation on additions (disposals) is provided on a pro-rata basis i.e., from (up to) the date on which asset is ready for use (disposed of).

1.3 Impairment of non-financial assets

The Company's non-financial assets, other than deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment losses are recognised in the statement of profit and loss. Impairment loss recognised in respect of a CGU is allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets of the CGU (or group of CGUs) on a pro rata basis.

1.4 Intangible assets

Intangible assets are amortized over the estimated useful lives and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method are reviewed at least at each financial year end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as change in accounting estimates. The amortization expense on intangible assets with finite useful lives is recognized in profit or loss.

1.5 Inventory

Cost of inventories have been computed to include all costs of purchases (including materials), cost of conversion and other costs incurred, as the case may be, in bringing the inventories to their present location and condition.

Stores and consumables are valued at cost arrived at on FIFO basis or net realisable value, whichever is lower.

1.6 Foreign currencies transactions and translations

Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency closing rates of exchange at the reporting date.

The gain or loss on decrease/increase in reporting currency due to fluctuations in foreign exchange rates, in case of monetary current assets and liabilities in foreign currency, are recognised in the Statement of Profit and Loss.

Non-monetary items that are measured in terms of historical cost in a foreign currency are recorded using the exchange rates at the date of the transaction.

1.7 Provisions

A provision is recognised when the Company has a present legal or constructive obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. Provisions (other than employee benefits) are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

1.8 Revenue Recognition

The Company primarily earns revenue by providing Health care services.

Revenue is recognised when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and specific criteria have been met as described below.

Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of indirect taxes, trade allowances, rebates and amounts collected on behalf of third parties and is not recognised in instances where there is uncertainty with regard to ultimate collection. In such cases revenue is recognised on reasonable certainty of collection.

Interest Income

Interest income from a financial asset is recognised using effective interest rate method. However, in respect of certain financial assets where it is not probable that the economic benefits associated with the transaction will flow to the entity and amount of revenue cannot be measured reliably, in such cases interest income is not recognised.

1.9 Dividend Income

Dividends will be recognised when the company's right to receive has been established.

1.10 Employee benefits

1.10.1 Short term employee benefits

The undiscounted amount of short-term employee benefits is expected to be paid in exchange for the services rendered by employees are recognised as an expense during the period when the employees render the services.

1.10.2 Defined benefit plans

a) Gratuity

In accordance with the Payment of Gratuity Act, 1972, Company provides for gratuity, a defined retirement plan (the "Gratuity Plan") covering the eligible employees. The Gratuity Plan provides a lump sum payment to vested employees at retirement, death, incapacitation or termination of employment, of an amount based on the respective employee salary and the tenure of employment. Liability with regard to the Gratuity Plan are determined by actuarial valuation as per the requirements of Ind AS 19 as of the balance sheet date, based upon which, the Company contributes the ascertained liabilities to Insurer.

b) Provident fund

Eligible employees receive benefits from a provident fund, which is a defined contribution plan. Aggregate contributions along with interest thereon is paid at retirement, death, incapacitation or termination of employment. Both the employee and the Company make monthly contributions to the Regional Provident Fund Commissioner equal to a specified percentage of the covered employee's salary.

c) Employee State Insurance Fund

Eligible employees are entitled to receive benefit under employee state insurance fund scheme. The employer makes contribution to the scheme at a predetermined rate of employee's gross salary. The Company has no further obligations under the plan beyond its monthly contributions. These contributions are made to the fund administered and managed by the Government of India. contributions made on a monthly basis which are charged to the Statement of Profit and Loss.

d) Leave encashment

All the employees who have completed their eligible service in the Company are eligible for leave encashment as per policy of the Company and the same is paid to the eligible employee at retirement, death, incapacitation or termination of employment. This amount, as calculated for all the eligible employees, is charged to the Statement of Profit and Loss.

1.11 Tax Expenses

The tax expense for the period comprises current and deferred tax. Tax is recognised in Statement of Profit and Loss, except to the extent that it relates to items recognised in the comprehensive income or in equity. In which case, the tax is also recognised in other comprehensive income or equity.

Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any, related to income taxes. It is measured using tax rates (and tax laws) enacted or substantively enacted by the reporting date.

Current tax assets and current tax liabilities are off set only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis or simultaneously.

Deferred tax

Deferred tax is recognised on temporary differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax is also recognised in respect of carried forward tax losses and tax credits.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset is realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. The carrying amount of deferred tax liabilities and assets are reviewed at the end of each reporting period.

Minimum alternate tax (MAT)

Minimum alternate tax (MAT) paid in a year is charged to the Statement of Profit and Loss as current tax. The Company recognizes MAT credit available as an asset only to the extent that there is convincing evidence that the Company will pay normal income tax during the specified period, i.e., the period for which MAT credit is allowed to be carried forward. In the year in which the company recognizes MAT credit as an asset in accordance with the Guidance Note on Accounting for Credit Available in respect of Minimum Alternative Tax under the Income-tax Act, 1961, the said asset is created by way of credit to the Statement of Profit and Loss and shown as "MAT Credit Entitlement." The Company reviews the "MAT credit entitlement" asset at each reporting date and writes down the asset to the extent the company does not have convincing evidence that it will pay normal tax during the specified period.

1.12 Leases

At the date of commencement of the lease, the Company recognizes a right-of-use asset ("ROU") and a corresponding lease liability for all lease arrangements in which it is a lessee, except for leases with a term of twelve months or less (short-term leases) and low value leases. For these short-term and low value leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease.

As per Ind AS 116, Variable lease payments that do not depend on an index or rate and are not in substance or fixed, such as those based on performance (i.e. percentage of sales) are not included as lease payments and these payments are recognized in the statement of profit or loss in the period in which the event that triggers the payment occurrence.

Hence, the company did not recognize any ROU as the lease agreement does not contain fixed Minimum Lease payments.

1.13 Borrowing costs

Borrowing costs incurred for obtaining assets which takes substantial period to get ready for their intended use are capitalized to the respective assets wherever the costs are directly attributable to such assets and in other cases by applying weighted average cost of borrowings to the expenditure on such assets. Other borrowing costs are treated as expense for the year.

Transaction costs in respect of long-term borrowings are amortized over the tenor of respective loans using effective interest method.

1.14 Earnings per equity share

(i) Basic earnings per share

Basic earnings per share is calculated by dividing:

- The profit attributable to owner of the company.
- By the weighted number of equity shares outstanding during the financial year

(ii) Diluted earnings per share

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of share outstanding during the period is adjusted for the effects of all dilutive potential equity shares.

1.15 Financial Instruments

i. Financial assets

A. Initial recognition and measurement

All financial assets and liabilities are initially recognized at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities, which are not at fair value through profit or loss, are adjusted to the fair value on initial recognition.

a) Financial assets carried at amortized cost (AC)

A financial asset is measured at amortized cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

b) Financial assets at fair value through profit or loss (FVTPL)

A Financial asset which is not classified as AC or FVOCI are measured at FVTPL e.g. investments in mutual funds. A gain or loss on a debt investment that is subsequently measured at fair value through profit or loss is recognised in profit or loss and presented net in the Statement of Profit and Loss within other gains/(losses) in the period in which it arises.

c) Financial assets at fair value through other comprehensive income (FVTOCI)

A financial asset is measured at FVTOCI if it is held within a business model whose Objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

B. Investments in subsidiaries

In respect of equity investments, the entity prepares separate financial statements and account for its investments in subsidiaries at cost, net of impairment if any.

ii. Financial Liabilities

A. Initial recognition

All financial liabilities are recognized at fair value.

B. Subsequent measurement

Financial liabilities are carried at amortized cost using the effective interest method. For trade and other payables maturing within one year from the balance sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

Notes to accounts

NOTE NO 2: PROPERTY, PLANT AND EQUIPMENT

(Amount in Rs.)

Particular	Computers	Furniture and Fixtures	Lab Equipments	Office Equipment	Total
Balance at 31 March 2019	1,64,593	-	1,35,440	1,99,829	4,99,862
Additions	-	-	-	-	-
Disposals	-	-	-	-	-
Balance at 31 March 2020	1,64,593	-	1,35,440	1,99,829	4,99,862
Additions	-	-	-	-	-
Disposals	-	-	-	-	-
Balance at 31 March 2021	1,64,593	-	1,35,440	1,99,829	4,99,862
Additions	-	-	-	-	-
Disposals	-	-	-	-	-
Balance at 31 March 2022	1,64,593	-	1,35,440	1,99,829	4,99,862
Balance at 31 March 2019	58,121	-	4,413	54,480	1,17,014
Depreciation for the year	54,864	-	13,544	39,966	1,08,374
Balance at 31 March 2020	1,12,985	-	17,957	94,446	2,25,388
Depreciation for the year	42,504	-	13,544	39,966	96,014
Balance at 31 March 2021	1,55,489	-	31,501	1,34,412	3,21,402
Depreciation for the year	-	-	13,645	39,966	53,611
Balance at 31 March 2022	1,55,489	-	45,146	1,74,378	3,75,013
Carrying amounts(net)					
At 31 March 2019	1,06,472	-	1,31,027	1,45,349	3,82,848
At 31 March 2020	51,608	-	1,17,483	1,05,383	2,74,474
At 31 March 2021	9,104	-	1,03,939	65,417	1,78,460
At 31 March 2022	9,104	-	90,294	25,451	1,24,849

Notes to Financial Statements

NOTE NO: 3 INTANGIBLE ASSETS UNDER DEVELOPMENT

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Intangible Assets		
Intangible Assets Under Development	3,25,95,370	3,25,95,370
	3,25,95,370	3,25,95,370

Capital work-in-progress (CWIP) ageing schedule for the Year ended 31/03/2022

PARTICULARS	Amount of CWIP for a period of				Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
(i) Projects in Progress	-	2272848	8867047	21455475	32595370
(ii) Projects temporarily suspended	-	-	-	-	-

Capital work-in-progress (CWIP) ageing schedule for the Year ended 31/03/2021

PARTICULARS	Amount of CWIP for a period of				Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
(i) Projects in Progress	2272848	8867047	12289614	9165861	32595370
(ii) Projects temporarily suspended					

NOTE NO: 4 NON CURRENT INVESTMENTS:

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Investment In Subsidiary Company carried at Cost		
Krisani Bio Sciences Private Limited (58,68,200 equity shares of Rs. 10 each subscribed at Rs. 8.3 per share)	4,87,06,060	4,87,06,060
	4,87,06,060	4,87,06,060

NOTE NO: 5 OTHER NON-CURRENT FINANCIAL ASSETS

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Security Deposits	2,00,25,000	2,03,98,662
	2,00,25,000	2,03,98,662

NOTE NO: 6 INVENTORIES

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Stores and consumables	-	12,92,128
	-	12,92,128

NOTE NO: 7 TRADE RECEIVABLES

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
(a) Outstanding for a period exceeding six months from the date they are due for payment Unsecured, considered good	2,08,99,089	2,11,25,710
(b) Outstanding for a period not exceeding six months Unsecured, considered good	3,46,319	3,00,000
	2,12,45,408	2,14,25,710

- a) No trade or other receivables are due from directors or other officers of the Company either severally or jointly with any other person. Nor any trade or other receivables are due from firms or private companies respectively in which any director is a partner, a director or a member.
- b) Trade receivables are non-interest bearing and are generally on terms of 30 – 120 days.

Trade Receivables Ageing Schedule for the Year ended 31/03/2022

PARTICULARS	Outstanding for following periods from date of payment					Total
	Less Than 6 Months	6m to 1 Year	1-2 years	2-3 years	> 3 Years	
(i) Undisputed Trade Receivables -Considered Good	2,51,485	-	-	-	2,09,93,923	2,12,45,408
(ii) Undisputed Trade Receivables -Considered Doubtful	-	-	-	-	-	-
(iii) Disputed Trade Receivables -Considered Good	-	-	-	-	-	-
(iv) Disputed Trade Receivables -Considered Doubtful	-	-	-	-	-	-

Trade Receivables Ageing Schedule for the Year ended 31/03/2021

PARTICULARS	Outstanding for following periods from date of payment					Total
	Less Than 6 Months	6m to 1 Year	1-2 years	2-3 years	> 3 Years	
(i) Undisputed Trade Receivables -Considered Good	--	-	-	-	2,14,25,710	2,14,25,710
(ii) Undisputed Trade Receivables -Considered Doubtful	-	-	-	-	-	-
(iii) Disputed Trade Receivables -Considered Good	-	-	-	-	-	-
(iv) Disputed Trade Receivables -Considered Doubtful		-	-	-	+	-

NOTE NO: 8 CASH AND CASH EQUIVALENTS:

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
(a) Balance with banks	91,964	24,399
(b) Cash on Hand	1,249	16,918
	93,213	41,317

NOTE NO: 9 LOANS & ADVANCES

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
(a) Inter Corporate Loan given to group company M/s Innovision Life Sciences Private Limited	94,00,000	94,00,000
	94,00,000	94,00,000

NOTE NO: 10 OTHER FINANCIAL ASSETS

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Interest receivable On Inter Corporate Loan given to M/s Innovision Life Sciences Pvt. Ltd	52,58,630	37,76,850
	52,58,630	37,76,850

NOTE NO: 11 OTHER CURRENT ASSETS:

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
(a) GST Receivable	30,833	31,866
(b) MAT Credit Entitlement	2,06,409	2,06,409
(c) Advance Tax & TDS	4,33,625	2,89,313
(d) Other Advances	2,98,82,681	2,99,10,913
(e) Advance and Security Deposit	40,00,000	40,00,000
	3,45,53,548	3,44,38,501

NOTE NO: 12: EQUITY SHARE CAPITAL

PARTICULARS	As At March 31, 2022		As At March 31, 2021	
	Number	Amount in Rs.	Number	Amount in Rs.
Authorised Equity Shares of Rs. 10/- each	1,60,00,000	16,00,00,000	1,60,00,000	16,00,00,000
Issued, Subscribed and Paid up Equity Shares of Rs. 10/- each fully paid up (Refer foot note (a) to (c) below)	1,48,08,706	14,80,87,060	1,48,08,706	14,80,87,060
Total	1,48,08,706	14,80,87,060	1,48,08,706	14,80,87,060

Foot note:**(a) Reconciliation of the number of shares outstanding as at March 31, 2022 and March 31, 2021 :**

PARTICULARS	As At March 31, 2022		As At March 31, 2021	
	Number	Amount in Rs.	Number	Amount in Rs.
Equity Shares outstanding at the beginning of the year	1,48,08,706	14,80,87,060	1,48,08,706	14,80,87,060
Equity Shares Issued during the year for Cash*	-	-	-	-
Equity Shares Issued during the year for other than cash	-	-	-	-
Equity Shares bought back during year	-	-	-	-
Equity Shares outstanding at the end of the year	1,48,08,706	14,80,87,060	1,48,08,706	14,80,87,060

(b) Details of Shareholders holding more than 5 % shares:

PARTICULARS	As At March 31, 2022		As At March 31, 2021	
	No. of Shares	% of Holding	No. of Shares	% of Holding
1 K. Krishnam Raju	28,99,630	19.58%	28,99,630	19.58%
2 Mohammed Aejaz Habeeb	17,79,124	12.01%	17,79,124	12.01%
3 Syed Ameer Basha Paspala	16,61,800	11.22%	16,61,800	11.22%
4 K. Sarada Vijaya Kumari	8,65,690	5.85%	8,65,690	5.85%
5 K. Nirusha	10,29,200	6.95%	10,29,200	6.95%
6 P. Parvathi	3,93,586	2.66%	3,93,586	2.66%
7 Arun Kumar Bhangadia (Public)	56,000	0.38%	7,73,728	5.22%

(c) Terms and rights attached to the equity shares:

The Company has only one class of equity shares having par value of Rs.10/- each. Each holder of equity shares is entitled for one vote per share. Distribution of dividends and repayment of capital, if any, by the company, shall be subject to the provisions of applicable laws.

NOTE NO: 13 RESERVES AND SURPLUS

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
(a) Securities Premium:	4,55,00,000	4,55,00,000
(b) Retained earnings:		
Opening balance	(7,72,39,849)	(6,95,42,777)
(+) Net profit during the year	1,49,83,901	(76,97,072)
Closing balance	(6,22,55,948)	(7,72,39,849)
(c) Other Comprehensive income:		
Opening balance	16,56,783	2,48,284
(+) During the year	-	14,08,499
Closing balance	16,56,783	16,56,783
Total (a+b+c)	(1,50,99,165)	(3,00,83,066)

NOTE NO: 14 LONG TERM PROVISIONS

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Provision for employee Gratuity	6,44,769	4,17,577
Provision for Leave Encashment	63,722	38,768
	7,08,491	4,56,345

NOTE NO: 15 SHORT TERM BARROWINGS

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Un Secured Loans from Unsecured Loans (from promoters) (The above loans are interest free loans and repayable on demand)	2,74,07,000	2,34,05,000
	2,74,07,000	2,34,05,000

NOTE NO: 16 TRADE PAYABLES

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Dues to Micro, Small and Medium Enterprises	-	-
Dues to Others	12,15,251	28,72,255
	12,15,251	28,72,255

Trade Payables Ageing Schedule for the year ended 31/03/2022

PARTICULARS	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
(i) MSME	-	-	-	-	-
(ii) Others	2,41,843	-	9,73,408	-	12,15,251
(iii) Disputed Dues- MSME	-	-	-	-	-
(iv) Disputed Dues- Others	-	-	-	-	-

Trade Payables Ageing Schedule for the year ended 31/03/2021

PARTICULARS	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
(i) MSME	-	-	-	-	-
(ii) Others	56,440	-	28,15,815	-	28,72,255
(iii) Disputed Dues- MSME	-	-	-	-	-
(iv) Disputed Dues- Others	-	-	-	-	-

NOTE NO: 17 OTHER CURRENT LIABILITIES:

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
(a) Statutory Liabilities	9,420	42,72,892
(b) Expenses Payable	12,90,751	79,82,704
(c) Employee Benefits Payable	81,02,270	1,50,16,897
(d) Audit Fees Payable	2,81,000	2,42,875
	96,83,441	2,75,15,368

NOTE NO: 18 Short term Provisions

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Provision for Gratuity Payable	-	96
	-	96

NOTE NO: 19 REVENUE FROM OPERATIONS

PARTICULARS	Year ended March 31, 2022	Year ended March 31, 2021
	Amount in Rs.	Amount in Rs.
Revenue from Operations		
Sale of Medicines	2,24,541	-
Diagnostic Services	-	1,03,204
OP Services	-	26,520
	2,24,541	1,29,724

NOTE NO: 20 OTHER INCOME

PARTICULARS	Year ended March 31, 2022	Year ended March 31, 2021
	Amount in Rs.	Amount in Rs.
Non Operating Income		
Finance Income on		
Interest on ICD	16,46,423	14,77,331
Creditors for expenses W/o (Refer Note No 32)	1,74,16,194	-
	1,90,62,617	14,77,331

NOTE NO: 21: PURCHASES

PARTICULARS	Year ended March 31, 2022	Year ended March 31, 2021
	Amount in Rs.	Amount in Rs.
Purchases of Mediciens	2,15,932	-
	2,15,932	-

NOTE NO: 22(a): MATERIAL AND COMPONENTS CONSUMED

PARTICULARS	Year ended March 31, 2022	Year ended March 31, 2021
	Amount in Rs.	Amount in Rs.
Inventory at the beginning of the year	-	13,11,401
Add: Purchases Of Consumed Material	-	-
Less: Inventory at the end of the year	-	12,92,128
Diminution in the value of Raw Materials	-	19,273

NOTE NO: 22(b): CHANGES IN INVENTORIES (Raw Materials)

PARTICULARS	Year ended March 31, 2022	Year ended March 31, 2021
	Amount in Rs.	Amount in Rs.
Inventory at the beginning of the year	12,92,128	-
Less: Inventory at the end of the year	-	-
Change in Raw Material (Expiry of Stock)	12,92,128	-

NOTE NO: 23: EMPLOYEE BENEFIT EXPENSES

PARTICULARS	Year ended March 31, 2022	Year ended March 31, 2021
	Amount in Rs.	Amount in Rs.
Salaries & Wages	8,94,000	30,66,896
Contribution to PF & ESI	-	53,700
Gratuity and Leave Encashment	2,52,050	1,82,891
EPF Admin Charges	900	4,440
Staff welfare expenses	-	9,370
Total	11,46,950	33,17,297

NOTE NO: 24 OTHER EXPENSES

PARTICULARS	Year ended March 31, 2022	Year ended March 31, 2021
	Amount in Rs.	Amount in Rs.
Rent	1,15,000	32,886
Rates and Taxes	5,09,241	8,24,379
Professional & Consultancy Fee	23,600	1,44,537
Auditors remuneration(refer Note below)	1,28,500	2,56,500
Office Maintenance	49,183	1,36,236
Printing & Stationery	25,640	33,980
Communication Expenses	-	24,937
Travelling & Conveyance	-	36,575
Power & Fuel Expenses	3,817	24,61,427
Repairs & Maintenance	18,732	33,800
Postage & Courier	-	1,290
Bank Charges	38,206	26,397
Advertisement & Business Promotion Expenses	58,058	96,568
Diagnostic outsourcing expenses	-	5,130
Listing Processing & Annual Listing Fees	5,49,893	5,36,900
Registrar & Transfer Fees	74,766	84,441
HK, Security and Hospital Maintenance	-	8,73,398
Directors Sitting Fees	-	2,25,000
Other Expenses	-	37,162
Total	15,94,636	58,71,543

Note: Payment to Auditors :

As Auditors	2021-22	2020-21
Statutory Audit Fees	75,000	75,000

* Statutory Audit fees is exclusive of GST

Note No: 28 Earnings Per Share (EPS)

	As at 31.03.2022	As at 31.03.2021
EPS – Basic		
Net Profit (Loss)	1,49,83,901	(62,88,573)
Appropriations	-	-
Net Profit (Loss) Attributable to Share Holders as at 31st March (Numerator)	1,49,83,901	(62,88,573)
No of Shares outstanding at the beginning of the year	1,48,08,706	1,48,08,706
No of Shares outstanding at the end of the year	1,48,08,706	1,48,08,706
Adjusted Weighted average number of equity shares	1,48,08,706	1,48,08,706
Nominal Value of Ordinary Shares	10	10
Computation of EPS - Basic (in Rs)	1.01	(0.42)
EPS – Diluted		
Net Profit (Loss) Attributable to Share Holders as at	1,49,83,901	(62,88,573)
Adjusted Weighted average number of equity shares	1,48,08,706	1,48,08,706
Weighted average number of equity shares that would	-	-
Total Weighted average number of equity shares for	1,48,08,706	1,48,08,706
Nominal Value of Ordinary Shares	10	10
Computation of EPS - Diluted (in Rs)	1.01	(0.42)
Particulars	31-03-2022	31-03-2021
Opening balance	1,48,08,706	1,48,08,706
No of shares allotted	-	-
Date of allotment	-	-
No of Days outstanding	-	-
Therefore weighted no. of Shares	-	-
No of shares allotted	-	-
Date of allotment	-	-
No of Days outstanding	-	-
Therefore weighted no. of Shares	-	-
Total No of Weighted equity Shares	1,48,08,706	1,48,08,706

25. Related Party Disclosures

As per Ind AS 24 the disclosure of transactions with the related parties are given below.

a) Related Parties and nature of relationship:

Mr.K. Krishnam Raju	Promoter & Whole-time Director & Chairman
Mr. Nagavenkata Narendra Kumar Konagalla	Whole-time Director & CFO
Mr. Suryaprakasa Rao Bommiseti	Independent Non – Executive Director
Dr. Akella Satya Surya Visweswara Srinivasa	Independent Non – Executive Director
Mrs. Aakanksha	Independent Non – Executive Director
Mr. Rama Mohan Reddy Yarragudi	Independent Non – Executive Director
Ms. Deepa R. Dudani	Company Secretary
Krisani Bio Sciences Pvt.Ltd	Associate of Dr Habeebullah Life Sciences Ltd
Mrs. K. Sarada Vijaya Kumari	Promoter Group

The Promoters of DRHLSL are major Promoters and/or Shareholders / Partners of the below entities –

1. Innovision Life Sciences Pvt.Ltd – Company
2. Centre For Liver Research and Diagnostics – Partnership Firm

b) Transactions with Related parties:

Name of the related party	Nature of Transaction	Year ended 31-03-2022 (Rupees)	Year ended 31-03-2021 (Rupees)
K. Krishnam Raju	Remuneration	-	27,00,000
	Rent expenses	1,15,000	-
	Demand Loan taken	40,02,000	55,30,000
	Demand Loan Repaid	-	40,000
Dr. Syed Ameer Basha Paspala	Professional Fee	-	51,037
K.N.V. Narendra Kumar	Remuneration	6,30,000	5,25,000
Ms. Neha Kankariya	Remuneration	-	3,13,928
Ms. Deepa R Dudani	Remuneration	2,64,000	33,785
CLRD Lease Rental Expense	Rent expenses	-	30,615
Innovision Life Sciences Pvt. Ltd	Interest Income	16,46,423	14,77,331

c) Related parties outstanding balances:

Name of the related party	Particulars	As at 31-03-2022 (Rupees)	As at 31-03-2021 (Rupees)
K. Krishnam Raju	Rent payable	4,52,500	3,37,500
	Remuneration payable	29,25,800	49,50,800
	Demand Loan taken	2,74,07,000	2,34,05,000
	Travelling Expenses Payable	-	16,570
K.S.V. Kumari	Rent payable	5,94,000	5,94,000
Dr. Mohammed Aejaz Habeeb	Professional Fee Payable	-	3,25,337
Dr.Syed Ameer Basha Paspala	Professional Fee Payable	-	39,74,933
Centre for Liver Research and Diagnostics	Advance (Asset)	2,98,22,681	2,98,22,681
Krisani Bio Sciences Pvt. Ltd	Advance (Asset)	40,00,000	40,00,000
Innovision Life Sciences Pvt. Ltd	Inter-Corporate Loan	94,00,000	94,00,000
Innovision Life Sciences Pvt. Ltd	Interest Receivable on Inter-Corporate Loan	52,58,630	37,76,850
K.N.V. Narendra Kumar	Remuneration payable	13,28,280	11,90,080

26. Auditors' Remuneration:

PARTICULARS	2021-22 (Rupees)	2020-21 (Rupees)
Audit Fee (Exclusive of GST)	75,000	75,000
Total	75,000	75,000

27. The Board of Directors assesses the financial performance of the Company and make strategic decisions and has been identified as being the Chief Operating Decision Maker (CODM). Based on the internal reporting provided to the CODM, the Company has only one reportable segment i.e., 'healthcare services which includes hospital, diagnostics, Pharma and Biotechnology (R&D)' and hence no separate disclosures are required under Ind AS 108.

28. Earnings per share (EPS):

The details of number of Equity shares used in calculating Basic and Diluted earnings per share and the EPS are set out below:

PARTICULARS	Year ended 31-03-2022	Year ended 31-03-2021
Weighted average Equity shares for computing Basic EPS	1,48,08,706	1,48,08,706
Dilutive impact of Share Warrants	-	-
Weighted average Equity shares for computing Diluted EPS	1,48,08,706	1,48,08,706
Net Profit (Loss) Attributable to Share Holders as at 31st March	1,49,83,901	(63,98,265)
Earnings per Share-Basic	1.01	(0.43)
Earnings per Share-Diluted	1.01	(0.43)

29. The Company has not received any information from any of the supplier of their being Micro, Small and medium enterprises. Hence, the amounts due to Micro, Small and Medium enterprises outstanding as on 31-03-2022 was Rs. Nil

30. Balance Confirmations:

Confirmations of receivables and payable balances have not been received by the Company, hence, reliance is placed on the balances as per books. In the opinion of the management, the amounts are realizable /payable in the ordinary course of business.

31. Fair Value Measurements:**i) Fair Value hierarchy**

Financial assets and financial liabilities measured at fair value in the statement of financial position are grouped into three levels of a fair value hierarchy. The three levels are defined based on the observability of significant input to the measurement, follows:

Level 1: Quoted prices (unadjusted) in active markets for financial instruments.

Level 2: The fair value of financial instruments that are not traded in and active market is determined using valuation techniques which maximize the use of observable market data rely as little as possible on entity specific estimates.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

ii) Financial assets and liabilities measured at fair values:

Financial Assets & Liabilities Valuation	Year ended 31-03-2022	Year ended 31-03-2021
Fair Value Hierarchy	2	2
a) Financial Assets		
Non-Current Investments		
Investment in equity instruments of Associate (cost) Unquoted (Formerly a subsidiary) Krisani Biosciences Pvt Ltd (58,68,200 equity shares of Rs 10 each subscribed at Rs. 8.3 per Share)	487,06,060	487,06,060
Total Investment in Associate	487,06,060	487,06,060
Aggregate book value of quoted investments	-	-
Aggregate market value of quoted investments	-	-
Other Financial Assets (Non-Current)		
Security Deposits at (at amortised cost)	2,00,25,000	2,03,98,662
Total Financial assets	6,87,31,060	6,91,04,722
b) Financial Liabilities		
Short term Borrowings	2,74,07,000	2,34,05,000
Total Financial Liabilities	2,74,07,000	2,34,05,000

iii. Financial Instruments by category

For amortized cost instruments, carrying value represents the best estimate of fair value:

Particulars	31st March, 2022			31st March, 2021		
	FVTPL	FVOCI	Amortized Cost	FVTPL	FVOCI	Amortized Cost
Financial Assets						
Equity Investments	487,06,060	-	-	487,06,060	-	-
Other Financial Assets	-	-	2,00,25,000	-	-	2,03,98,662
Trade Receivables	-	-	2,12,45,408	-	-	2,14,25,710
Loans	-	-	94,00,000	-	-	94,00,000
Cash and Cash Equivalents	-	-	93,213	-	-	41,317
Other Bank Balances	-	-	-	-	-	-
Others	-	-	3,98,12,178	-	-	3,82,15,351
Total	487,06,060	-	9,05,75,799	487,06,060	-	8,94,81,040
Financial Liabilities						
Borrowings	-	-	2,74,07,000	-	-	2,34,05,000
Trade Payables	-	-	12,15,251	-	-	28,72,255
Other Current Liabilities	-	-	96,83,441	-	-	2,75,15,367
Total	-	-	3,83,05,692	-	-	5,37,92,622

The Company's principal financial liabilities comprise loans and borrowings, trade and other payable. The main purpose of these financial liabilities is to finance the Company's operations.

The Company's principal financial assets include loans. Trade and other receivables, and cash and cash equivalents that derive directly from its operations. The Company also holds FVTPL investments and investments in its associates.

The Company is exposed to market risk, credit risk and liquidity risk. The Company's Board of Directors oversee the management of these risks. The company's Board of Directors is supported by the senior management that advises on financial risks and the appropriate financial risk governance framework for the Company. The senior management provides assurance to the Company's board of directors that the company's financial risk activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with the Company's policies and risk objectives.

The Carrying amounts reported in the statement of financial position for cash and cash equivalents, trade and other receivables. Trade and other payables and other liabilities approximate their respective fair values due to their short maturity.

31.1 Financial Risk Management

In course of its business, the company is exposed to certain financial risk such as market risk (Including currency risk and other price risks), credit risk and liquidity risk that could have significant influence on the company's business and operational/financial performance. The Board of directors reviews and approves risk management framework and policies for managing these risks and monitor suitable mitigating actions taken by the management to minimize potential adverse effects and achieve greater predictability to earnings.

31.2 Credit risk

Credit risk refers to the risk that counterparty will default on its contractual obligations resulting in financial loss to the company. The company has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral, where appropriate, a means of mitigating the risk of financial loss from defaults.

The company makes an allowance for doubtful debts/advances using expected credit loss model.

31.3 Liquidity risk

Liquidity risk refers to the risk that the company cannot meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. The Company's exposure to liquidity risk is minimal.

31.4 Market Risk

Market risk is the risk that changes in market prices, such as foreign exchanges rates, interest rate And equity prices, which will affect the company's income of the value of its holdings of financial Instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return.

a) Interest Rate Risk

Interest risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate Because of changes in market interest rates. The company has exposure only to financial instruments at fixed interest rates. Hence, the company is not exposed to significant interest rate Risk.

b) Price Risk

The company's exposure to equity securities price risk arises from investments held by the company and classified in the balance sheet either at fair value through OCI or at fair value through profit and loss. The majority of the company's equity instruments are publicly traded.

32. Capital Management Risk

The Company's objective when managing capital is to safeguard the Company's ability to continue as a going concern in order to provide returns for shareholders and benefits for stake holders. The company also proposes to maintain an optimal capital structure to reduce the cost of capital. Hence, the company may adjust any dividend payments, return capital to shareholders or issue new shares. Total capital is the equity as shown in the statement of financial position. Currently, the company primarily monitors its capital structure on the basis of gearing ratio. Management is continuously evolving strategies to optimize the returns and reduce the risks. It includes plans to optimize the financial leverage of the company.

The capital for the reporting year under review is summarized as under:

Particulars	March 31, 2022	March 31, 2021
Non-Current Borrowings	0	0
Current Borrowings	2,74,07,000	2,34,05,000
Total Debt	2,74,07,000	2,34,05,000
As a percentage of total capital	17.08%	16.55%
Equity	13,29,87,895	11,80,03,994
As a percentage of total capital	82.91*%	83.44%
Total Capital (Debt and Equity)	16,03,94,895	14,14,08,994
Gearing Ratio (total debt/Total Equity)	0.206	0.198

33. Impact of Global Health Pandemic - COVID-19

COVID-19 is the infectious disease caused by the most recently discovered coronavirus, SARSCoV-2. In March 2020, the WHO declared COVID-19 a pandemic. Company has adopted measures to curb the spread of infection in order to protect the health of employees and ensure business continuity with minimal disruption.

The Company's management has made initial assessment of likely adverse impact on business and financial risks on account of COVID-19. It is well appreciated that situation as well as its assessment is continuously evolving, and the way ahead is to avoid living in denial leading to acceptance & pro-active measures. The Company's management currently believes that the impact is likely to be short term in nature. Given the severity of impact, this financial year is likely to get affected, but also given the measures from Government and inherent resilience in Indian Economy, next year onwards are expected to show normal growth scenarios. Accordingly, at present the management does not see any medium to long term risks in the Company's ability to continue as a going concern and meeting its liabilities as and when they fall due, and compliance with the debt covenants, as applicable.

In assessing the recoverability of receivables and other financial assets, Company has considered internal and external information upto the date of approval of these financial results. The impact of the global health pandemic may be different from that of estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes to future economic conditions.

34. Standards Issued But Not Effective

The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.

As at the date of issue of financial statements, there are no new standards or amendments which have been notified by the MCA but not yet adopted by the Company. Hence, the disclosure is not applicable.

35. Due to a fresh issue of equity shares in the subsidiary firm, the company has lost control of its former subsidiary (Krisani Bio Sciences Private Limited) as of November 12, 2021. The stake of investment has decreased to 32.91 percent from 51.33 percent. Consequent to which, the company's former subsidiary is now an associate due to decrement in share of investment.
36. The TDS Payable amounts of Rs. 35,13,198, interest accounted on such payable amounts of INR 13,85,335 and related expenses of INR 1,25,17,661 that were claimed in prior years have been written down during the year and have been shown as income in the profit and loss statement under other income. But to the extent of INR 15,89,044 out of above mentioned TDS liability the related expenses has not been written off. The break up of section wise the Non written off expenses against the written down TDS liability is as follows:

Section	Amount (INR)
192B	12,58,200
194C	88285
194I	307320
194J	78894
Total	15,89,044

37. Solvency Ratios:

Particulars	Numerator	Denominator	March 31, 2022	March 31, 2021	Variance	Decrease was primarily on account of decrease in profits and increase in the borrowings
Current Ratio	Current Assets	Current Liabilities	1.84	1.31	28.97%	Increase in current assets on account of writing off the liability during the year
Debt-Equity Ratio	Total Debt	Shareholders Equity	0.21	0.20	3.76%	
Debt Service Coverage Ratio	Earnings Available for Debt Services	Debt Service	NA	NA		
Return on Equity (ROE)	Net Profit After Taxes	Average Shareholders Equity	0.12	(0.06)	153.21%	Increase income due to writing off the liabilities during the year
Inventory Turnover Ratio	revenue from Operations	Average Inventory	0.35	0.10	71.33%	Increase was on account of decrease in inventory and increase in revenue
Trade Receivables Turnover Ratio	revenue from Operations	Average Receivables	0.01	0.01	0.00%	
Trade Payables Turnover Ratio	Purchases	Average Trade payables	0.11	-	100.00%	
Net Capital Turnover Ratio	revenue from Operations	Working Capital	0.01	0.01	0.00%	
Net Profit ratio	Net Profit	revenue from Operations	0.78	(4.79)	716.51%	Increase income due to writing off the liabilities during the year
Return on Capital Employed (ROCE)	Earnings before interest and taxes (EBIT)	Capital Employed	0.11	(0.07)	157.89%	Increase income due to writing off the liabilities during the year
Return on Investment	Income generated from Investments	Investment	NA	NA		

38. Other Statutory Information:

- The Company does not have any Benami property, where any proceeding has been initiated or pending against the Group for holding any Benami property.
- The Company does not have any transactions with companies struck off.
- The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities

(Intermediaries) with the understanding that the Intermediary shall:

- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
- (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- vii. The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Group shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- viii. The Company has not any such transaction which is not recorded in the books of account that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.
- 39. Previous year's figures have been regrouped/reclassified wherever necessary, to confirm to current period's classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1st April, 2021.

As per our report of even date
for A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No: 009068S

Sd/-
(D.Rama Krishna Reddy)
Partner
Membership No. 209211
UDIN: 22209211AJGLBW9448

Place: Hyderabad
Date : 19-05-2022

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

INDEPENDENT AUDITOR'S REPORT

To the Members of Dr Habeebullah Life Sciences Limited

Report on the Audit of the Consolidated Financial Statements**Opinion**

We have audited the accompanying consolidated financial statements of Dr Habeebullah Life Sciences Limited (hereinafter referred to as the "Holding Company") and its Associate (Holding Company and its Associate together referred to as "the Group"), which comprise the Consolidated Balance Sheet as at March 31, 2022, and the Consolidated Statement of Profit and Loss, the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flows for the year then ended, and notes to the Consolidated Financial Statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, and based on consideration of reports of other auditors on separate financial statements and on the other financial information of associate the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015 as amended and other accounting principles generally accepted in India, of their consolidated state of affairs of the Group, as at March 31, 2022, of consolidated profit, consolidated changes in equity and its consolidated cash flows for the year then ended.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the consolidated financial statements in India in terms of the Code of Ethics issued by Institute of Chartered Accountant of India ("ICAI"), and the relevant provisions of the Act and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined the matters described below to be the key audit matters to be communicated in our report.

S.No	Key Audit Matter	Auditor's Response
1.	Parent company during the year ended 31 March 2022, The company has written off the TDS liabilities and interest there on and the same offered as Income and related expenses on which tds had been deducted has also offered as income except expenses related to the extent of TDS liability INR 15,89,044 has not written off. Because this is a non-routine transaction which requires the management judgement and the accounting treatment is complex, we consider this a key audit matter for our audit. (refer Note No 36 of notes to financial statements)	Our audit procedures included, among others, the following: <ul style="list-style-type: none"> We have analysed the transactions and identified the TDS liability and related expenses and discussed it with the Directors and management of the Company. We ensured that the total TDS liability and related expenses are offered as income. But to the extent of the TDS liability of INR 15,89,044 has not offered as income. We assessed the relevant disclosures in the financial statements.

Information Other than the Consolidated Financial Statements and Auditor's Report Thereon

The Holding Company's Board of Directors is responsible for the other information. The other information comprises the Director's report but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the preparation and presentation of these consolidated financial statements in term of the requirements of the Act that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Auditing ("SAs") will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

We give in "Annexure A" a detailed description of Auditor's responsibilities for Audit of the Consolidated Financial Statements.

Other Matters

We did not audit the financial statements of Krisani Bio Sciences Private Limited ("associate"), whose financial statements reflect total assets (before consolidation adjustment) of Rs. 16,45,19,540 as at March 31, 2022, total revenues (before consolidation adjustment) are Nil and Cash and cash equivalents (before consolidation adjustment) amounting to Rs. 60,591 for the year ended on that date, as considered in the consolidated financial statements. The Consolidated financial statements also include the Group's share of net loss of Rs. 1,10,900 for the year ended March 31, 2022, as considered in the consolidated financial statements, whose financial

statements have not been audited by us. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of this associate and our report in terms of sub-section (3) of Section 143 of the Act, in so far as it relates to the aforesaid associate, is based solely on the reports of the other auditors.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, we report, to the extent applicable, that:

- a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements;
- b. In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books and the reports of the other auditors;
- c. The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, the Consolidated Statement of Changes in Equity and the Consolidated Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements;
- d. In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e. On the basis of the written representations received from the directors of the Holding Company as on March 31, 2022 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its associate company incorporated in India, none of the directors of the Group company incorporated in India is disqualified as on March 31, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
- f. With respect to the adequacy of internal financial controls over financial reporting of the Group and the operating effectiveness of such controls, refer to our separate report in "Annexure B".
- g. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us and based on the auditors reports of the associate company incorporated in India the remuneration paid by the parent and such associate Company to their respective directors during the year is in accordance with the provisions of section 197 of the Act.
- h. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. There were no pending litigations which would impact the consolidated financial position of the Group.
- ii. The Group did not have any material foreseeable losses on long-term contracts including derivative contracts.
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Holding Company, and its associate company incorporated in India.
- iv. a) The respective managements of the parent and its associate which are companies incorporated in India whose financial statements have been audited under the Act, have represented to us and to the other auditors of such associate respectively that, to the best of its knowledge and belief, as disclosed in the note 42(vi) to the Standalone financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

- b) The respective managements of the parent and its associate which are companies incorporated in India whose financial statements have been audited under the Act, have represented to us and to the other auditors of such associate respectively that, to the best of their knowledge and belief, as disclosed in the note 34(vii) to Consolidated financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- c) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances performed by us and performed by the auditors of the associate which are companies incorporated in India whose financial statements audited under the Act, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- v. No Interim dividend has declared by the company during the year or previous year so the provisions of section 123 of the Companies Act, 2013 are not applicable to the company.
2. With respect to the matters specified in clause (xxi) of paragraph 3 and paragraph 4 of the Companies (Auditor's Report) Order, 2020 ("CARO" / "the Order") issued by the Central Government in terms of Section 143(11) of the Act, according to the information and explanations given to us, and based on the CARO reports issued by us and the auditors of respective companies included in the consolidated financial statements to which reporting under CARO is applicable, as provided to us by the Management of the Parent, we report that there are no qualifications or adverse remarks by the respective auditors in the CARO reports of the said companies included in the consolidated financial statements.

For A M Reddy & D R Reddy
Chartered Accountants
ICAI Firm Registration No. 009068S

Sd/-
D.Rama Krishna Reddy
Partner
Membership No.209211
UDIN: 22209211AOVJDL2511

Place: Hyderabad,
Date: 10/08/2022

ANNEXURE A TO THE INDEPENDENT AUDITOR'S REPORT ON EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF DR HABEEBULLAH LIFE SCIENCES LIMITED**Auditor's Responsibilities for the Audit of the Consolidated Financial Statements**

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities included in the consolidated financial statements of which we are the independent auditors. For the other entities included in the consolidated financial statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

For A M Reddy & D R Reddy
Chartered Accountants
ICAI Firm Registration No. 009068S

Sd/-
D.Rama Krishna Reddy
Partner
Membership No.209211
UDIN: 22209211AOVJDL2511

Place: Hyderabad,
Date: 10/08/2022

ANNEXURE B TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF DR HABEEBULLAH LIFE SCIENCES LIMITED

[Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' in the Independent Auditors' Report of even date to the Members of Dr Habeebullah Life Sciences Limited on the consolidated Financial Statements for the year ended March 31, 2022]

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

In conjunction with our audit of the consolidated financial statements of the Company as of and for the year ended March 31, 2022, we have audited the internal financial controls with reference to consolidated financial statements of Dr Habeebullah Life Sciences Limited (hereinafter referred to as "the Holding Company") and its associate company which is incorporated in India, as of that date.

Management's Responsibility for Internal Financial Controls

The respective Board of Directors of the Holding company, its associate company which is incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control with reference to consolidated financial statements criteria established by the respective companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India ("the ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls with reference to consolidated financial statements of the Holding company, its associate company, which is incorporated in India, based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the ICAI and the Standards on Auditing prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether internal financial controls with reference to consolidated financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the internal financial controls with reference to consolidated financial statements and their operating effectiveness. Our audit of internal financial controls with reference to consolidated financial statements included obtaining an understanding of internal financial controls with reference to consolidated financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors in terms of their reports referred to in the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to consolidated financial statements of the Holding company, its associate company which is incorporated in India.

Meaning of Internal Financial Controls with Reference to Consolidated Financial Statements

A company's internal financial control with reference to consolidated financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to consolidated financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the

company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the consolidated financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Consolidated Financial Statements

Because of the inherent limitations of internal financial controls with reference to consolidated financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to consolidated financial statements to future periods are subject to the risk that the internal financial control with reference to consolidated financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, and to the best of our information and according to the explanations given to us, the Holding Company, its associate company incorporated in India, have, in all material respects, internal financial controls with reference to consolidated financial statements and such internal financial controls with reference to consolidated financial statements were operating effectively as at March 31, 2022, based on the internal control with reference to consolidated financial statements criteria established by the respective companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI.

Other Matters

Our aforesaid reports under Section 143(3)(i) of the Act on the adequacy and operating effectiveness of the internal financial controls with reference to consolidated financial statements insofar as it relates to associate company which is incorporated in India, is based on the corresponding reports of the auditors of such company incorporated in India.

For A M Reddy & D R Reddy
Chartered Accountants
ICAI Firm Registration No. 009068S

Sd/-
D.Rama Krishna Reddy
Partner
Membership No.209211
UDIN: 22209211AOVJDL2511

Place: Hyderabad
Date: 10/08/2022

CONSOLIDATED BALANCE SHEET AS AT 31st MARCH 2022

(Amount in Rs.)

	PARTICULARS	Note No.	As at March 31, 2022	As at March 31, 2021
I	ASSETS:			
(1)	Non-current assets			
	(a) Property, Plant and Equipment	2	1,24,849	1,78,460
	(b) Capital work-in-progress		-	-
	(c) Goodwill		-	-
	(d) Other Intangible Assets		-	-
	(e) Intangible Assets under development	3	3,25,95,370	3,25,95,370
	(f) Financial assets			
	(i) Investments	4	4,79,90,427	4,22,21,421
	(ii) Other Financial Assets	5	2,00,25,000	2,03,98,662
(2)	Current assets			
	(a) Inventories	6	-	12,92,128
	(b) Financial assets			
	(i) Investments		-	-
	(i) Trade receivables	7	2,12,45,408	2,14,25,710
	(ii) Cash and cash equivalents	8	93,213	41,317
	(iii) Loans and advances	9	94,00,000	94,00,000
	(iv) Other financial assets	10	52,58,630	37,76,850
	(c) Other current assets	11	3,45,53,548	3,44,38,501
	TOTAL ASSETS		17,12,86,445	16,57,68,418
II	EQUITY AND LIABILITIES:			
	Equity			
	(a) Equity Share Capital	12	14,80,87,060	14,80,87,060
	(b) Other Equity			
	(i) Reserves and Surplus	13	(1,58,14,798)	(3,65,67,705)
	Liabilities			
(1)	Non Current Liabilities			
	(a) Financial Liabilities			
	(a) Provisions	14	7,08,491	4,56,345
(2)	Current Liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	15	2,74,07,000	2,34,05,000
	(ii) Trade Payables	16	12,15,251	28,72,255
	(b) Other current liabilities	17	96,83,441	2,75,15,367
	(c) Provisions	18	-	96
	TOTAL EQUITY AND LIABILITIES		17,12,86,445	16,57,68,418
		1 to 37		

As per our report of even date
for A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No: 009068S

Sd/-
(D.Rama Krishna Reddy)
Partner
Membership No. 209211
UDIN: 22209211AOVJDL2511

Place: Hyderabad
Date : 10.08.2022

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

CONSOLIDATED STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31st MARCH 2022

(Amount in Rs.)

S.No.	PARTICULARS	Note No.	Year Ended March 31, 2022	Year Ended March 31, 2021
I	Revenue from operations	19	2,24,541	1,29,724
II	Other Income	20	1,90,62,617	14,77,331
III	Total Income (I+II)		1,92,87,158	16,07,055
IV	Expenses:			
	Purchase of Medicines	21	2,15,932	-
	Raw materials consumed	22(a)	-	19,273
	Change in Inventories (Raw Materials)	22(b)	12,92,128	-
	Employee Benefits Expenses	23	11,46,950	33,17,297
	Depreciation and amortization expenses	2	53,611	96,014
	Other expenses	24	15,94,636	58,71,543
	Total Expenses		43,03,257	93,04,127
V	Profit before tax (III-IV)		1,49,83,901	(76,97,072)
VI	Tax Expenses			
	- Current tax		-	-
	- Deferred tax		-	-
VII	Profit for the period (V-VI)		1,49,83,901	(76,97,072)
VIII	Share of loss of an Associate		(1,10,900.00)	(22,922)
IX	Profit for the year after share of loss of an associate		1,48,73,001	(77,19,994)
VIII	Other Comprehensive Income (OCI)			
	i) Items that will not be reclassified to profit & loss		-	14,08,499
	Other comprehensive income for the year (net of tax)		-	14,08,499
IX	Total Comprehensive Income (VII+VIII)		1,48,73,001	(63,11,495)
X	Earnings per equity share: (Equity shares of par value of Rs.10/- each)			
	- Basic	28	1.00	(0.42)
	- Diluted	28	1.00	(0.42)
Significant accounting policies and notes to accounts		1 to 37		

As per our report of even date
for A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No: 009068S

Sd/-
(D.Rama Krishna Reddy)
Partner
Membership No. 209211
UDIN: 22209211AOVJDL2511

Place: Hyderabad
Date : 10.08.2022

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31st MARCH, 2022

(Amount in Rs.)

PARTICULARS	Year Ended March 31, 2022	Year Ended March 31, 2021
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	1,49,83,901	(62,88,573)
Adjustment for:		
Depreciation and Amortisation	53,611	96,014
Interest Expenses	-	-
Interest Earned	-	-
Cash Flows from Operations before changes in assets and liabilities	1,50,37,512	(61,92,559)
Movements in Working Capital::		
(Increase)/ Decrease in trade receivables	1,80,302	3,25,722
(Increase)/ Decrease in Short Term Loans and Advances	-	-
(Increase)/ Decrease in other Current Assets	(1,15,047)	(7,173)
(Increase)/ Decrease in other other financial Assets	(14,81,780)	(13,66,531)
(Increase)/ Decrease in Inventories	12,92,128	19,273
Increase /(Decrease) in Trade Payables	(16,57,004)	(1,77,649)
Increase/ (Decrease) in Other current liabilities	(1,78,31,926)	51,95,363
Increase/ (Decrease) in Current Provisions	(96)	(2,42,944)
Change in Working Capital	(1,96,13,423)	37,46,061
Changes in non current assets and liabilities		
Decrease/(Increase) in other financials Assets	3,73,662	29,000
(Decrease)/Increase in Long Term Borrowings	-	-
(Decrease)/Increase in Long Term Provisions	2,52,146	(9,93,399)
Changes in non current assets and liabilities	6,25,808	(9,64,399)
Cash Generated From Operations	(39,50,103)	(34,10,897)
Less: Taxes paid	-	-
Net Cash from operating activities(A)	(39,50,103)	(34,10,897)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Increases) / Decrease in Fixed assets and Capital Work In progress	-	(22,72,849)
Bank Balances not considered as Cash and Cash equivalents	-	-
Investment in equity Shares	-	-
Balance of Unclaimed Dividend	-	-
Net cash used in Investing activities (B)	-	(22,72,849)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	-	-
Increase / (Decrease) in Borrowings	40,02,000	54,90,000
Interest paid	-	-
Net cash Flow from Financing Activities (C)	40,02,000	54,90,000
D. Effect of exchange differences on translation of foreign currency cash and cash equivalents	-	-
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	51,897	(1,93,745)
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	41,317	2,35,061
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	93,213	41,317

As per our report of even date
for A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No: 009068S

Sd/-
(D.Rama Krishna Reddy)
Partner
Membership No. 209211
UDIN: 22209211AOVJDL2511

Place: Hyderabad
Date : 10.08.2022

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31st MARCH, 2022

a. Equity share capital

(Amount in Rs.)	
Particular	Amount
Balance as at the 31 March 2020	14,80,87,060
Changes in equity share capital during 2020-21	-
Balance as at the 31 March 2021	14,80,87,060
Changes in equity share capital during 2021-22	-
Balance as at the 31 March 2022	14,80,87,060

b. Other equity

(Amount in Rs.)					
Particular	Share Warrants	Reserves and surplus		Items of Other comprehensive income (OCI)	Total
		Securities Premium Reserve	Retained earnings	Others	
Balance at 31 March 2020	50,00,000	4,55,00,000	(6,95,42,776)	2,48,284	(1,87,94,492)
Profit or loss	-	-	(77,19,994)	-	(77,19,994)
Loss on Adjustment of Investment Value in Associate	-	-	(64,61,717)	-	-
Other comprehensive income(net of tax)	-	-	-	14,08,499	14,08,499
Total income	-	-	(1,41,81,711)	14,08,499	(63,11,495)
Transactions with owners in their capacity as owners	-	-	-	-	-
Balance at 31 March 2021	-	4,55,00,000	(8,37,24,487)	16,56,783	(3,65,67,704)
Profit or loss	-	-	1,48,73,001	-	1,48,73,001
gain on retaining the non controlling Interest	-	-	58,79,906	-	-
Other comprehensive income(net of tax)	-	-	-	-	-
Total Income	-	-	2,07,52,907	-	1,48,73,001
Transactions with owners in their capacity as owners	-	-	-	-	-
Balance at 31 March 2022	-	4,55,00,000	(6,29,71,580)	16,56,783	(1,58,14,797)

As per our report of even date
for A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No: 009068S

Sd/-
(D.Rama Krishna Reddy)
Partner
Membership No. 209211
UDIN: 22209211AOVJDL2511

Place: Hyderabad
Date : 10.08.2022

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

Notes to Consolidated Financial Statements**1. Significant Accounting Policies & Notes annexed to and forming part of the Consolidated financial Statements****1.1. Basis for preparation of Consolidated financial statements:****a) Compliance with Indian Accounting Standards (Ind AS)**

The financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) as per the Companies (Indian Accounting Standards) Rules, 2015 notified under section 133 of the Companies Act, 2013.

The same accounting policies have been applied for all the periods presented except when the company has made use of certain exceptions.

The financial statements have been prepared on the historical cost basis except for certain instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies below.

Historical cost is generally based on the fair value of the consideration given in exchange for goods and services. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique.

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the schedule III of the Act. The Company has determined its operating cycle as twelve months for the purpose of current-noncurrent classification of assets and liabilities.

The financial statements are presented in Indian Rupees which is also its functional currency. All amounts have been rounded – off to the nearest rupees, unless otherwise indicated.

b) Basis of consolidation

The consolidated financial statements comprise the financial statements of the Company and share of profit or loss of its Associate as at 31 March 2022.

If an entity holds, directly or indirectly (eg through subsidiaries), 20 per cent or more of the voting power of the investee, it is presumed that the entity has significant influence, unless it can be clearly demonstrated that this is not the case. Conversely, if the entity holds, directly or indirectly (eg through subsidiaries), less than 20 per cent of the voting power of the investee, it is presumed that the entity does not have significant influence, unless such influence can be clearly demonstrated. A substantial or majority ownership by another investor does not necessarily preclude an entity from having significant influence.

Specifically, the Group controls an investee if and only if the Group has:

- representation on the board of directors or equivalent governing body of the investee;
- participation in policy-making processes, including participation in decisions about dividends or other distributions;
- material transactions between the entity and its investee;
- interchange of managerial personnel; or
- provision of essential technical information.

Consolidation of a Association begins when the Group obtains control over the associate and ceases when the Group loses control of the Associate.

Consolidated financial statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances. If a member of the group uses accounting policies other than those adopted in the consolidated financial statements for like transactions and events in similar circumstances, appropriate adjustments are made to that group member's financial statements in preparing the

consolidated financial statements to ensure conformity with the group's accounting policies.

The financial statements of all entities used for the purpose of consolidation are drawn up to same reporting date as that of the parent company, i.e., year ended on 31st March.

Consolidation procedure

Under the equity method, on initial recognition the investment in an associate or a joint venture is recognised at cost, and the carrying amount is increased or decreased to recognise the investor's share of the profit or loss of the investee after the date of acquisition. The investor's share of the investee's profit or loss is recognised in the investor's profit or loss. Distributions received from an investee reduce the carrying amount of the investment. Adjustments to the carrying amount may also be necessary for changes in the investor's proportionate interest in the investee arising from changes in the investee's other comprehensive income. Such changes include those arising from the revaluation of property, plant and equipment and from foreign exchange translation differences. The investor's share of those changes is recognised in the investor's other comprehensive income (see Ind AS 1, Presentation of Financial Statements).

The recognition of income on the basis of distributions received may not be an adequate measure of the income earned by an investor on an investment in an associate or a joint venture because the distributions received may bear little relation to the performance of the associate or joint venture. Because the investor has joint control of, or significant influence over, the investee, the investor has an interest in the associate's or joint venture's performance and, as a result, the return on its investment. The investor accounts for this interest by extending the scope of its financial statements to include its share of the profit or loss of such an investee. As a result, application of the equity method provides more informative reporting of the investor's net assets and profit or loss.

c) Use of estimates and judgment

In preparing these financial statements, management has made judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of certain assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.

1.2. Property, Plant and Equipment & Depreciation

Items of Property, Plant and Equipment are stated at cost less accumulated depreciation.

Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labor, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in profit or loss.

Assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less cost of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units).

Depreciation on the fixed assets has been provided based on useful lives as prescribed under part C of the schedule II of the companies' act, 2013.

Depreciation method, useful lives and residual values are reviewed at each financial year-end and adjusted if appropriate.

Depreciation on additions (disposals) is provided on a pro-rata basis i.e., from (up to) the date on which asset is ready for use (disposed of).

1.3 Impairment of non-financial assets

The Company's non-financial assets, other than deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment losses are recognised in the statement of profit and loss. Impairment loss recognised in respect of a CGU is allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets of the CGU (or group of CGUs) on a pro rata basis.

1.4 Intangible assets

Intangible assets are amortized over the estimated useful lives and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method are reviewed at least at each financial year end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as change in accounting estimates. The amortization expense on intangible assets with finite useful lives is recognized in profit or loss.

1.5 Inventory

Cost of inventories have been computed to include all costs of purchases (including materials), cost of conversion and other costs incurred, as the case may be, in bringing the inventories to their present location and condition.

Stores and consumables are valued at cost arrived at on FIFO basis or net realisable value, whichever is lower.

1.6 Foreign currencies transactions and translations

Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency closing rates of exchange at the reporting date.

The gain or loss on decrease/increase in reporting currency due to fluctuations in foreign exchange rates, in case of monetary current assets and liabilities in foreign currency, are recognised in the Statement of Profit and Loss.

Non-monetary items that are measured in terms of historical cost in a foreign currency are recorded using the exchange rates at the date of the transaction.

1.7 Provisions

A provision is recognised when the Company has a present legal or constructive obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. Provisions (other than employee benefits) are not discounted to its

present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

1.8 Revenue Recognition

The Company primarily earns revenue by providing Health care services.

Revenue is recognised when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and specific criteria have been met as described below.

Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are net of indirect taxes, trade allowances, rebates and amounts collected on behalf of third parties and is not recognised in instances where there is uncertainty with regard to ultimate collection. In such cases revenue is recognised on reasonable certainty of collection.

Interest Income

Interest income from a financial asset is recognised using effective interest rate method. However, in respect of certain financial assets where it is not probable that the economic benefits associated with the transaction will flow to the entity and amount of revenue cannot be measured reliably, in such cases interest income is not recognised.

1.9 Dividend Income

Dividends will be recognised when the company's right to receive has been established.

1.10 Employee benefits

1.10.1 Short term employee benefits

The undiscounted amount of short-term employee benefits is expected to be paid in exchange for the services rendered by employees are recognised as an expense during the period when the employees render the services.

1.10.2 Defined benefit plans

a) Gratuity

In accordance with the Payment of Gratuity Act, 1972, Company provides for gratuity, a defined retirement plan (the "Gratuity Plan") covering the eligible employees. The Gratuity Plan provides a lump sum payment to vested employees at retirement, death, incapacitation or termination of employment, of an amount based on the respective employee salary and the tenure of employment. Liability with regard to the Gratuity Plan are determined by actuarial valuation as per the requirements of IndAS 19 as of the balance sheet date, based upon which, the Company contributes the ascertained liabilities to Insurer.

b) Provident fund

Eligible employees receive benefits from a provident fund, which is a defined contribution plan. Aggregate contributions along with interest thereon is paid at retirement, death, incapacitation or termination of employment. Both the employee and the Company make monthly contributions to the Regional Provident Fund Commissioner equal to a specified percentage of the covered employee's salary.

c) Employee State Insurance Fund

Eligible employees are entitled to receive benefit under employee state insurance fund scheme. The employer makes contribution to the scheme at a predetermined rate of employee's gross salary. The Company has no further obligations under the plan beyond its monthly contributions. These contributions are made to the fund administered and managed by the Government of India. contributions made on a monthly basis which are charged to the Statement of Profit and Loss.

d) Leave encashment

All the employees who have completed their eligible service in the Company are eligible for leave encashment as per policy of the Company and the same is paid to the eligible employee at retirement,

death, incapacitation or termination of employment. This amount, as calculated for all the eligible employees, is charged to the Statement of Profit and Loss.

1.11 Tax Expenses

The tax expense for the period comprises current and deferred tax. Tax is recognised in Statement of Profit and Loss, except to the extent that it relates to items recognised in the comprehensive income or in equity. In which case, the tax is also recognised in other comprehensive income or equity.

Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any, related to income taxes. It is measured using tax rates (and tax laws) enacted or substantively enacted by the reporting date.

Current tax assets and current tax liabilities are off set only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis or simultaneously.

Deferred tax

Deferred tax is recognised on temporary differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax is also recognised in respect of carried forward tax losses and tax credits.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset is realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. The carrying amount of deferred tax liabilities and assets are reviewed at the end of each reporting period.

Minimum alternate tax (MAT)

Minimum alternate tax (MAT) paid in a year is charged to the Statement of Profit and Loss as current tax. The Company recognizes MAT credit available as an asset only to the extent that there is convincing evidence that the Company will pay normal income tax during the specified period, i.e., the period for which MAT credit is allowed to be carried forward. In the year in which the company recognizes MAT credit as an asset in accordance with the Guidance Note on Accounting for Credit Available in respect of Minimum Alternative Tax under the Income-tax Act, 1961, the said asset is created by way of credit to the Statement of Profit and Loss and shown as "MAT Credit Entitlement." The Company reviews the "MAT credit entitlement" asset at each reporting date and writes down the asset to the extent the company does not have convincing evidence that it will pay normal tax during the specified period.

1.12 Leases

At the date of commencement of the lease, the Company recognizes a right-of-use asset ("ROU") and a corresponding lease liability for all lease arrangements in which it is a lessee, except for leases with a term of twelve months or less (short-term leases) and low value leases. For these short-term and low value leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease.

As per Ind AS 116, Variable lease payments that do not depend on an index or rate and are not in substance or fixed, such as those based on performance (i.e. percentage of sales) are not included as lease payments and these payments are recognized in the statement of profit or loss in the period in which the event that triggers the payment occurrence.

Hence, the company did not recognize any ROU as the lease agreement does not contain fixed Minimum Lease payments.

1.13 Borrowing costs

Borrowing costs incurred for obtaining assets which takes substantial period to get ready for their intended use are capitalized to the respective assets wherever the costs are directly attributable to such assets and in other cases by applying weighted average cost of borrowings to the expenditure on such assets. Other borrowing costs are treated as expense for the year.

Transaction costs in respect of long-term borrowings are amortized over the tenor of respective loans using effective interest method.

1.14 Earnings per equity share

(i) Basic earnings per share

Basic earnings per share is calculated by dividing:

- The profit attributable to owner of the company.
- By the weighted number of equity shares outstanding during the financial year

(ii) Diluted earnings per share

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of share outstanding during the period is adjusted for the effects of all dilutive potential equity shares.

1.15 Financial Instruments

i. Financial assets

A. Initial recognition and measurement

All financial assets and liabilities are initially recognized at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities, which are not at fair value through profit or loss, are adjusted to the fair value on initial recognition.

a) Financial assets carried at amortized cost (AC)

A financial asset is measured at amortized cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

b) Financial assets at fair value through profit or loss (FVTPL)

A Financial asset which is not classified as AC or FVOCI are measured at FVTPL e.g. investments in mutual funds. A gain or loss on a debt investment that is subsequently measured at fair value through profit or loss is recognised in profit or loss and presented net in the Statement of Profit and Loss within other gains/(losses) in the period in which it arises.

c) Financial assets at fair value through other comprehensive income (FVTOCI)

A financial asset is measured at FVTOCI if it is held within a business model whose Objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

B. Investments in subsidiaries

In respect of equity investments, the entity prepares separate financial statements and account for its investments in subsidiaries at cost, net of impairment if any.

ii. Financial Liabilities**A. Initial recognition**

All financial liabilities are recognized at fair value.

B. Subsequent measurement

Financial liabilities are carried at amortized cost using the effective interest method. For trade and other payables maturing within one year from the balance sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

Notes to accounts
NOTE NO 2: PROPERTY, PLANT AND EQUIPMENT

(Amount in Rs.)

Particular	Computer s	Furniture and Fixtures	Lab Equipment s	Office Equipment	Total
Balance at 31 March 2019	1,64,593	-	1,35,440	1,99,829	4,99,862
Additions	-	-	-	-	-
Disposals	-	-	-	-	-
Balance at 31 March 2020	1,64,593	-	1,35,440	1,99,829	4,99,862
Additions	-	-	-	-	-
Disposals	-	-	-	-	-
Balance at 31 March 2021	1,64,593	-	1,35,440	1,99,829	4,99,862
Additions	-	-	-	-	-
Disposals	-	-	-	-	-
Balance at 31 March 2022	1,64,593	-	1,35,440	1,99,829	4,99,862
Balance at 31 March 2019	58,121	-	4,413	54,480	1,17,014
Depreciation for the year	54,864	-	13,544	39,966	1,08,374
Balance at 31 March 2020	1,12,985	-	17,957	94,446	2,25,388
Depreciation for the year	42,504	-	13,544	39,966	96,014
Balance at 31 March 2021	1,55,489	-	31,501	1,34,412	3,21,402
Depreciation for the year	-	-	13,645	39,966	53,611
Balance at 31 March 2022	1,55,489	-	45,146	1,74,378	3,75,013
Carrying amounts(net)					
At 31 March 2019	1,06,472	-	1,31,027	1,45,349	3,82,848
At 31 March 2020	51,608	-	1,17,483	1,05,383	2,74,474
At 31 March 2021	9,104	-	1,03,939	65,417	1,78,460
At 31 March 2022	9,104	-	90,294	25,451	1,24,849

Notes to Financial Statements

NOTE NO: 3 INTANGIBLE ASSETS UNDER DEVELOPMENT

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Intangible Assets		
Intangible Assets Under Development	3,25,95,370	3,25,95,370
	3,25,95,370	3,25,95,370

Capital work-in-progress (CWIP) ageing schedule for the Year ended 31/03/2022

PARTICULARS	Amount of CWIP for a period of				Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
(i) Projects in Progress	-	2272848	8867047	21455475	32595370
(ii) Projects temporarily suspended	-	-	-	-	-

Capital work-in-progress (CWIP) ageing schedule for the Year ended 31/03/2021

PARTICULARS	Amount of CWIP for a period of				Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
(i) Projects in Progress	22,72,848.00	88,67,047.00	1,22,89,614.00	1,22,89,614.00	3,25,95,370.00
(ii) Projects temporarily suspended					

NOTE NO: 4 NON CURRENT INVESTMENTS:

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Investment In Subsidiary Company carried at Cost		
Krisani Bio Sciences Private Limited (58,68,200 equity shares of Rs. 10 each subscribed at Rs. 8.3 per share)	4,79,90,427	4,22,21,421
	4,79,90,427	4,22,21,421

NOTE NO: 5 OTHER NON-CURRENT FINANCIAL ASSETS

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Security Deposits	2,00,25,000	2,03,98,662
	2,00,25,000	2,03,98,662

NOTE NO: 6 INVENTORIES

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Stores and consumables	-	12,92,128
	-	12,92,128

NOTE NO: 7 TRADE RECEIVABLES

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
(a) Outstanding for a period exceeding six months from the date they are due for payment Unsecured, considered good	2,08,99,089	2,11,25,710
(b) Outstanding for a period not exceeding six months Unsecured, considered good	3,46,319	3,00,000
	2,12,45,408	2,14,25,710

- a) No trade or other receivables are due from directors or other officers of the Company either severally or jointly with any other person. Nor any trade or other receivables are due from firms or private companies respectively in which any director is a partner, a director or a member.
- b) Trade receivables are non-interest bearing and are generally on terms of 30 – 120 days.

Trade Receivables Ageing Schedule for the Year ended 31/03/2022

PARTICULARS	Outstanding for following periods from date of payment					Total
	Less Than 6 Months	6m to 1 Year	1-2 years	2-3 years	> 3 Years	
(i) Undisputed Trade Receivables -Considered Good	2,51,485	-	-	-	2,09,93,923	2,12,45,408
(ii) Undisputed Trade Receivables -Considered Doubtful	-	-	-	-	-	-
(iii) Disputed Trade Receivables -Considered Good	-	-	-	-	-	-
(iv) Disputed Trade Receivables -Considered Doubtful	-	-	-	-	-	-

Trade Receivables Ageing Schedule for the Year ended 31/03/2021

PARTICULARS	Outstanding for following periods from date of payment					Total
	Less Than 6 Months	6m to 1 Year	1-2 years	2-3 years	> 3 Years	
(i) Undisputed Trade Receivables -Considered Good	--	-	-	-	2,14,25,710	2,14,25,710
(ii) Undisputed Trade Receivables -Considered Doubtful	-	-	-	-	-	-
(iii) Disputed Trade Receivables -Considered Good	-	-	-	-	-	-
(iv) Disputed Trade Receivables -Considered Doubtful	-	-	-	-	-	-

NOTE NO: 8 CASH AND CASH EQUIVALENTS:

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
(a) Balance with banks	91,964	24,399
(b) Cash on Hand	1,249	16,918
	93,213	41,317

NOTE NO: 9 LOANS & ADVANCES

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
(a) Inter Corporate Loan given to group company M/s Innovision Life Sciences Private Limited	94,00,000	94,00,000
	94,00,000	94,00,000

NOTE NO: 10 OTHER FINANCIAL ASSETS

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Interest receivable On Inter Corporate Loan given to M/s Innovision Life Sciences Pvt. Ltd	52,58,630	37,76,850
	52,58,630	37,76,850

NOTE NO: 11 OTHER CURRENT ASSETS:

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
(a) GST Receivable	30,833	31,866
(b) MAT Credit Entitlement	2,06,409	2,06,409
(c) Advance Tax & TDS	4,33,625	2,89,313
(d) Other Advances	2,98,82,681	2,99,10,913
(e) Advance and Security Deposit	40,00,000	40,00,000
	3,45,53,548	3,44,38,501

NOTE NO: 12: EQUITY SHARE CAPITAL

PARTICULARS	As At March 31, 2022		As At March 31, 2021	
	Number	Amount in Rs.	Number	Amount in Rs.
Authorised Equity Shares of Rs. 10/- each	1,60,00,000	16,00,00,000	1,60,00,000	16,00,00,000
Issued, Subscribed and Paid up Equity Shares of Rs. 10/- each fully paid up (Refer foot note (a) to (c) below)	1,48,08,706	14,80,87,060	1,48,08,706	14,80,87,060
Total	1,48,08,706	14,80,87,060	1,48,08,706	14,80,87,060

Foot note:**(a) Reconciliation of the number of shares outstanding as at March 31, 2022 and March 31, 2021 :**

PARTICULARS	As At March 31, 2022		As At March 31, 2021	
	Number	Amount in Rs.	Number	Amount in Rs.
Equity Shares outstanding at the beginning of the year	1,48,08,706	14,80,87,060	1,48,08,706	14,80,87,060
Equity Shares Issued during the year for Cash*	-	-	-	-
Equity Shares Issued during the year for other than cash	-	-	-	-
Equity Shares bought back during year	-	-	-	-
Equity Shares outstanding at the end of the year	1,48,08,706	14,80,87,060	1,48,08,706	14,80,87,060

(b) Details of Shareholders holding more than 5 % shares:

PARTICULARS	As At March 31, 2022		As At March 31, 2021	
	No. of Shares	% of Holding	No. of Shares	% of Holding
1 K. Krishnam Raju	28,99,630	19.58%	28,99,630	19.58%
2 Mohammed Aejaaz Habeeb	17,79,124	12.01%	17,79,124	12.01%
3 Syed Ameer Basha Paspala	16,61,800	11.22%	16,61,800	11.22%
4 K. Sarada Vijaya Kumari	8,65,690	5.85%	8,65,690	5.85%
5 K. Nirusha	10,29,200	6.95%	10,29,200	6.95%
6 P. Parvathi	3,93,586	2.66%	3,93,586	2.66%
7 Arun Kumar Bhangadia (Public)	56,000	0.38%	7,73,728	5.22%

(c) Terms and rights attached to the equity shares:

The Company has only one class of equity shares having par value of Rs.10/- each. Each holder of equity shares is entitled for one vote per share. Distribution of dividends and repayment of capital, if any, by the company, shall be subject to the provisions of applicable laws.

NOTE NO: 13 RESERVES AND SURPLUS

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
(a) Securities Premium:	4,55,00,000	4,55,00,000
(b) Retained earnings:		
Opening Balance	(8,37,24,488)	(6,95,42,777)
Loss on adjustment of Investment Value In Associate		(64,61,717)
Profit on Retaining the Non controlling Interest	58,79,906	
(+) During the year	1,48,73,001	(77,19,994)
	(6,29,71,581)	(8,37,24,488)
(c) Other Comprehensive income:		
Opening Balance	16,56,783	2,48,284
(+) During the year	-	14,08,499
Closing Balance	16,56,783	16,56,783
Total (a+b+c)	(1,58,14,798)	(3,65,67,705)

NOTE NO: 14 LONG TERM PROVISIONS

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Provision for employee Gratuity	6,44,769	4,17,577
Provision for Leave Encashment	63,722	38,768
	7,08,491	4,56,345

NOTE NO: 15 SHORT TERM BARROWINGS

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Un Secured Loans from Unsecured Loans (from promoters) (The above loans are interest free loans and repayable on demand)	2,74,07,000	2,34,05,000
	2,74,07,000	2,34,05,000

NOTE NO: 16 TRADE PAYABLES

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Dues to Micro, Small and Medium Enterprises	-	-
Dues to Others	12,15,251	28,72,255
	12,15,251	28,72,255

Trade Payables Ageing Schedule for the year ended 31/03/2022

PARTICULARS	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
(i) MSME	-	-	-	-	-
(ii) Others	2,41,843	-	9,73,408	-	12,15,251
(iii) Disputed Dues- MSME	-	-	-	-	-
(iv) Disputed Dues- Others	-	-	-	-	-

Trade Payables Ageing Schedule for the year ended 31/03/2021

PARTICULARS	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	
(i) MSME	-	-	-	-	-
(ii) Others	56,440	-	28,15,815	-	28,72,255
(iii) Disputed Dues- MSME	-	-	-	-	-
(iv) Disputed Dues- Others	-	-	-	-	-

NOTE NO: 17 OTHER CURRENT LIABILITIES:

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
(a) Statutory Liabilities	9,420	42,72,892
(b) Expenses Payable	12,90,751	79,82,704
(c) Employee Benefits Payable	81,02,270	1,50,16,897
(d) Audit Fees Payable	2,81,000	2,42,875
	96,83,441	2,75,15,368

NOTE NO: 18 Short term Provisions

PARTICULARS	As at March 31, 2022	As at March 31, 2021
	Amount in Rs.	Amount in Rs.
Provision for Gratuity Payable	-	96
	-	96

NOTE NO: 19 REVENUE FROM OPERATIONS

PARTICULARS	Year ended March 31, 2022	Year ended March 31, 2021
	Amount in Rs.	Amount in Rs.
Revenue from Operations		
Sale of Medicines	2,24,541	-
Diagnostic Services	-	1,03,204
OP Services	-	26,520
	2,24,541	1,29,724

NOTE NO: 20 OTHER INCOME

PARTICULARS	Year ended March 31, 2022	Year ended March 31, 2021
	Amount in Rs.	Amount in Rs.
Non Operating Income		
Finance Income on		
Interest on ICD	16,46,423	14,77,331
Creditors for expenses W/o	1,74,16,194	-
(Refer Note No 32)		
	1,90,62,617	14,77,331

NOTE NO: 21: PURCHASES

PARTICULARS	Year ended March 31, 2022	Year ended March 31, 2021
	Amount in Rs.	Amount in Rs.
Purchases of Mediciens	2,15,932	-
	2,15,932	-

NOTE NO: 22(a): MATERIAL AND COMPONENTS CONSUMED

PARTICULARS	Year ended March 31, 2022	Year ended March 31, 2021
	Amount in Rs.	Amount in Rs.
Inventory at the beginning of the year	-	13,11,401
Add: Purchases Of Consumed Material	-	-
Less: Inventory at the end of the year	-	12,92,128
Diminution in the value of Raw Materials	-	19,273

NOTE NO: 22(b): CHANGES IN INVENTORIES (Raw Materials)

PARTICULARS	Year ended March 31, 2022	Year ended March 31, 2021
	Amount in Rs.	Amount in Rs.
Inventory at the beginning of the year	12,92,128	-
Less: Inventory at the end of the year	-	-
Change in Raw Material (Expiry of Stock)	12,92,128	-

NOTE NO: 23: EMPLOYEE BENEFIT EXPENSES

PARTICULARS	Year ended March 31, 2022	Year ended March 31, 2021
	Amount in Rs.	Amount in Rs.
Salaries & Wages	8,94,000	30,66,896
Contribution to PF & ESI	-	53,700
Gratuity and Leave Encashment	2,52,050	1,82,891
EPF Admin Charges	900	4,440
Staff welfare expenses	-	9,370
Total	11,46,950	33,17,297

NOTE NO: 24 OTHER EXPENSES

PARTICULARS	Year ended March 31, 2022	Year ended March 31, 2021
	Amount in Rs.	Amount in Rs.
Rent	1,15,000	32,886
Rates and Taxes	5,09,241	8,24,379
Professional & Consultancy Fee	23,600	1,44,537
Auditors remuneration(refer Note below)	1,28,500	2,56,500
Office Maintenance	49,183	1,36,236
Printing & Stationery	25,640	33,980
Communication Expenses	-	24,937
Travelling & Conveyance	-	36,575
Power & Fuel Expenses	3,817	24,61,427
Repairs & Maintenance	18,732	33,800
Postage & Courier	-	1,290
Bank Charges	38,206	26,397
Advertisement & Business Promotion Expenses	58,058	96,568
Diagnostic outsourcing expenses	-	5,130
Listing Processing & Annual Listing Fees	5,49,893	5,36,900
Registrar & Transfer Fees	74,766	84,441
HK, Security and Hospital Maintenance	-	8,73,398
Directors Sitting Fees	-	2,25,000
Other Expenses	-	37,162
Total	15,94,636	58,71,543

Note: Payment to Auditors :

As Auditors	2021-22	2020-21
Statutory Audit Fees	75,000	75,000

* Statutory Audit fees is exclusive of GST

Note No: 28 Earnings Per Share (EPS)

	As at 31.03.2022	As at 31.03.2021
EPS – Basic		
Net Profit (Loss)	1,48,73,001	(63,11,495)
Appropriations	-	-
Net Profit (Loss) Attributable to Share Holders as at 31st March (Numerator)	1,48,73,001	(63,11,495)
No of Shares outstanding at the beginning of the year	1,48,08,706	1,48,08,706
No of Shares outstanding at the end of the year	1,48,08,706	1,48,08,706
Adjusted Weighted average number of equity shares	1,48,08,706	1,48,08,706
Nominal Value of Ordinary Shares	10	10
Computation of EPS - Basic (in Rs)	1.00	(0.43)
EPS – Diluted		
Net Profit (Loss) Attributable to Share Holders as at	1,48,73,001	(63,11,495)
Adjusted Weighted average number of equity shares	1,48,08,706	1,48,08,706
Weighted average number of equity shares that would	-	-
Total Weighted average number of equity shares for	1,48,08,706	1,48,08,706
Nominal Value of Ordinary Shares	10	10
Computation of EPS - Diluted (in Rs)	1.00	(0.43)
Particulars	31-03-2022	31-03-2021
Opening balance	1,48,08,706	1,48,08,706
No of shares allotted	-	-
Date of allotment	-	-
No of Days outstanding	-	-
Therefore weighted no. of Shares	-	-
No of shares allotted	-	-
Date of allotment	-	-
No of Days outstanding	-	-
Therefore weighted no. of Shares	-	-
Total No of Weighted equity Shares	1,48,08,706	1,48,08,706

25. Related Party Disclosures

As per Ind AS 24 the disclosure of transactions with the related parties are given below.

a) Related Parties and nature of relationship:

Mr.K. Krishnam Raju	Promoter & Whole-time Director & Chairman
Mr. Nagavenkata Narendra Kumar Konagalla	Whole-time Director & CFO
Mr. Suryaprakasa Rao Bommiseti	Independent Non – Executive Director
Dr. Akella Satya Surya Visweswara Srinivasa	Independent Non – Executive Director
Mrs. Aakanksha	Independent Non – Executive Director
Mr. Rama Mohan Reddy Yarragudi	Independent Non – Executive Director
Ms. Deepa R. Dudani	Company Secretary
Krisani Bio Sciences Pvt.Ltd	Associate of Dr Habeebullah Life Sciences Ltd
Mrs. K. Sarada Vijaya Kumari	Promoter Group

The Promoters of DRHLSL are major Promoters and/or Shareholders / Partners of the below entities –

1. Innovision Life Sciences Pvt.Ltd – Company
2. Centre For Liver Research and Diagnostics – Partnership Firm

b) Transactions with Related parties:

Name of the related party	Nature of Transaction	Year ended 31-03-2022 (Rupees)	Year ended 31-03-2021 (Rupees)
K. Krishnam Raju	Remuneration	-	27,00,000
	Rent expenses	1,15,000	-
	Demand Loan taken	40,02,000	55,30,000
	Demand Loan Repaid	-	40,000
Dr. Syed Ameer Basha Paspala	Professional Fee	-	51,037
K.N.V. Narendra Kumar	Remuneration	6,30,000	5,25,000
Ms. Neha Kankariya	Remuneration	-	3,13,928
Ms. Deepa R Dudani	Remuneration	2,64,000	33,785
CLRD Lease Rental Expense	Rent expenses	-	30,615
Innovision Life Sciences Pvt. Ltd	Interest Income	16,46,423	14,77,331

c) Related parties outstanding balances:

Name of the related party	Particulars	As at 31-03-2022 (Rupees)	As at 31-03-2021 (Rupees)
K. Krishnam Raju	Rent payable	4,52,500	3,37,500
	Remuneration payable	29,25,800	49,50,800
	Demand Loan taken	2,74,07,000	2,34,05,000
	Travelling Expenses Payable	-	16,570
K.S.V. Kumari	Rent payable	5,94,000	5,94,000
Dr. Mohammed Aejaaz Habeeb	Professional Fee Payable	-	3,25,337
Dr.Syed Ameer Basha Paspala	Professional Fee Payable	-	39,74,933
Centre for Liver Research and Diagnostics	Advance (Asset)	2,98,22,681	2,98,22,681
Krisani Bio Sciences Pvt. Ltd	Advance (Asset)	40,00,000	40,00,000
Innovision Life Sciences Pvt. Ltd	Inter-Corporate Loan	94,00,000	94,00,000
Innovision Life Sciences Pvt. Ltd	Interest Receivable on Inter-Corporate Loan	52,58,630	37,76,850
K.N.V. Narendra Kumar	Remuneration payable	13,28,280	11,90,080

26. Auditors' Remuneration:

PARTICULARS	2021-22 (Rupees)	2020-21 (Rupees)
Audit Fee (Exclusive of GST)	75,000	75,000
Total	75,000	75,000

27. The Board of Directors assesses the financial performance of the Company and make strategic decisions and has been identified as being the Chief Operating Decision Maker (CODM). Based on the internal reporting provided to the CODM, the Company has only one reportable segment i.e., 'healthcare services which includes hospital, diagnostics, Pharma and Biotechnology (R&D)' and hence no separate disclosures are required under Ind AS 108.

28. Earnings per share (EPS):

The details of number of Equity shares used in calculating Basic and Diluted earnings per share and the EPS are set out below:

PARTICULARS	Year ended 31-03-2022	Year ended 31-03-2021
Weighted average Equity shares for computing Basic EPS	1,48,08,706	1,48,08,706
Dilutive impact of Share Warrants	-	-
Weighted average Equity shares for computing Diluted EPS	1,48,08,706	1,48,08,706
Net Profit (Loss) Attributable to Share Holders as at 31st March	1,48,73,001	(63,11,495)
Earnings per Share-Basic	1.00	(0.43)
Earnings per Share-Diluted	1.00	(0.43)

29. The Company has not received any information from any of the supplier of their being Micro, Small and medium enterprises. Hence, the amounts due to Micro, Small and Medium enterprises outstanding as on 31-03-2022 was Rs. Nil

30. Balance Confirmations:

Confirmations of receivables and payable balances have not been received by the Company, hence, reliance is placed on the balances as per books. In the opinion of the management, the amounts are realizable /payable in the ordinary course of business.

31. Fair Value Measurements:**i) Fair Value hierarchy**

Financial assets and financial liabilities measured at fair value in the statement of financial position are grouped into three levels of a fair value hierarchy. The three levels are defined based on the observability of significant input to the measurement, follows:

Level 1: Quoted prices (unadjusted) in active markets for financial instruments.

Level 2: The fair value of financial instruments that are not traded in and active market is determined using valuation techniques which maximize the use of observable market data rely as little as possible on entity specific estimates.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

ii) Financial assets and liabilities measured at fair values:

Financial Assets & Liabilities Valuation	Year ended 31-03-2022	Year ended 31-03-2021
Fair Value Hierarchy	2	2
a) Financial Assets		
Non-Current Investments		
Investment in equity instruments of Associate (cost) Unquoted (Formerly a subsidiary) Krisani Biosciences Pvt Ltd (58,68,200 equity shares of Rs 10 each subscribed at Rs. 8.3 per Share)	4,79,90,427	4,22,21,421
Total Investment in Associate	487,06,060	487,06,060
Aggregate book value of quoted investments	-	-
Aggregate market value of quoted investments	-	-
Other Financial Assets (Non-Current)		
Security Deposits at (at amortised cost)	2,00,25,000	2,03,98,662
Total Financial assets	6,87,31,060	6,91,04,722
b) Financial Liabilities		
Short term Borrowings	2,74,07,000	2,34,05,000
Total Financial Liabilities	2,74,07,000	2,34,05,000

iii. Financial Instruments by category

For amortized cost instruments, carrying value represents the best estimate of fair value:

Particulars	31st March, 2022			31st March, 2021		
	FVTPL	FVOCI	Amortized Cost	FVTPL	FVOCI	Amortized Cost
Financial Assets						
Equity Investments	4,79,90,427	-	-	4,79,90,427	-	-
Other Financial Assets	-	-	2,00,25,000	-	-	2,03,98,662
Trade Receivables	-	-	2,12,45,408	-	-	2,14,25,710
Loans	-	-	94,00,000	-	-	94,00,000
Cash and Cash Equivalents	-	-	93,213	-	-	41,317
Other Bank Balances	-	-	-	-	-	-
Others	-	-	3,98,12,178	-	-	3,82,15,351
Total	4,79,90,427	-	9,05,75,799	4,79,90,427	-	8,94,81,040
Financial Liabilities						
Borrowings	-	-	2,74,07,000	-	-	2,34,05,000
Trade Payables	-	-	12,15,251	-	-	28,72,255
Other Current Liabilities	-	-	96,83,441	-	-	2,75,15,367
Total	-	-	3,83,05,692	-	-	5,37,92,622

The Company's principal financial liabilities comprise loans and borrowings, trade and other payable. The main purpose of these financial liabilities is to finance the Company's operations.

The Company's principal financial assets include loans. Trade and other receivables, and cash and cash equivalents that derive directly from its operations. The Company also holds FVTPL investments and investments in its associates.

The Company is exposed to market risk, credit risk and liquidity risk. The Company's Board of Directors oversee the management of these risks. The company's Board of Directors is supported by the senior management that advises on financial risks and the appropriate financial risk governance framework for the Company. The senior management provides assurance to the Company's board of directors that the company's financial risk activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with the Company's policies and risk objectives.

The Carrying amounts reported in the statement of financial position for cash and cash equivalents, trade and other receivables. Trade and other payables and other liabilities approximate their respective fair values due to their short maturity.

31.1 Financial Risk Management

In course of its business, the company is exposed to certain financial risk such as market risk (Including currency risk and other price risks), credit risk and liquidity risk that could have significant influence on the company's business and operational/financial performance. The Board of directors reviews and approves risk management framework and policies for managing these risks and monitor suitable mitigating actions taken by the management to minimize potential adverse effects and achieve greater predictability to earnings.

31.2 Credit risk

Credit risk refers to the risk that counterparty will default on its contractual obligations resulting in financial loss to the company. The company has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral, where appropriate, a means of mitigating the risk of financial loss from defaults.

The company makes an allowance for doubtful debts/advances using expected credit loss model.

31.3 Liquidity risk

Liquidity risk refers to the risk that the company cannot meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. The Company's exposure to liquidity risk is minimal.

31.4 Market Risk

Market risk is the risk that changes in market prices, such as foreign exchanges rates, interest rate And equity prices, which will affect the company's income of the value of its holdings of financial Instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return.

a) Interest Rate Risk

Interest risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate Because of changes in market interest rates. The company has exposure only to financial instruments at fixed interest rates. Hence, the company is not exposed to significant interest rate Risk.

b) Price Risk

The company's exposure to equity securities price risk arises from investments held by the company and classified in the balance sheet either at fair value through OCI or at fair value through profit and loss. The majority of the company's equity instruments are publicly traded.

32. Capital Management Risk

The Company's objective when managing capital is to safeguard the Company's ability to continue as a going concern in order to provide returns for shareholders and benefits for stake holders. The company also proposes to maintain an optimal capital structure to reduce the cost of capital. Hence, the company may adjust any dividend payments, return capital to shareholders or issue new shares. Total capital is the equity as shown in the statement of financial position. Currently, the company primarily monitors its capital structure on the basis of gearing ratio. Management is continuously evolving strategies to optimize the returns and reduce the risks. It includes plans to optimize the financial leverage of the company.

The capital for the reporting year under review is summarized as under:

Particulars	March 31, 2022	March 31, 2021
Non-Current Borrowings	0	0
Current Borrowings	2,74,07,000	2,34,05,000
Total Debt	2,74,07,000	2,34,05,000
As a percentage of total capital	17.16%	17.34%
Equity	13,22,72,262	11,15,19,354
As a percentage of total capital	82.83%	82.65%
Total Capital (Debt and Equity)	15,96,79,261	13,49,24,354
Gearing Ratio (total debt/Total Equity)	0.207	0.209

33. Impact of Global Health Pandemic - COVID-19

COVID-19 is the infectious disease caused by the most recently discovered coronavirus, SARSCoV-2. In March 2020, the WHO declared COVID-19 a pandemic. Company has adopted measures to curb the spread of infection in order to protect the health of employees and ensure business continuity with minimal disruption.

The Company's management has made initial assessment of likely adverse impact on business and financial risks on account of COVID-19. It is well appreciated that situation as well as its assessment is continuously evolving, and the way ahead is to avoid living in denial leading to acceptance & pro-active measures. The Company's management currently believes that the impact is likely to be short term in nature. Given the severity of impact, this financial year is likely to get affected, but also given the measures from Government and inherent resilience in Indian Economy, next year onwards are expected to show normal growth scenarios. Accordingly, at present the management does not see any medium to long term risks in the Company's ability to continue as a going concern and meeting its liabilities as and when they fall due, and compliance with the debt covenants, as applicable.

In assessing the recoverability of receivables and other financial assets, Company has considered internal and external information upto the date of approval of these financial results. The impact of the global health pandemic may be different from that of estimated as at the date of approval of these financial results and the Company will continue to closely monitor any material changes to future economic conditions.

34. Standards Issued But Not Effective

The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.

As at the date of issue of financial statements, there are no new standards or amendments which have been notified by the MCA but not yet adopted by the Company. Hence, the disclosure is not applicable.

35. Other Statutory Information:

- i. The Company does not have any Benami property, where any proceeding has been initiated or pending against the Group for holding any Benami property.
- ii. The Company does not have any transactions with companies struck off.
- iii. The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- iv. The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- v. The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- vi. The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities

(Intermediaries) with the understanding that the Intermediary shall:

- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
 - vii. The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Group shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - viii. The Company has not any such transaction which is not recorded in the books of account that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.
36. The TDS Payable amounts of Rs. 35,13,198, interest accounted on such payable amounts of INR 13,85,335 and related expenses of INR 1,25,17,661 that were claimed in prior years have been written down during the year and have been shown as income in the profit and loss statement under other income. But to the extent of INR 15,89,044 out of above mentioned TDS liability the related expenses has not been written off. The break up of section wise the Non written off expenses against the written down TDS liability is as follows:

Section	Amount (INR)
192B	12,58,200
194C	88285
194I	307320
194J	78894
Total	15,89,044

37. Previous year's figures have been regrouped/reclassified wherever necessary, to confirm to current period's classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1st April, 2021.

As per our report of even date
for A.M.REDDY & D.R.REDDY
Chartered Accountants
Firm Registration No: 009068S

Sd/-
(D.Rama Krishna Reddy)
Partner
Membership No. 209211
UDIN: 22209211AOVJDL2511

Place: Hyderabad
Date : 10.08.2022

for and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED

Sd/-
(K.Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650

Sd/-
(K. N.V.Narendra Kumar)
Chief Financial Officer

Sd/-
(B. Suryaprakasa Rao)
Director
DIN: 08089189

Sd/-
(Deepa Rajendra Dudani)
Company Secretary

If Undelivered please return to :

DR HABEEBULLAH LIFE SCIENCES LIMITED

6-3-354/13/B2, Flat.No.B2, Suryateja Apartments,
Hindi Nagar, Punjagutta, Hyderabad-500082, Telangana